UNITED STATESSECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K/A

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2007

Commission file number 0-23272

NPS PHARMACEUTICALS, INC.(Exact name of Registrant as Specified in its Charter)



|Delaware                                                       | 87-0439579                          
|-------------------------------------------------------------- | ------------------------------------
|(State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.)

550 Hills Drive, 3rd Floor

                              Bedminster, New Jersey       07921

(908) 450-5300

Securities registered pursuant to Section 12(b) of the Act:





|Title Of Each Class                                                                                  |  | Name Of Each Exchange On Which Registered
|---------------------------------------------------------------------------------------------------- |  | -----------------------------------------
|Common Stock, $.001 Par Value Per Share
                             Preferred Share Purchase Rights |  | The NASDAQ Global Market                 

Securities registered pursuant to Section 12(g) of the Act: None

---

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act.    YES

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities
Exchange Act.    YES

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant
was required to file such reports), and (2) has been subject to such filing requirements for at least the past 90
days.    YES

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be
contained, to the best of Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form
10-K/A or any amendment to this Form 10-K/A.

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or a
smaller reporting company. See the definitions of "large accelerated filer," and large "accelerated filer" and "smaller
reporting company" in Rule 12b-2 of the Exchange Act.



|Large Accelerated Filer | o |  | Accelerated Filer         | x
|----------------------- | - |  | ------------------------- | -
|Non-accelerated filer   | o |  | Smaller reporting company | o

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).    YES  o
NOx

The aggregate market value of the common stock held by non-affiliates of the Registrant was $190,455,281 as of June 29, 2007,
based upon the closing price for the shares of common stock reported on The NASDAQ Global Market on such date.

As of March 6, 2008, there were  47,039,955 shares of common stock, par value $0.001 per share, outstanding.

DOCUMENTS INCORPORATED BY REFERENCE:

Portions of the Registrant's definitive Proxy Statement for the Annual Meeting of Stockholders scheduled to be held
on May 22, 2008, to be filed with the Commission not later than 120 days after December 31, 2007 (Part III).




PDF provided as courtesy

TABLE OF CONTENTS

|PART I    
|----------
|Item 1.   
|Item 1A.  
|Item 1B.  
|Item 2.   
|Item 3.   
|Item 4.   
|PART II   
|Item 5.   
|Item 6.   
|Item 7.   
|Item 7A.  
|Item 8.   
|Item 9.   
|Item 9A.  
|Item 9B.  
|PART III  
|Item 10.  
|Item 11.  
|Item 12.  
|Item 13.  
|Item 14.  
|PART IV   
|Item 15.  
|SIGNATURES

2

---

EXPLANATORY NOTE

This Amendment No. 1 on Form 10-K/A amends our Annual Report on Form 10-K for the year ended December 31, 2007,
as filed with the Securities and Exchange Commission on March 17, 2008, for the purpose of restating our audited consolidated
financial statements and related notes as of and for the year ended December 31, 2007 contained in Item 8 of Part II.During the preparation of the financial results for the quarter ended March 31, 2008, the Company identified an error in the
computation of the redemption premium interest expense, under the effective interest method, for the year ended December 31,
2007, associated with the Secured 8.0% Notes due on March 30, 2017 (Class A Notes).  Accordingly, the Company has restated its
Consolidated Balance Sheet as of December 31, 2007 to increase accrued interest expense related to the Class A Notes by $3.8
million.  Additionally, the Company discovered an error in computing interest expense, under the effective interest method, related to
the amortization of debt issuance costs, the correction of which increased debt issuance costs by $96,000.  The tax impact on both
entries resulted in a decrease of income taxes payable by $74,000.  The Company has also restated its Consolidated Statement of
Operations as of December 31, 2007 to increase interest expense related to the Class A notes by $3.8 million, decrease interest
expense related to reduced amortization of debt issuance costs by $96,000 and decrease income tax expense for the tax effect of
these entries by $74,000.  See Notes 2, 11, 14 and 21 to the audited consolidated financial statements for further discussion of the
restatement and related disclosures.We have also updated Item 1A of Part I - Risk Factors, Items 6, 7 and 9A of Part II, Selected Financial Data, Management's
Discussion and Analysis of Financial Condition and Results of Operations and Controls and Procedures, and Exhibit 12.1, to give
effect to the restatement.PART I
Unless the context requires otherwise, references in this report to "NPS", the "Company",
"we", "us", "our" and similar terms mean NPS Pharmaceuticals, Inc. and its subsidiaries.

This Annual Report on Form 10-K and the documents incorporated by reference into this report contain certain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on our current expectations and are subject to uncertainty and
changes in circumstances. We cannot guarantee the accuracy of such statements, and you should be aware that results and events could differ materially
from those contained in such statements. You should consider carefully the statements set forth in Item 1A of this report entitled "Risk
Factors" and Item 7 of this report entitled "Management's Discussion and Analysis of Financial Condition and Results of
Operations".

ITEM 1. Business

Overview

We are a biopharmaceutical company engaged in the development of specialty therapeutics to treat gastrointestinal (GI) and endocrine disorders with
high unmet medical need.  Our lead clinical programs involve two proprietary proteins to restore or replace biological function: GATTEXTM (teduglutide)
and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection).  GATTEX is an analog of GLP-2, a protein involved in the regeneration and repair of the
intestinal lining, and is in Phase 3 clinical development for short bowel syndrome (SBS).  SBS affects patients who have had 50% or more of their small
intestine removed.  Given GATTEX's activity in promoting gastrointestinal repair, we are also evaluating its role in treating other GI conditions associated
with intestinal failure, specifically GI mucositis (GIM), necrotizing enterocolitis (NEC), and Crohn's disease.  NPSP558 is in Phase 2 clinical testing as a
hormone therapy for hypoparathyroidism, a disorder that decreases blood calcium due to an insufficiency of parathyroid hormone.  In addition to our
proprietary clinical portfolio, we have a number of royalty-based clinical- and commercial-stage programs.

In 2007, we restructured our operations and implemented a new business strategy to focus our resources on developing GATTEX and NPSP558 for
specialty indications with a high unmet medical need.  Previously, our strategic priority was to obtain U.S. regulatory approval of
PREOS® (parathyroid hormone 1-84 [rDNA origin] injection) for the treatment of osteoporosis.  We have studied PREOS in a number of
clinical settings to document its safety and effects on bone.  Our pivotal Phase 3 study, known as TOP (Treatment of Osteoporosis with PTH), was a
multi-center, randomized, double-blind placebo-controlled clinical trial designed to evaluate the potential of PREOS to reduce the risk of first and subsequent
vertebral fractures in post-menopausal women.  In the TOP study, PREOS demonstrated a3statistically significant reduction in the risk of new vertebral
fractures in women with and without pre-existing osteoporosis-related fractures.  Results from the TOP study were the basis of the 2006 European approval
of Preotact® (the European brand name for PREOS) for the treatment of postmenopausal women with osteoporosis at high risk for
fractures.  Our partner, Nycomed Danmark ApS (Nycomed) sells Preotact in Europe under a licensing agreement with us.



In 2006, we received an approvable letter and guidance from the U.S. Food and Drug Administration (FDA) to support a U.S. marketing application for
PREOS.  While we continue to believe that the U.S. osteoporosis market
remains a viable commercial opportunity for this compound, we elected to focus
our resources on specialty opportunities within our pipeline and pursue osteoporosis only on a partnered, rather than a proprietary, basis.

During 2007, we took the following actions to support our business plan of developing specialty therapeutics to treat GI and endocrine disorders with a
high unmet medical need:


Refocused our resources and implemented a clinical development strategy for GATTEX and NPSP558 for specialty indications with high unmet medical
need
Substantially reduced annual operating expenses and cash utilization, which included consolidating our operations into one facility in Bedminster,
NJ
Raised more than $275.0 million in capital through new financings and the monetization of assets that were no longer strategically aligned
Retired more than $191.0 million in convertible debt due in 2008
Completed a Phase 3 clinical study of GATTEX for the treatment of SBS
Secured an ex-North America partnership for GATTEX with Nycomed
Enhanced our leadership team with several key appointmentsStrategy

We intend to achieve our business objectives through the following strategies:
Build a broad pipeline of specialty therapeutics for unmet medical needs.  We are building a broad pipeline of product candidates that are currently
in various stages of preclinical and clinical development.  Our clinical strategy focuses on indications treated by specialist physicians with significant unmet
medical needs and limited competition.  We are also mitigating our exposure to any one product or program and maintaining the flexibility to allocate
resources to or accelerate our most promising programs.  We believe this strategy will help us create a balanced product portfolio that we can
successfully commercialize through a small, specialized commercial team.
Open innovation.  We believe the open innovation component of our strategy is an efficient and cost effective approach to our business that blends
traditional outsourcing with collaborations that enhance our internal capabilities.  We are applying this model to all areas of our business.    Rather than
investing substantial resources in building and maintaining infrastructure, we are complementing our internal knowledge base by collaborating with
established technological, clinical, regulatory, and commercial.  By blending internal and external innovation, we expect to optimize each stage of our clinical
programs and effectively manage our resources, risk, and time-to-market for our key clinical programs.
Collaborate or license to manage risk and accelerate the commercialization of product candidates.  We believe that collaborating with
pharmaceutical and biotechnology companies with relevant expertise in complementary therapeutic areas will facilitate the development and
commercialization of our products.    We also selectively pursue new product development opportunities in specialty indications.  This strategy allows us to
allocate our resources to proprietary programs that we believe can match our financial capabilities and have an appropriate probability of development and
commercial success.

4Product Pipeline

The table below summarizes our proprietary and royalty-based product pipeline and the status of each program.

|Program and Indication(s)                                                                                                                                                                              | Status      | Market        | Licensee        
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ----------- | ------------- | ----------------
|                                                                                                                                                                                                       |             |               |                 
|Proprietary Product Candidates:                                                                                                                                                                        |             |               |                 
|GATTEXTM (teduglutide)                                                                                                                                                                                  |             |               |                 
|Short Bowel Syndrome                                                                                                                                                                                   | Phase 3     | North America | Proprietary     
|GI Mucositis                                                                                                                                                                                           | Preclinical | North America | Proprietary     
|Necrotizing Enterocolitis                                                                                                                                                                              | Preclinical | North America | Proprietary     
|Crohn's Disease                                                                                                                                                                                        | Phase 2     | North America | Proprietary     
|                                                                                                                                                                                                       |             |               |                 
|Parathyroid hormone 1-84 [rDNA origin]                                                                                                                                                                 |            
|NPSP558 in Hypoparathyroidism                                                                                                                                                                          | Phase 2     | North America | Proprietary     
|PREOS® in Osteoporosis                                                                                                                                                                                 | Phase 3     | North America | Proprietary     
|                                                                                                                                                                                                       |             |               |                 
|NPSP156 (d-serine analog)                                                                                                                                                                              |             |               |                 
|Central Nervous System Disorders                                                                                                                                                                       | Preclinical | Worldwide     | Proprietary     
|                                                                                                                                                                                                       |             |               |                 
|Royalty-Based Products and Product Candidates:                                                                                                                                                         |             |              
|Sensipar® in U.S. and Mimpara®in EU(cinacalcet HCl)                                                                                                                                                    |             |              
|Secondary Hyperparathyroidism                                                                                                                                                                          | Market      | U.S. and EU   | Amgen           
|Hypercalcemia                                                                                                                                                                                          | Market      | U.S. and EU   | Amgen           
|Primary Hyperparathyroidism                                                                                                                                                                            | Phase 2     | U.S. and EU   | Amgen           
|                                                                                                                                                                                                       |             |               |                 
|REGPARA® (cinacalcet HCl)                                                                                                                                                                              |             |               |                 
|Secondary Hyperparathyroidism                                                                                                                                                                          | Approved    | Asia          | Kirin           
|                                                                                                                                                                                                       |             |               |                 
|Preotact®(parathyroid hormone 1-84 [rDNA origin] injection                                                                                                                                             |            
|Osteoporosis                                                                                                                                                                                           | Market      | Non-U.S. **   | Nycomed         
|                                                                                                                                                                                                       |             |               |                 
|GATTEXTM (teduglutide)                                                                                                                                                                                  |             |               |                 
|Short Bowel Syndrome                                                                                                                                                                                   | Phase 3     | Ex-N. America | Nycomed         
|                                                                                                                                                                                                       |             |              
|Ronacaleret (751689, calcilytic compound)                                                                                                                                                              |             |              
|Osteoporosis                                                                                                                                                                                           | Phase 2     | Worldwide     | GlaxoSmithKline*
|                                                                                                                                                                                                       |             |               |                 
|Glycine Reuptake Inhibitors                                                                                                                                                                            | Phase 1     | Worldwide     | Janssen         
|                                                                                                                                                                                                       |             |               |                 
|* We retain co-promotion rights in the U.S. for product candidates from this collaboration
** If the product receives U.S. approval, Nycomed's license in Canada and Mexico revert to us or a licensee

Proprietary Product Candidates

Our internal programs focus on GI and endocrine disorders with a high unmet medical need.  We are advancing  two proprietary  programs in orphan
indications:  GATTEX is in Phase 3 clinical development for SBS and NPSP558 is in Phase 2 clinical development for hypoparathyroidism.  In addition, we
are pursuing the development of GATTEX for pediatric NEC, GIM, and Crohn's disease.  We are also advancing NPSP156, our proprietary D-serine analog,
which is in preclinical development for various central nervous system disorders.

GATTEX (teduglutide)

GATTEX is the brand name for our proprietary analog of naturally occurring human glucagon-like peptide 2 (GLP-2), a peptide secreted primarily in the
distal intestine and involved in the regeneration and repair of the intestinal epithelium.

5

---



Crohn's disease.  In September 2007, we licensed to Nycomed the right to develop and commercialize GATTEX outside of North America for the treatment of
GI disorders.  We discuss the license agreement in further detail below under the captions "Royalty-Based Products and Product Candidates"
and "Collaborative Research, Development and License Agreements".

Intestinal function is involved in the digestion and the absorption of nutrients.  It also plays an important role in the excretion of toxic chemicals,
pathogens and byproducts of metabolic and digestive processes, and in balancing the absorption and secretion of electrolytes and water.  Intestinal failure
results from obstruction, dysmotility, surgical resection, congenital defect or disease-associated loss of absorption; it is characterized by the inability to
maintain protein-energy, fluid, electrolyte or micronutrient balances when on a conventionally accepted normal diet.  Our most advanced program for
GATTEX is in Phase 3 clinical testing in patients with SBS who are dependent on parenteral nutrition (PN).

SBS is a highly disabling condition that impairs quality of life and can lead to serious life-threatening complications.  SBS typically arises after extensive
resection of the small bowel.  SBS patients suffer from malnutrition, severe diarrhea, dehydration, fatigue, osteopenia, and weight loss due to a loss in the
ability to absorb adequate amounts of nutrients and water.  The goals of current treatment are to maintain fluid electrolyte, and nutrient balances through
dietary management, including the use of PN.

SBS Market Opportunity

Scientific journal articles and our own market studies indicate there are 10,000 to 15,000 SBS patients in North America who are PN-dependent, the
cost of which can exceed $100,000 annually per patient.  Currently, only somatropin (rDNA origin) for injection (human growth hormone) and glutamine
when used in conjunction with a recombinant human growth hormone are FDA-approved treatments for SBS in patients receiving specialized nutritional
support and for only four weeks of therapy.  We believe the SBS market is attractive because of the high cost of PN, PN-associated morbidities, the absence
of effective drug therapies, and the potential improvement in the quality of life of SBS patients.

GATTEX for SBS

Preclinical and clinical studies have demonstrated that GATTEX stimulates the repair and regeneration of cells lining the small intestine, expanding the
surface area for absorption of nutrients.  In animal models of small bowel resections, the administration of GATTEX resulted in increased mucosal and total
weight, crypt-villus height, and D-xylose absorption and restored the adaptive capacity post resection. Additionally, in PN-induced atrophy animal studies,
the administration of GATTEX prevented PN-induced atrophy when administered prior to or with PN and restored the intestinal integrity.

In 2000, we received orphan drug designation for GATTEX from the FDA for SBS, which provides

We have completed a pivotal Phase 3 clinical study in adult SBS patients to measure the ability of GATTEX to reduce a patient's dependency on PN.
The Phase 3 clinical study was a double-blind, randomized, placebo-controlled trial with a study duration of six months.  Eighty-three PN-dependent SBS
patients were randomized to receive a low dose of GATTEX, (0.05 mg/kg/day), a higher dose of GATTEX (0.10 mg/kg/day) or placebo. The original primary
endpoint for the study was a twenty percent (20%) or greater reduction in PN for study subjects at weeks 20 to 24 of the study compared to baseline. During
the finalization of the Phase 3 study's statistical analysis plan, the primary endpoint for the Phase 3 trial was expanded to incorporate several data points
that were originally included as secondary endpoints in the protocol. The expanded endpoint was designed to account for the degree of effect and duration
of a patient's response to GATTEX. Accordingly, the expanded endpoint of the study called for a reduction in PN of at least twenty percent (20%) comparing
baseline to weeks 16 to 24, measured as a graded response to capture reductions up to 100%.

In October 2007, we reported the top-line results from the Phase 3 study.  In an intent-to-treat analysis, forty-six percent (46%) of patients receiving the
lower dose of GATTEX (n=35) responded and achieved a highly statistically significant reduction in PN compared to placebo (p=0.007).  Twenty-five percent
(25%) of patients receiving the higher dose of GATTEX (n=32) responded and showed a trend in the difference between the treatment group and placebo,
but this did not reach statistical significance (p=0.161).  In this Phase 3 study, there were no statistical differences in the incidence rates of adverse events or
serious adverse events among the treatment groups when compared to placebo.

6

---



Two low-dose patients gained independence from and discontinued PN by
week 16 and a third high-dose patient discontinued PN at the end of treatment. The study's criteria for conducting the statistical analysis of the primary
endpoint required that the results for the high-dose group show statistical significance before considering the results of the low-dose group.  Given
GATTEX's orphan designation in SBS and the statistically strong (p=0.007) and clinically meaningful findings in the low-dose group, we met with the FDA to
discuss the regulatory requirements for the development of GATTEX for SBS.  During our meeting, the FDA recommended that we conduct a confirmatory
Phase 3 study prior to submitting a new drug application (NDA).  We plan to initiate this study and are currently finalizing a protocol that will incorporate the
FDA's input, as well as the results from our Phase 3 extension study which is discussed below.

We recently completed a Phase 3 extension study for GATTEX.  Sixty-five of the 71 patients (91%) who completed the pivotal Phase 3 study elected to
enroll in the 28-week extension study.  Patients already on GATTEX in the pivotal Phase 3 study continued to receive the dose to which they were already
receiving for an additional 28 weeks of GATTEX for a total of 52 weeks of treatment.  Patients who were on placebo in the Phase 3 clinical study were
randomized in the extension study to receive either a low dose of GATTEX (0.05 mg/kg/day) or a high dose of GATTEX (0.10 mg/kg/day).  The objective of
this extension study is to evaluate the long-term safety and efficacy of daily dosing of GATTEX as well as its impact on reductions in PN.  Preliminary results
support our Phase 3 results.  We are currently finalizing our analysis and expect to report top-line data in March 2008.

In a Phase 2 proof-of-concept study, 16 patients with SBS received subcutaneous injection of GATTEX for 21 days.  Three patients received 0.03
mg/kg/day, ten patients received 0.10 mg/kg/day, and three patients received 0.15 mg/kg/day. Results of the Phase 2 study indicated that GATTEX was
safe and well tolerated, resulted in intestinal epithelial regeneration and significantly increased intestinal absorption and body weight in PN-dependent SBS
patients.  These results were published in the international peer-reviewed journal Gut (Peppesen et al Gut 2005; 54:1223-1231).

We have also completed a single-center, double-blind, randomized, placebo-controlled ascending-dose study. Separate cohorts of healthy subjects
were administered multiple doses of GATTEX or placebo in order to investigate the tolerability and pharmacokinetics of GATTEX. Following completion of
eight days of treatment in a cohort and prior to the initiation of the next scheduled cohort(s), safety and tolerability were reviewed and assessed by an
Independent Safety Review Panel.  The study involved 95 subjects and results indicated that subcutaneous injections of 10 mg to 80 mg of GATTEX were
safe and well tolerated.

Analysis and a final report of a two-year rat carcinogenicity study for GATTEX have been completed and will be included as part of our NDA submission.
All of the findings were considered to be either sporadic (not of statistical or biological significance), benign, or expected due to the pharmacological
properties of the test material.  Non-neoplastic changes were observed at all doses tested.  No malignant tumors were observed following treatment with
GATTEX.

A study was conducted to assess the pharmacokinetics of a single fixed subcutaneous 20 mg dose of GATTEX in patients with moderate hepatic
impairment compared to healthy subjects. This open-label single center study enrolled 24 patients.  Administration of GATTEX 20 mg appeared to be safe
and generally well tolerated by the male and female subjects with normal liver function and moderate liver impairment in this study.

GATTEX for Other Indications

We are also evaluating the development of GATTEX in several other GI indications, including GIM, NEC, and Crohn's disease.  Consistent with our
refocused strategy, our initial priority will focus on pursuing the development of GATTEX for GIM and NEC, given the serious unmet medical needs of these
two specialty indications.

GI mucositis or GIM is a side effect associated with certain cancer treatments.  Some chemotherapies and radiotherapy, individually or in combination,
damage rapidly dividing normal cells of the GI tract, which can result in mucositis.  Mucositis can occur anywhere along the GI tract and can become a dose-
limiting side effect of cancer treatment.  In fact, mucositis is one of the four major side effects that severely limit chemotherapy treatment along with nausea
and vomiting, neutropenia, and anemia.

Necrotizing enterocolitis or NEC is a GI disease that mostly affects premature infants.  NEC involves infection and inflammation that causes destruction
of the bowel or intestine or part of the bowel. NEC affects one in 2,000 to 4,000 births or between 1% and 5% of neonatal intensive care unit admissions and
is the most common surgical emergency and serious GI disorder among hospitalized preterm infants.

7

---



We are currently completing the preclinical studies to pursue the clinical development of GIM and NEC.Encouraging findings from preclinical
studies with GATTEX demonstrated its potential to prevent chemotherapy-induced GI mucositis in animal models.

Crohn's disease is a chronic disorder characterized by inflammation of the GI tract.  The inflammation can lead to obstruction or blockage of the
intestine, the development of sores or ulcers within the intestinal tract, diarrhea, and malnutrition or the presence of nutritional deficiencies. Treatment
includes medications to manage the inflammation and associated complications, administration of vitamins and other nutritional supplements, and/or surgery
to reduce or eliminate any resulting obstruction.

The Crohn's & Colitis Foundation of America estimates that as many as one million people in the United States have inflammatory bowel
disease with approximately one-half of those being afflicted with Crohn's disease. There currently is no cure for Crohn's disease.  The goal of current
medical treatment is to suppress the inflammatory response, bring the symptoms under control, and then administer medical therapy to decrease the
frequency of the disease flares and to maintain remission.

A Phase 2a proof-of-concept clinical study with GATTEX in patients with Crohn's disease has been completed. The four-arm, eight-week clinical trial
compared three doses of GATTEX delivered by daily subcutaneous injection to a placebo.  The study was designed to evaluate GATTEX's safety and
potential efficacy in the treatment of Crohn's disease.  The study results showed a positive and consistent trend toward efficacy and a dose response
favoring the highest dose group, with 36.8% of patients receiving the highest dose of GATTEX reaching clinical remission, at week two versus 16.7% of the
placebo group, while 55.6% of patients in the highest dose group reached clinical remission by week eight compared to 33.3% of the placebo group.
Clinical remission was defined as a Crohn's Disease Activity Index score, or CDAI score, of less than 150 points.  GATTEX was well tolerated with no
serious adverse events related to the drug. The most common treatment-related adverse event in the trial was redness at the injection site.  While this study
was not powered to demonstrate statistical significance and the primary end point was not met due to the relatively small number of study subjects and a
high placebo response, we believe clinical remission rates seen in patients receiving the highest dose of GATTEX support further evaluation of GATTEX for
the treatment of Crohn's disease.

NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection)

NPSP558 is our proprietary recombinant, full-length (1-84), human parathyroid hormone that we are developing in the U.S. as a potential treatment for
hypoparathyroidism. Our previous clinical studies of this compound for the treatment of osteoporosis under the brand name PREOS have demonstrated that
daily subcutaneous dosing causes parathyroid hormone levels to rise rapidly and then return to normal levels within a few hours.  In light of the results from
these studies, we believe NPSP558 has the potential to be the first true hormone therapy for hypoparathyroidism.

Hypoparathyroidism is a condition in which the body produces too little parathyroid hormone.  Injury to or removal of the parathyroid glands during neck
surgery is the most common cause.  Hypoparathyroidism also occurs as an autoimmune disorder, either sporadically or in conjunction with polyglandular
endocrine deficiency type 1.  It causes lower than normal levels of calcium in the blood and rapid drops in these same levels.  Most symptoms of
hypoparathyroidism result from low levels of calcium in the blood and include:  muscle spasm or cramping, typically in hands or feet often referred to as
tetany; hair loss, dry skin or malformed nails; and numbness, tingling or burning especially around the mouth and fingers.  The consequences of
hypoparathyroidism include vitamin D deficiency, hypercalciuria, and bones of poor material quality.

Hypoparathyroidism Market Opportunity

An estimated 65,000 patients suffer from hypoparathyroidism in the U.S.  It is one of the few remaining hormone production disorders without an
approved replacement therapy.It is a rare disease and affects males and females equally.Presently, the only available treatments
approved for hypoparathyroidism include life-long supplementation of calcium and Vitamin D analogs.  Severe hypocalcemia can be life threatening and is
usually treated with intravenous calcium.  Normalization of serum calcium is usually obtainable with conventional therapy; however, it can be accompanied
by excessive urinary calcium excretion or hypercalciuria.  Chronic hypercalciuria can lead to renal function impairment, nephrocalcinosis and renal
insufficiency.  With its ideal mechanism of action, NPSP558 has the potential to fulfill the unmet need of this chronic condition and return the body to a
normalized or eucalcemic state.  In 2007, the FDA granted orphan drug status for NPSP558 for the treatment of hypoparathyroidism.

8

---



NPSP558 for Hypoparathryoidism

We are currently supporting an investigator-initiated trial to explore the use of NPSP558 as a hormone therapy to treat hypoparathyroidism. The
study calls for 50 patients, most of whom are already enrolled, to be dosed with NPSP558 every-other-day for a period of up to 24 months.  The
objectives of this study are to understand the effect of NPSP558 on bone quality in hypoparathyroidism and demonstrate the safety and efficacy of
NPSP558 as a parathyroid hormone therapy.

In December 2007, we met with the FDA to discuss the regulatory path for NPSP558 for hypoparathyroidism.  During 2008, we expect to file an
Investigational New Drug Application (IND) and initiate a pivotal registration study to evaluate the safety and efficacy of NPSP558 for the treatment of
hypoparathyroidism.  This study would call for 24-week dosing of approximately 75 to 100 patients after an initial eight-to-ten week screening and
stabilization process.   The efficacy endpoints will include achieving eucalcemia (calcium serum levels within normal ranges) while targeting a clinically
significant reduction of calcium and vitamin D analog supplementation.  The study preparation has started and we expect top line results by the second half
of 2010.

NPSP156(D-serine)

NPSP156 is our proprietary D-serine analog of a naturally occurring neurotransmitter and endogenous ligand at the glycine site of the NMDA receptor.
We believe NPSP156 may have therapeutic potential in the treatment of epilepsy, neuropathic pain, and other central nervous system (CNS) disorders.   We
are in the process of completing the preclinical work required for filing an IND with the FDA

Royalty-Based Products and Product Candidates

Cinacalcet HCl (Sensipar® in U.S., Mimpara® in EU, REGPARA® in Japan)

Cinacalcet HCl is a small molecule compound used in treating hyperparathyroidism in patients with chronic kidney disease on dialysis and
hypercalcemia in patients with parathyroid cancer.  Hyperparathyroidism is a medical condition in which excessive amounts of parathyroid hormone circulate
in the blood.  It is typically characterized as being either primary or secondary.  Cinacalcet is a calcimimetic compound that interacts with the calcium
receptor on parathyroid cells and thereby decreases the production of parathyroid hormone in such cells.

In 1995, we licensed cinacalcet HCl to Kirin Pharma, a wholly-owned subsidiary of Kirin Holdings, for the drug's development and commercial sale in
Japan, China, North and South Korea, and Taiwan.  In 1996, we licensed worldwide rights (with the exception of the previously licensed Asian territories) to
Amgen, Inc. to develop and commercialize cinacalcet HCl for the treatment of hyperparathyroidism.

In March 2004, Amgen received FDA approval for cinacalcet HCl for the treatment of secondary hyperparathyroidism in chronic kidney disease patients
on dialysis, often referred to as "Stage V" chronic kidney disease, or CKD, patients, and for the treatment of hypercalcemia, or excess serum
calcium levels, in patients with parathyroid carcinoma.  In October 2004, Amgen received approval from the EMEA for cinacalcet HCl for the treatment of
secondary hyperparathyroidism in Stage V chronic kidney disease patients and for treatment of hypercalcemia in patients with parathyroid carcinoma.
Amgen markets cinacalcet HCl as Sensipar® in the U.S. and as Mimpara® in the EU.

In October 2007, Kirin received approval from the Japanese Pharmaceuticals and Medical Devices Agency to market cinacalcet HCl in Japan for the
treatment of patients with secondary hyperparathyroidism during maintenance dialysis.  In the first quarter of 2008, Kirin began commercializing cinacalcet
HC1 in Japan under the trade name REGPARA®.   We expect to begin receiving royalties on Kirin's sales of REGPARA during the
second half of 2008.

Cinacalcet HCl for Secondary Hyperparathyroidism

Parathyroid hormone is produced by four parathyroid glands located in the neck.  Serum levels of parathyroid hormone directly influence serum levels of
calcium. As the body needs additional calcium, the parathyroid glands release additional parathyroid hormone.  When there is excess serum calcium, the
parathyroid glands release less parathyroid hormone.

9

---



Secondary hyperparathyroidism most commonly results from chronic renal disease, which can develop in hemodialysis patients. Chronic
hypocalcemia and secondary hyperparathyroidism can also be products of pseudohypoparathyroidism, vitamin D deficiency, and intestinal malabsorption
syndromes that are characterized by inadequate vitamin D and calcium absorption.  Parathyroid hormone acts in the kidneys and bones to elevate levels of
calcium in the blood. Normal functioning healthy kidneys convert the parent vitamin D into the active form of vitamin D. Vitamin D helps in intestinal
absorption of dietary calcium. Chronic kidney disease generally results in (i) reduced intestinal absorption of calcium due to reduced vitamin D levels, and (ii)
reduced removal of phosphorus from the blood, elevating serum phosphate, which then combines with serum calcium to further reduce serum calcium
levels. This in turn leads to the chronic overproduction of parathyroid hormone as the body tries to raise serum calcium levels. Symptoms of secondary
hyperparathyroidism include excessive bone loss, bone pain and chronic, severe itching. Current treatments for secondary hyperparathyroidism, in addition
to cinacalcet, include phosphate binders and vitamin D supplements.

In October 2003, the National Kidney Foundation released Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease.
These guidelines set goals for the four key measures involved in managing secondary hyperparathyroidism: the serum level of parathyroid hormone; the
serum level of calcium; the serum level of phosphorus; and the product of the serum level of calcium multiplied by the serum level of phosphorus ("Ca
x P"); Traditional therapies such as phosphate binders and vitamin D supplements lower parathyroid hormone levels only by increasing one or more of
the other measures, particularly calcium and/or Ca x P levels. Thus, under traditional therapies, patients and their physicians have typically had to choose
between elevated parathyroid hormone or elevated calcium and/or Ca x P levels. Elevated parathyroid hormone levels cause excessive bone loss, bone
pain and chronic, severe itching, while elevated calcium and/or Ca x P levels can lead to calcification of the heart and blood vessels and increases the risk
of kidney stones.

Cinacalcet HCl is the only FDA-approved medication that simultaneously lowers all four of the key measures. By directly suppressing production of
parathyroid hormone, cinacalcet HCl also causes serum levels of calcium, phosphorus and Ca x P to decline, providing patients and their physicians an
effective treatment to avoid both elevated parathyroid hormone and elevated calcium and Ca x P.

Amgen has announced that it has elected not to file for the expanded indication for the treatment of secondary hyperparathyroidism in the setting of
chronic renal insufficiency based on a recently completed Phase 3 study with Sensipar.  Amgen indicated that all efficacy endpoints were positive,
supporting the ability of Sensipar to reduce parathyroid hormone levels in these patients; however, the occurrence of asymptomatic hypocalcemia in
Sensipar-treated patients as observed in this trial was felt to be incompatible with routine use of Sensipar in this setting.  Amgen stated that additional
analyses are underway that may permit the identification of a dosing regimen that would allow the use of Sensipar in this patient group.

Cinacalcet HCl for Primary Hyperparathyroidism

Generally, primary hyperparathyroidism is an age-related disorder that results from one or more non-cancerous tumor(s) causing the affected
parathyroid gland(s) to become enlarged and overactive, secreting excessive levels of parathyroid hormone.  As a result, serum calcium levels become
high, bones may lose calcium, and kidneys may excrete too much calcium.  Symptoms may include loss of bone density, muscle weakness, depression and
cognitive dysfunction. There are currently no approved pharmaceutical therapies for the treatment of primary hyperparathyroidism. Surgical removal of the
affected parathyroid gland(s) from the neck region is presently the only effective treatment.

Cinacalcet HCl may be a therapeutic alternative to surgery for patients with primary hyperparathyroidism. Cinacalcet HCl could be particularly useful for
the estimated 10% of primary hyperparathyroidism patients with multi-parathyroid gland involvement, whose only treatment option would otherwise be
surgery. A common side effect of the surgery is permanent hypoparathyroidism, or insufficient amounts of parathyroid hormone in the blood. Cinacalcet HCl
has not been approved by the FDA for the treatment of primary hyperparathyroidism.



Amgen has paid us $38.5 million, which consists of license fees, research support payments, milestone payments (including the milestone payment for
the filing of an NDA) and equity purchases of our common stock. Amgen will pay us up to an additional $7.0 million if it achieves other development and
regulatory milestones. Amgen is also paying us royalties, which totaled $93.0 million through 2007, from the sales of Sensipar and Mimpara in its territories.
In December 2004, we completed a private placement of $175.0 million in Secured 8.0% Notes due March 30, 2017, or

10

---



Class A Notes.   Additionally,
in August 2007, we closed a private placement of $100.0 million in Secured 15.5% Class B Notes due 2017, or Class B Notes.  The Class A Notes and
Class B Notes are non-recourse to us and are secured by our royalty and milestone payment rights under our agreement with Amgen. While the Class A
Notes and Class B Notes are outstanding, all payments from Amgen will go to the payment of interest and principal on the notes.

Kirin has paid us $25.0 million in license fees, research and development support payments and milestone payments, which include a $2.0 million
milestone payment we received in October 2007 after the approval of cinacalcet HCl in Japan.  Under the terms of our agreement, Kirin is also required to
pay us royalties on any sales of cinacalcet HCl in its territories.

Preotact®(parathyroid hormone 1-84 [rDNA origin]
injection)

In April 2004, we licensed to Nycomed the exclusive right to develop and market Preotact® (parathyroid hormone 1-84 [rDNA origin]
injection) in Europe.  In April 2006, Nycomed received authorization from the EMEA to market Preotact for the treatment of postmenopausal women with
osteoporosis at high risk for fracture.  The marketing authorization is valid in all EU-member states.    To date, Nycomed has launched Preotact in 12
markets, including Denmark, Germany, the United Kingdom, Italy, Spain, Greece, Netherlands and Austria.

In July 2007, we entered into a new license agreement with Nycomed for PREOTACT that granted Nycomed the right to commercialize PREOTACT in
all non-U.S. territories, excluding Japan and Israel.  We discuss this new license agreement in detail below under the caption "Collaborative Research,
Development and License Agreements".

In July 2007, we entered into an agreement with DRI Capital, or DRI (formerly Drug Royalty L.P.3) under which we sold to DRI our right to receive future
royalty payments arising from sales of Preotact under our license agreement with Nycomed.  Under the agreement, DRI paid us an up-front purchase price
of $50.0 million for the royalty rights.  An additional $25.0 million will be due in 2010 if certain Preotact sales thresholds are achieved.  If DRI receives two
and a half times the amount of principal advanced, our agreement with DRI will terminate and the remainder of the royalties, if any, will revert to us.  In
connection with the sales agreement, we granted DRI a security interest in our license agreement with Nycomed and certain of our patents and other
intellectual property underlying our license agreement with Nycomed.  In the event of a default by us under the agreement, DRI would be entitled to enforce
its security interest against us and the property described above.

GATTEX (Teduglutide, ex-North American Development)

In September 2007, we licensed to Nycomed the right to develop and commercialize GATTEX outside of North America for the treatment of GI
disorders.  Under the terms of the agreement, Nycomed paid us $35 million.  We also have the potential to earn up to $190.0 million in payments related to
the attainment of certain regulatory and sales milestones for SBS, the successful development of new indications and the achievement of sales-based
milestones. Additionally, the agreement provides for double-digit royalties on GATTEX sales in the licensed territories and provides an option for
development cost sharing on a 50:50 basis for indications that we elect to pursue jointly.  We are working with Nycomed to define the clinical development
path forward.

Ronacaleret (751689)

Ronacaleret (751689) is a calcilytic compound developed under a November 1993 collaborative research and worldwide exclusive license agreement
with GlaxoSmithKline (GSK) for the research, development and commercialization of calcium receptor active compounds for the treatment of osteoporosis
and other bone metabolism disorders, excluding hyperparathyroidism.  Calcilytic compounds are small molecule antagonists of the calcium receptor that
temporarily increase the secretion of the body's own parathyroid hormone, which may result in the formation of new bone.  In animal studies, we
demonstrated that intermittent increases in circulating levels of parathyroid hormone could be obtained using calcilytics. In these studies, increased levels of
parathyroid hormone were achieved by this mechanism and were equivalent to those achieved by an injection of parathyroid hormone sufficient to cause
bone growth.  As a result, we believe that orally administered calcilytic drugs that act on the parathyroid cell calcium receptors could provide a safe and
effective treatment for osteoporosis.

GSK is sponsoring a Phase 2 dose-range finding study with the 751689 compound in post-menopausal women with osteoporosis.  GSK's Phase 2,
double blind, placebo-controlled study will evaluate the efficacy and safety of compound 751689 over a twelve-month period.  The study will enroll
approximately 520 post-menopausal women with osteoporosis.  The study is designed to assess the overall efficacy, safety, and tolerability of 751689 in
comparison with placebo and two active comparators.  Outcome measures include bone mineral density of the lumbar spine and hip,

11

---



vertebral and hip
strength parameters, and biomarkers of bone turnover.  Data from this study, along with other data, will be used to select a dose of 751689 for further
evaluation based on the effect seen on bone mineral density, safety and tolerability.

Payments from GSK

GSK has paid us a total of $26.1 million for license fees, research support, milestone payments and equity purchases as part of our collaboration.  We
will receive additional payments of up to an aggregate of $32.0 million, which includes additional milestones under the December 2006 amendment noted
below, if certain clinical milestones are achieved.  Our agreement also provides for royalties on any sales by GSK of commercialized products based on
compounds identified in this collaboration. In addition to the milestone and royalty payments, we have a limited right to co-promote any products that are
developed through our collaboration and we will receive co-promotion revenue if we elect to exercise these rights.  Upon termination, the rights and licenses
we granted GSK revert to us.  In December 2006, we entered into an amendment to our agreement with GSK under which we provided GSK rights to
additional compounds discovered by us.  In connection with such amendment GSK paid a one-time licensing fee of $3.0 million and agreed to pay additional
milestone payments for the achievement of certain clinical milestones with such compounds as well as royalties on sales of such compounds should GSK
commercialize any such compounds.

Glycine Reuptake Inhibitors for Schizophrenia and Dementia

We collaborated with Janssen on glycine reuptake inhibitors to identify prospective drug candidates for schizophrenia and dementia.  Janssen has now
assumed full responsibility for the development of product candidates identified under the collaboration. We are not expending any significant resources in
the program.  In November 2001, we received a milestone payment from Janssen upon their selection of a preclinical compound for further development as
a potential treatment for schizophrenia. Under the terms of the license agreement, Janssen may seek a third party to share in the future development costs
and risks of the program and they have informed us they intend to do so. Similarly, subject to the diligence provisions, we may reacquire rights to the
program. In the event Janssen enters into a collaborative agreement with a third party or sublicenses the program, we will continue to be eligible to receive
additional milestone payments of up to $20.5 million from Janssen or a licensee, if certain milestones are met, as well as royalties on sales of any drugs
developed or sold by Janssen or a licensee.  We also have the right to co-promote in Canada any products developed under the collaboration.

Discontinued Research and Development

During 2007, we reprioritized our proprietary clinical development activities to focus on specialty indications for GI and endocrine disorders with a high
unmet medical need.  In connection with this strategic shift, we performed a detailed analysis of the required investment, development timeframe, and
development risks, associated with our clinical development of PREOS for the U.S. osteoporosis market.  While we believe PREOS remains a viable
commercial opportunity in the U.S., we elected to redirect our PREOS investment to the specialty opportunities within our pipeline and only pursue the
osteoporosis indication on a partnered, rather than proprietary basis.

To support our refocused strategy, we also discontinued our investment in early-stage research and discovery, which resulted in the October 2007 sale
of our interests in an early-stage research and development collaboration with AstraZeneca for metabotropic glutamate receptors (mGluRs) for $30.0 million
and terminated the research collaboration agreement entered into in March 2001.  Under the 2001 agreement, we were required to co-direct the research
and pay for an equal share of the preclinical research costs for a designated period.

PREOS for Osteoporosis

We have studied PREOS in a number of clinical settings to document its safety and effects on bone. The pivotal Phase 3 study, known as TOP
(Treatment of Osteoporosis with PTH), was a multi-center, randomized, double blind and placebo-controlled clinical trial designed to evaluate the potential of
PTH to reduce the risk of first and subsequent vertebral fractures in post-menopausal women.  In the TOP Study PREOS demonstrated a statistically
significant reduction in the risk of new vertebral fractures in women with and without pre-existing osteoporosis-related fractures.

In May 2005, we filed a NDA with the FDA seeking approval to market PREOS in the U.S.  On March 9, 2006, we
received notification from the FDA that the PREOS NDA is approvable.  In the approvable letter, the FDA indicated that our pivotal Phase 3 study with
PREOS demonstrated significant fracture risk reductions in post-menopausal women with osteoporosis, but noted the higher incidence of hypercalcemia
with PREOS compared to placebo.  The FDA

12

---



expressed concern regarding hypercalcemia associated with the proposed daily dose of PREOS and
requested additional clinical information. The FDA also requested additional information regarding the reliability and use of the injection device for delivery of
PREOS.

Since receiving the approvable letter from the FDA, we have had further communications with the FDA including an in-person meeting with senior staff
from the FDA's Division of Endocrine and Metabolism Drug Products. During the meeting, the FDA proposed that we generate additional clinical data
through a new clinical trial to address the hypercalcemia issue raised in the approvable letter. Since receiving the approvable letter, we have been carefully
evaluating the appropriate regulatory path forward for PREOS.  We submitted a new clinical trial protocol for PREOS to the FDA to support U.S. registration.
After multiple communications with the FDA, we believe the protocol design is now finalized.  The clinical study under the protocol is a 12-month
bone-mineral density bridging study designed to evaluate the relative efficacy and safety of three dosing regimens of PREOS (100 mcg once daily, 100 mcg
every-other-day, and 75 mcg once daily) compared to placebo in women with post-menopausal osteoporosis.  As noted above, we would only continue our
internal efforts to develop and commercialize PREOS for osteoporosis in the U.S. market if we were to secure a partner who would be willing to assume part
of the cost and risk of such development.

Osteoporosis Market Opportunity

Osteoporosis, the most common bone and mineral disorder, is an age-related disease characterized by reduced bone mineral density and increased
susceptibility to fractures. Although bone loss is a universal consequence of aging, the process is accelerated in women following menopause. Osteoporosis
is often diagnosed only after a fracture occurs. Fractures of the hip, spine or wrist can result in serious long-term disability and mortality.  The National
Osteoporosis Foundation estimates that approximately 8 million American women aged 50 and over have osteoporosis and another 34 million
men and women have low bone mass and are at high risk of osteoporotic fractures. This number is expected to rise to 52 million men and women by
2010, and is expected to climb to 61 million by 2020, making low bone mass and osteoporosis a significant health threat. In addition, 50 percent of
women over age 50 in the United States will suffer an osteoporosis-related fracture during their lifetime. The consequences of osteoporotic fractures can be
devastating, potentially resulting in pain, disfigurement, disability and death. Additionally, the costs associated with osteoporosis and osteoporosis-related
fractures are significant and in 2002 were estimated at $18.0 billion, and rising. Because post-menopausal osteoporosis is a chronic disease that
requires many years of attention and management, we believe that there exists a significant unmet need for an improved approach to treating women with
this often-devastating disease.

Current therapies for osteoporosis include anti-resorptive agents like bisphosphonates, raloxifene, a selective estrogen receptor modulator, and
calcitonin, and the anabolic agent teriparatide, a recombinant parathyroid-hormone fragment, marketed by Eli Lilly, Inc., or Lilly, in the U.S. under the brand
name Forteo®. With the exception of teriparatide, all of these therapies act to
prevent further bone loss by inhibiting bone resorption but have not been shown to stimulate new bone formation at a rate comparable to parathyroid
hormone therapy.

Collaborative Research, Development and License Agreements

We selectively enter into collaboration agreements and licenses with pharmaceutical and biotechnology companies to leverage our financial investment
in our development and commercialization programs.  We currently have collaborative research, development or license agreements with several
collaborators, including Amgen, GSK, Janssen, Kirin and Nycomed. These agreements generally include payments to us for the achievement of specified
milestones, and royalties on sales of products developed under the terms of the particular agreement. In return for these financial benefits, we grant to the
particular collaborator an exclusive license to the technology that is the subject of the collaboration as well as to the products developed under the
agreement. This strategy allows us to devote greater resources to selected programs and to pursue a greater number of programs and products than would
otherwise be possible. In addition, we believe collaborators with clinical development and marketing expertise in specific therapeutic areas will facilitate
more rapid entry into the market for our products and accelerate their acceptance by healthcare providers and third-party payers. These agreements
generally contain provisions restricting the transfer of such agreements to a third party upon a change of control of the company, sale of substantially all of
the assets of the company or a sale of a majority of the voting shares of the company, without first obtaining the written consent of the collaborator. In some
instances, the collaborator has the right to terminate the agreement on the occurrence of such an event.

13

---



From time to time, we also enter into research support agreements with various academic and other not-for-profit institutions. These agreements
generally require us to fund certain research at the institution over a specific period of time in exchange for which we acquire the right to use the results of
the research and obtain an option to exclusively license from the institution any inventions made during the term of the research on terms mutually agreed to
at that time.

GSK

In November 1993, we entered into a collaborative research and worldwide exclusive license agreement with GSK for the research, development and
commercialization of calcium receptor active compounds for the treatment of osteoporosis and other bone metabolism disorders, excluding
hyperparathyroidism.  We initially received from GSK an upfront license fee payment of $6.0 million and we later began receiving payments from GSK in
support of our research efforts under the initial research term of the agreement. GSK also has a first right to negotiate for an exclusive license regarding
other company research for indications within the field of bone metabolism disorders, and an exclusive right to negotiate for a license to compounds
developed under the agreement for indications outside the field of bone metabolism disorders, which rights expire upon termination of this agreement.

GSK has the authority and responsibility to conduct and fund all product development, including clinical trials and regulatory submissions, and
manufacturing for any compounds selected for development. We have the right to co-promote, in the U.S., products resulting from the collaboration. We
may earn up to an additional $32.0 million, which includes new milestones under the 2006 amendment noted below, upon achievement of certain additional
development or marketing milestones. GSK must also pay us royalties on any sales of products for osteoporosis and other bone metabolism disorders that
include compounds developed by GSK under the agreement, and a percentage of profits from co-promotion of such products.

To date, we have received license fee, milestone, research, and development support payments totaling $26.1 million under this agreement. GSK may
terminate the agreement on 30 days written notice. Additionally, in the event we breach the agreement, GSK may terminate the agreement on 60 days
written notice for our breach. If GSK terminates the agreement, none of their payments to us are refundable unless such termination is due to our material
breach which is not cured, in which case we would be required to return to GSK all milestone payments received by us, other than the initial license fee.
Upon termination, the rights and licenses we granted GSK revert to us. In December 2006, we entered into an amendment to our agreement with GSK
under which we provided GSK rights to additional compounds discovered by us. In connection with such amendment GSK paid a one time licensing fee of
$3.0 million and agreed to pay additional milestones payments for the achievement of certain clinical milestones with such compounds, as well as royalties
on sales of such compounds should GSK commercialize any of such compounds.

Janssen

In October 1998, we entered into a collaborative agreement with Janssen for the research, development and commercialization of new drugs for the
treatment of schizophrenia and dementia. The research phase of this collaboration ended in October 2000. In addition, Janssen controls and is responsible
for development and commercialization of the compounds, including manufacturing, and including all costs and expenses associated with the development
and commercialization efforts. While Janssen has the right to market products worldwide, we may co-promote, in Canada, any products developed under
the agreement. We will receive up to an aggregate of $21.5 million in milestone payments if Janssen reaches certain milestones, and royalties from any
product sales resulting from the collaboration. To date, we have received research support and milestone payments totaling $2.9 million under this
agreement. We may terminate the agreement if Janssen breaches the agreement and does not cure the breach within 60 days of receiving notice of the
breach. In that case, all rights granted to Janssen revert to us. Janssen may terminate, for any reason, on 90 days notice to us. If Janssen terminates, other
than for our breach, then the rights to any compounds or products are transferred to us. We can also terminate Janssen's rights if Janssen does not launch
the product in the U.S., but we must pay a royalty to Janssen on product sales after that termination. If Janssen terminates the agreement, their payments to
us are non-refundable.  Janssen has informed us that they plan to seek a third party to share in the future development costs and risks of the program. In
the event Janssen enters into a collaborative agreement with a third party or sublicenses the program, we will continue to be eligible to receive additional
milestone payments of up to $20.5 million from Janssen or a licensee, if certain milestones are met and royalties on sales of any drugs developed or sold by
Janssen or a licensee under this collaboration agreement.

14

---



Kirin

In June 1995, we entered into a collaborative research and license agreement with Kirin to develop and commercialize cinacalcet HCl and other related
compounds for the treatment of hyperparathyroidism and any other indications other than osteoporosis and bone metabolism disorders in Japan, China,
Hong Kong, North and South Korea and Taiwan. Kirin is responsible for all costs associated with developing, obtaining regulatory approvals and
commercializing products within its territories. The agreement also requires Kirin to use reasonable good faith efforts to introduce a product to market. Kirin
paid us an initial up-front license fee of $5.0 million and agreed to pay us certain milestone payments on the achievement of specified events up to an
aggregate of $13.0 million. To date, we have received $13.0 million in milestone payments from Kirin, which includes a $2.0 million milestone payment we
received in October 2007 for the approval of cinacalcet HCl in Japan. Kirin is required to pay us royalties on any sales of products containing cinacalcet HCl
or a similar compound within its territories.  We may terminate the agreement if Kirin breaches the agreement and does not cure the breach within 90 days
of receiving notice of the breach. In this event, Amgen would receive rights to develop and commercialize cinacalcet HCl for the treatment of
hyperparathyroidism and other indications except osteoporosis, in the terminated territories.  Kirin may terminate the agreement for any reason on 90 days
prior written notice, and on a country-by-country basis on specified conditions relating to market size.  If Kirin terminates the agreement, Amgen would
receive the rights to develop and commercialize cinacalcet HCl for the treatment of hyperparathyroidism and other indications, except osteoporosis, in the
terminated territories.  If Kirin terminates the agreement, their payments to us are non-refundable. We are advised that Kirin and Amgen have executed a
separate data sharing agreement related to clinical data under their separate agreements with us.  We have also authorized them to enter into a
manufacturing agreement with one or more manufacturing companies for clinical and commercial supplies.

Nycomed

In April 2004, we signed a distribution and license agreement with Nycomed, in which we granted Nycomed the exclusive right to develop and market
Preotact in Europe. Nycomed also made an equity investment in our business of $40.0 million through the purchase of 1.3 million shares of our
common stock in the form of a private placement, which closed in July 2004. The agreement also requires Nycomed to pay us up to
€20.8 million in milestone payments upon regulatory approvals and achievement of certain sales targets to purchase drug product and devices from
us and to pay us royalties on product sales. Through December 31, 2007, we have received €5.6 million in milestone payments from Nycomed.  This
agreement was superseded by our July 2007 license agreement with Nycomed described below.

In July 2007, we entered into a new license agreement with Nycomed for Preotact, which we refer to as the 2007 license agreement.  Under the 2007
license agreement, we granted to Nycomed the right to commercialize Preotact in all non-U.S. territories, excluding Japan and Israel; however, if the
compound receives marketing approval in the U.S., Nycomed's licensed rights in Canada and Mexico will revert to us or a licensee.  The 2007 license
agreement contains milestone and royalty payment obligations similar to those under our 2004 license agreement with Nycomed. Nycomed is required to
pay us royalties on sales of Preotact only in the European Union, the Commonwealth of Independent States and Turkey.  The 2007 license agreement
provides for the assumption by Nycomed of our manufacturing and supply obligations and patent prosecution and maintenance obligations under the 2004
license and distribution agreement, as of January 1, 2008.  As part of the manufacturing and supply transfer, Nycomed paid us $11.0 million for a significant
portion of our existing bulk drug inventory.  Nycomed may terminate the agreement for reasons related to the commercial viability of Preotact at any time
upon provision of six months written notice.  In that event ownership to all technology, products, regulatory filings and know how revert to us. Either party
may terminate the agreement should the other party commit a material breach that they do not cure within 60 days of written notice of such material
breach.

In September 2007, we signed a license agreement with Nycomed in which we granted Nycomed the right to develop and commercialize
GATTEX outside of North America for the treatment of GI disorders.  We received $35.0 million in up-front fees under the agreement. Under the terms of the
agreement, we have the potential to earn up to $190.0 million in development and sales milestone payments.  Additionally, the agreement provides for
double-digit royalties on GATTEX sales in the licensed territories.  Under the terms of the agreement, we were responsible to complete the original Phase 3
GATTEX clinical trials in SBS and there is an option to share future joint development costs 50:50 to advance and broaden the indications for GATTEX.
Nycomed may terminate the license agreement at will (i) prior to the first commercial sale of GATTEX or a comparable product upon 180 days written notice
to us, or (ii) after the first commercial sale of GATTEX or a comparable product upon 365 days written notice to us.  After we have received such a
termination notice, we may terminate the agreement anytime prior to the requisite period.  Either party may terminate the agreement should the other party
become insolvent or should the other party commit a material breach that is not cured within 30 days of written notice for a payment obligation and 60 days
of written notice for non-

15

---



payment obligations. Under the terms of these agreements, we recognized revenue in 2007, 2006 and 2005 of $37.4 million, $3.1
million and $234,000, respectively.

Sponsored and Government Funded Research Programs

We have entered into certain research and license agreements that require us to make research support payments to academic or research institutions
when the research is performed. Additional payments may be required upon the accomplishment of research milestones by the institutions or as license
fees or royalties to maintain the licenses.

In February 1993, we entered into a patent license agreement with The Brigham and Women's Hospital, an affiliate of Harvard University Medical
School. The patent license agreement grants us an exclusive license to certain calcium receptor and inorganic ion receptor technology covered by patents
we jointly own with the hospital. Under the patent license agreement, we are responsible for all costs relating to obtaining regulatory approval from the FDA
or any other federal, state or local government agency and carrying out any clinical studies, relating to the technology. The Brigham and Women's Hospital
is also entitled to a royalty on any sales of certain products under the patent license agreement, and we have committed to promote sales of any licensed
products for hyperparathyroidism for which we receive regulatory approval. Brigham and Women's Hospital may terminate the patent agreement if we
breach the terms of the patent agreement and do not cure the breach within 60 days of receiving notice of the breach. Certain violations of terms of the
patent agreement, if pursued by Brigham and Women's Hospital, might result in the exclusive, royalty-free license of the technology to Brigham and
Women's Hospital or other adverse consequences.

We have also entered into a license agreement with Dr. Daniel J. Drucker and his Canadian corporation 1149336 Ontario Inc. The license
agreement grants to us an exclusive license under Dr. Drucker's patent portfolio for glucagon-like peptide-2, or GLP-2, and its therapeutic uses.
Under the license agreement, we have agreed to ensure that reasonable commercial efforts are used to develop and commercialize any product covered by
the licensed patents. The agreement requires us to pay annual non-refundable license maintenance fees, royalties on sales and licensing fees, and
milestone payments. If we default on any of the material obligations under the agreement Dr. Drucker may terminate the license agreement and all
rights granted under the agreement will revert to Dr. Drucker.

New Drug Development and Approval Process

Regulation by governmental authorities in the U.S. and other countries is a significant factor in the manufacture and marketing of pharmaceuticals and in
our ongoing research and development activities. All of our product candidates will require regulatory approval by governmental agencies prior to
commercialization. In particular, all of our drug candidates are subject to rigorous preclinical testing, clinical trials, and other pre-marketing approval
requirements by the FDA and regulatory authorities in other countries. In the U.S., various federal, and in some cases state statutes and regulations also
govern or affect the manufacturing, safety, labeling, storage, record keeping and marketing of such products. The lengthy process of seeking required
approvals and the continuing need for compliance with applicable statutes and regulations require the expenditure of substantial resources. Regulatory
approval, when and if obtained, may significantly limit the indicated uses for which our products may be marketed. Further, approved drugs, as well as their
manufacturers, are subject to ongoing review and discovery of previously unknown problems with such products may result in restrictions on their
manufacture, sale or use or in their withdrawal from the market.

The steps required by the FDA before our drug candidates may be marketed in the U.S. include, among other things:

| | • |  | The performance of preclinical laboratory and animal tests and formulation studies;                                                                 
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------
| | • |  | The submission to the FDA of an Investigational New Drug application, or IND, which must become effective before human clinical
trials may commence;
| | • |  | The completion of adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug; and                          
| | • |  | The submission and FDA approval of a new drug application or NDA.                                                                                   

The testing and approval process requires substantial time, effort and financial resources and we cannot be certain that any approvals for any of our
proposed products will be granted on a timely basis, if at all.

Prior to commencing a clinical trial, we must submit an IND to the FDA. The IND becomes effective 30 days after receipt by the FDA, unless within the
30-day period, the FDA raises concerns or questions with respect to the conduct of the trial. In such a case, the IND sponsor and the FDA must resolve any
outstanding concerns before the study can begin. As a result, the submission of an IND may not necessarily result in FDA authorization to commence a

16

---



clinical trial. Further, an independent institutional review board at the medical center or centers proposing to conduct the trial must review and approve the
plan for any clinical trial before it commences.

Human clinical trials are typically conducted in three sequential phases that may overlap:

| | • |  | Phase 1: the drug is initially introduced into healthy human subjects or patients and tested for safety, dosage tolerance, absorption,
metabolism, distribution and excretion.                                                                                                                                                       
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | • |  | Phase 2: involves studies in a limited patient population to identify possible adverse effects and safety risks, to determine the efficacy
of the product for specific targeted diseases and to determine optimal dosage.                                                                                                            
| | • |  | Phase 3: when Phase 2 evaluations demonstrate that a dosage range of the product is effective and has an acceptable safety profile,
Phase 3 trials are undertaken to further evaluate dosage and clinical efficacy and to further test for safety in an expanded patient population at
geographically dispersed clinical study sites.



The results of product development, preclinical studies and clinical trials are submitted to the FDA as part of an NDA. The FDA may withhold approval
for an NDA if the applicable regulatory criteria are not satisfied or may require additional clinical data. Even if such data are submitted, the FDA may
ultimately decide that the NDA does not satisfy the criteria for approval.  If approved, the FDA may withdraw product approval if compliance with regulatory
standards is not maintained or if problems occur after the product reaches the market. In addition, the FDA may require testing and surveillance programs to
monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based
on the results of these post-marketing programs.

The FDA's fast track program is intended to facilitate the development and expedite the review of drugs intended for the treatment of serious or
life-threatening diseases and that demonstrate the potential to address unmet medical needs for such conditions. Under this program, the FDA can, for
example, review portions of an NDA for a fast track product before the entire application is complete, thus potentially beginning the review process at an
earlier time. We cannot guarantee that the FDA will grant any requests that we may make for fast track designation, that any fast track designation would
affect the time of review, or that the FDA will approve the NDA submitted for any of our drug candidates, whether or not fast track designation is granted.
Additionally, the FDA's approval of a fast track product can include restrictions on the product's use or distribution, such as permitting use only for specified
medical procedures or limiting distribution to physicians or facilities with special training or experience.  Approval of fast track products can be conditional
with a requirement for additional clinical studies after approval.

Satisfaction of the above FDA requirements or similar requirements of state, local and foreign regulatory agencies typically takes several years and the
actual time required may vary substantially, based upon the type, complexity and novelty of a product or indication.

Government regulation may delay or prevent marketing of potential products for a considerable period and impose costly procedures upon our or our
partner's activities. The FDA or any other regulatory agency may not grant any approvals on a timely basis, if at all.  Success in early-stage clinical trials
does not assure success in later-stage clinical trials. Data obtained from clinical activities are not always conclusive and may be susceptible to varying
interpretations, which could delay, limit or prevent regulatory approval.  Even if a product receives regulatory approval, the approval may be significantly
limited to specific indications and dosages. Further, even if regulatory approval is obtained, later discovery of previously unknown problems with a product
may result in restrictions on the product or even complete withdrawal of the product from the market. Delays in obtaining, or failures to obtain regulatory
approvals may have a material adverse effect on our business.  In addition, we cannot predict what adverse governmental regulations may arise from future
U.S. or foreign governmental action.

Any products manufactured or distributed by us or our partners pursuant to FDA approvals are subject to pervasive and continuing regulation by the
FDA, including record-keeping requirements and reporting of adverse experiences with the drug. Drug manufacturers are required to register their
establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA for compliance with current Good
Manufacturing Practice, or cGMP, regulations, which impose certain procedural and documentation requirements.  We cannot be certain that we, or our
present or future suppliers, will be able to comply with the cGMP regulations and other FDA regulatory requirements.

17

---



Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a
disease or condition that affects fewer than 200,000 individuals in the U.S. Orphan drug designation must be requested before submitting an NDA. After the
FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan
drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. If a product that has orphan drug
designation subsequently receives FDA approval for the disease for which it has such designation, the product is entitled to orphan exclusivity. For example,
the FDA may not approve any other applications to market the same drug for the same disease, except in very limited circumstances, for seven years. We
intend to file for orphan drug designation for those diseases that meet the criteria for orphan exclusivity. Although obtaining FDA approval to market a
product with orphan drug exclusivity can be advantageous, there can be no assurance that it would provide us with a material commercial advantage.

Steps similar to those in the U.S. must be undertaken in virtually every other country comprising the market for our product candidates before any such
product can be commercialized in those countries. The approval procedure and the time required for approval vary from country to country and may involve
additional testing. There can be no assurance that approvals will be granted on a timely basis, or at all. In addition, regulatory approval of prices is required
in most countries other than the U.S. There can be no assurance that the resulting prices would be sufficient to generate an acceptable return to us.

Patents and Other Proprietary Technology

Our intellectual property portfolio includes patents, patent applications, trade secrets, know-how and trademarks. Our success will depend in part on our
ability to obtain additional patents, maintain trade secrets and operate without infringing the proprietary rights of others, both in the U.S. and in other
countries. We periodically file patent applications to protect the technology, inventions and improvements that may be important to the development of our
business. We rely on trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive
position.

We file patent applications on our own behalf as assignee and, when appropriate, have filed and expect to continue to file, applications jointly with our
collaborators. These patent applications cover compositions of matter, methods of treatment, methods of discovery, use of novel compounds and novel
modes of action, as well as recombinantly expressed receptors and gene sequences that are important in our research and development activities. Some of
our principal intellectual property rights related to processes, compounds, uses and techniques related to calcium receptor science are protected by issued
U.S. patents. We intend to file additional patent applications relating to our technology and to specific products, as we think appropriate.

We hold patents directed to potential therapeutic products such as new chemical entities, pharmaceutical compositions and methods of treating
diseases. We hold patents directed also to nucleic acid and amino acid sequences of novel cellular receptors and methods of screening for compounds
active at such cellular receptors. We continue actively to seek patent protection for these and related technologies in the U.S. and in foreign countries.

We have been issued approximately 188 patents in the U.S. Ten issued U.S. patents cover technology related to parathyroid hormone. These patents
have expiration dates (not including any patent term extensions) ranging from 2008 to 2017. Eight issued U.S. patents cover technology related to calcilytic
compounds. These patents have expiration dates (not including any patent term extensions) ranging from 2016 to 2019. Fifteen issued U.S. patents cover
calcimimetics (including cinacalcet HCl) and calcium receptor technology. These patents have expiration dates (not including any patent term extensions)
ranging from 2013 to 2017. Thirteen issued U.S. patents cover technology related to GATTEX and GLP-2, certain of which are licensed from 1149336
Ontario Inc. These patents have expiration dates (not including any patent term extensions) ranging from 2015 to 2018. Thirteen issued U.S. patents cover
technology related to glycine reuptake inhibitors. These patents have expiration dates (not including any patent term extensions) ranging from 2016 to 2022.
Our intellectual property portfolio also includes patents in countries outside the U.S., which also cover the technology referenced above.



18

---



patentable subject matter, we generally have the first right to negotiate for license rights related to that subject matter. Any resulting license would be expected to
require us to pay royalties on net sales of licensed products.

Competition

Competition in the pharmaceutical industry is intense and is expected to continue to increase.  Many competitors, including biotechnology and
pharmaceutical companies, are actively engaged in research and development in areas that we, or our partners, are also developing or commercializing
products, including the fields of gastrointestinal disorders, hyperparathyroidism, osteoporosis, and central nervous system disorders.

Our competition for GATTEX will depend on the applicable indication. For example, we have been granted orphan drug designation in SBS, where very
few competitors exist. Current therapies for SBS include parenteral nutrition, or PN, and somatropin (rDNA origin) for injection, a human growth hormone
marketed by Serono and glutamine in combination with somatropin (rDNA origin) for injection. PN is a costly option as studies show that it can cost from
$86,000 to $150,000 per year. In addition, there can be a negative impact on patient quality of life as well as morbidities associated with PN. Treatment with
somatropin (rDNA origin) for injection is limited to 28 days and requires a specialized diet. If approved by the FDA for SBS, GATTEX would compete directly
with somatropin (rDNA origin) for injection.  Necrotizing enterocolitis and gastrointestinal mucositis are other specialty indications where few competitors
exist.  Treatment for Crohn's includes several classes of drugs including aminosalicylates, immunosuppressants, antibiotics, corticosteroids,
immunomodulators, and the biologics.  While GATTEX, if approved by the FDA for the treatment of Crohn's, would compete with these therapies as a
potential treatment for Crohn's, GATTEX may create utility in this indication either as a mono or combination therapy.

We have been granted orphan drug status for NPSP558 for the treatment of hypoparathyroidism.  Presently, the only available treatments approved for
hypoparathyroidism include life-long supplementation of calcium and Vitamin D.  Severe hypocalcemia can be life threatening and is treated with
intravenous calcium.  We believe, with its ideal mechanism of action, NPSP558 has the potential to meet the unmet need of this chronic condition.

Many of our competitors have substantially greater financial, technical, marketing and personnel resources.  In addition, some of them have
considerable experience in preclinical testing, human clinical trials and other regulatory approval procedures.  Moreover, certain academic institutions,
governmental agencies and other research organizations are conducting research in the same areas in which we are working.  These institutions are
becoming increasingly aware of the commercial value of their findings and are more actively seeking patent protection and licensing arrangements to collect
royalties for the technology that they have developed. These institutions may also market competitive commercial products on their own or through joint
ventures and will compete with us in recruiting highly qualified personnel.  Our ability to compete successfully will depend, in part, on our ability to:

| | • |  | outsource activities critical to the advancement of our product candidates and manage those companies to whom such activities are
outsourced;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------
| | • |  | outsource manufacturing capabilities for our proprietary products;                                                                           
| | • |  | leverage our established collaborations and enter into new collaborations for the development of our products;                               
| | • |  | identify new product candidates;                                                                                                             
| | • |  | develop products that reach the market first;                                                                                                
| | • |  | develop products that are superior to other products in the market;                                                                          
| | • |  | develop products that are cost-effective and competitively priced; and                                                                       
| | • |  | obtain and enforce patents covering our technology.                                                                                          

Manufacturing

We do not have internal manufacturing capabilities to produce supplies of GATTEX or any of our other product candidates to support clinical trials or
commercial launch of these products, if they are approved.  We also do not have internal manufacturing capabilities to produce supplies of the injection
devices used to administer GATTEX and NPSP558.  We are dependent on third parties for manufacturing, supply, and storage of our product candidates
and injection devices.  If we are unable to contract for a sufficient supply of our product candidates or injection devices on acceptable terms or if we
encounter delays or difficulties in the manufacturing or supply process or our relationships with our manufacturers, we may not have sufficient product or
injection devices to conduct or complete our clinical trials or support preparations for the commercial launch of our product candidates, if approved.

19

---



We depend on a number of contract manufacturers to supply key components of GATTEX and NPSP558. For instance, we have entered into an
agreement with Boehringer Ingelheim Austria GmbH (BI) to produce bulk supplies of the active pharmaceutical ingredients of GATTEX and NPSP558 for
our clinical and any future commercial requirements.   We expect BI to be able to produce sufficient bulk supplies of GATTEX and NPSP558 on a timely
basis. Nevertheless, manufacturing biological products is complex and no assurances can be provided that BI will be able to produce commercial quantities
of bulk drug product in a timely manner or at all.

We have entered into a manufacturing agreement with Cangene Corporation, or Cangene, for the production of finished supplies of GATTEX.  Cangene
is currently our sole source for our fill and finish clinical supplies for GATTEX.  Although Cangene has only produced GATTEX for our clinical requirements,
we anticipate that Cangene will be able to produce sufficient finished commercial supplies of GATTEX, if GATTEX receives marketing approval from the
FDA.  Nevertheless, the fill and finish aspect of the manufacturing process is complex and no assurances can be provided that Cangene will be able to
produce commercial quantities of GATTEX in a timely manner or at all.

We depend on Vetter Pharma-Fertigung GmbH, or Vetter, for the production of finished supplies of NPSP558 for clinical use. Because the "fill and
finish" aspect of the manufacturing process for NPSP558 requires the use of Vetter's proprietary technology, Vetter is our sole source for finished
supplies of NPSP558. The fill and finish aspect of the manufacturing process for NPSP558 is complex and no assurances can be provided that Vetter will be
able to produce sufficient finished supplies of NPSP558 to satisfy our commercial requirements in a timely manner, or at all. Since we have not received
marketing approval for NPSP558 in the U.S., we currently do not have a formal manufacturing and supply agreement with Vetter for the production of
commercial quantities of finished supplies of NPSP558.  If we are unable to reach such an agreement on favorable terms, we may be required to seek
another manufacturing partner to produce finished supplies of NPSP558, which could result in significant added costs and delays.

We rely on Ypsomed AG, or Ypsomed, to manufacture clinical supplies of the injection pen device used for the administration of PREOS. Ypsomed is
our sole source for the pen and, absent the development of an alternative method of delivery of PREOS, we will remain dependent on Ypsomed's
technology to produce the pen in commercial quantities if the FDA approves PREOS. The pen has been specifically designed and developed for delivery of
PREOS. Manufacturing drug delivery devices such as the pen is a complex process and no assurances can be provided that Ypsomed will be able to
produce commercial quantities of the pen in a timely manner or at all. Since we have not received marketing approval for PREOS in the U.S., we currently
do not have a formal agreement with Ypsomed for the production of commercial quantities of injection pen devices.  If we are unable to reach such an
agreement on favorable terms, we may be required to seek another manufacturing partner to develop and produce a drug delivery device for the
administration of PREOS, which could result in significant added costs and delays.

We have experienced certain instances where our contract manufacturers have produced product and pens that have not met our required
specifications and could not be used in clinical trials or for commercialization. Any extended disruption or termination of our relationship with any of our
contract manufacturers could materially harm our business and financial condition and adversely affect our stock price.

A more complete description of the risks associated with our business, including our contract manufacturers, can be found below in Section 1A of
this Annual Report titled "Risk Factors."

Employees

As of March 6, 2008, we had approximately 41 employees.   None of our employees is covered by a collective bargaining agreement and we believe our
relationship with our employees is good.

Trademarks

"NPS", "NPS Pharmaceuticals" and "PREOS" are our registered trademarks. In addition, Preotact is our registered
trademark in the U.S.  All other trademarks, trade names or service marks appearing in this Annual Report on Form 10-K are the property of their respective
owners.

20

---



Available Information

Our Internet address is www.npsp.com. We make available free of charge on or through our Internet website our Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or
15(d) of the Securities Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.

|ITEM 1A. | Risk Factors.
|-------- | -------------

The following information sets forth risk factors that could cause our actual results to differ materially from those contained in forward-looking statements
we have made in this Annual Report on Form 10-K and those we may make from time to time. If any of the following risks actually occur, our business,
results of operation, prospects or financial condition could be harmed. These are not the only risks we face. Additional risks not presently known to us, or
that we currently deem immaterial, may also affect our business operations.

Risks Related to Our Business

We have a history of operating losses. We expect to incur net losses and we may never achieve or maintain profitability.

With the exception of 2007 and 1996, we have not been profitable since our inception in 1986.  As of December 31, 2007, we had an
accumulated deficit of approximately $873.2 million. To date, our revenue from product sales has been in the form of royalty payments from Amgen on sales
of cinacalcet HCl, royalty payments from Nycomed on sales of Preotact, milestone revenue from our collaborative agreements with Nycomed and product
sales to Nycomed of Preotact. We have assigned the right to receive future royalties from Amgen for sales of cinacalcet HCl to a wholly owned subsidiary.
The subsidiary has pledged the right to such royalties as security for the repayment of certain notes. As of December 31, 2007, there were approximately
$260.7 million of these notes outstanding, including $100.0 million of Class B Notes issued in August 2007 and $6.2 million of additional notes issued as
interest on the Class B Notes.  The principal amount of the notes issued in August will continue to increase through the issuance of the additional notes in
lieu of payment of cash interest until the initial class of notes is paid in full.  Though the notes are non-recourse to us, if the Amgen royalties are not sufficient
to repay the notes on a timely basis, or at all, then we may never receive additional cash flows from future royalty payments from Amgen on sales of
cinacalcet HCl.  In July 2007, we assigned our Preotact royalty interest to DRI.  Under our agreement with DRI, the Preotact royalty interest will return to us
only if DRI receives a certain sum of royalties based on Nycomed's net sales of Preotact.  We are entirely dependent on Nycomed for sales of Preotact and
we cannot assure you that DRI will receive royalties in an amount sufficient to cause the Preotact royalty interest to be returned to us. We have not
generated any other revenue from product sales to date, and it is possible that we will never have sufficient product sales revenue to achieve profitability.
We expect to continue to incur losses for at least the next several years as we and our collaborators and licensees pursue clinical trials and research and
development efforts. To become profitable, we, alone or with our collaborators and licensees, must successfully develop, manufacture and market our
current product candidates and continue to identify, develop, manufacture and market new product candidates. It is possible that we will never have
significant product sales revenue or receive significant royalties on our licensed product candidates.

We may require additional funds.

Currently, we are not a self-sustaining business and certain economic, operational and strategic factors may require us to secure additional funds. If we
lack sufficient funding at any time in the future, we may not be able to develop or commercialize our products, take advantage of business opportunities or
respond to competitive pressures.

Our current and anticipated operations require substantial capital. We expect that our existing cash, cash equivalents, and short-term investments will
sufficiently fund our current and planned operations through at least 2008. However, our future capital needs will depend on many factors, including the
extent to which we enter into collaboration agreements with respect to any of our proprietary product candidates, receive royalty and milestone payments
from our collaborators and make progress in our development and commercialization activities. Our capital requirements will also depend on the magnitude
and scope of these activities, our ability to maintain existing and establish new collaborations, the terms of those collaborations, the success of our
collaborators in developing and marketing products under their respective collaborations with us, our ability to effectively out-source our clinical
development, regulatory, data management, research, quality control and assurance, and other activities, the success of

21

---



our contract manufacturers in
producing clinical and commercial supplies of our product candidates and drug delivery devices on a timely basis and in sufficient quantities to meet our
requirements, competing technological and market developments, the time and cost of obtaining regulatory approvals, the cost of preparing, filing,
prosecuting, maintaining and enforcing patent and other rights and our success in acquiring and integrating complementary products, technologies or
companies. We do not have committed external sources of funding, and we cannot assure you that we will be able to obtain additional funds on acceptable
terms, if at all. If adequate funds are not available, we may be required to:

| | • |  | engage in equity financings that would be dilutive to current stockholders;                                                                                                                                                   
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | • |  | delay, reduce the scope of or eliminate one or more of our development programs;                                                                                                                                              
| | • |  | obtain funds through arrangements with collaborators or others that may require us to relinquish rights to technologies, product
candidates or products that we would otherwise seek to develop or commercialize ourselves; or
| | • |  | license rights to technologies, product candidates or products on terms that are less favorable to us than might otherwise be available.                                                                                      

If we do not receive regulatory approval to market GATTEX in a timely manner, or at all, or if we obtain regulatory approval to market GATTEX but the
approved label is not competitive with then existing competitive products, our business will be materially harmed and our stock price may be adversely
affected.

We are developing GATTEX as a potential treatment for a variety of gastrointestinal disorders, including SBS. In an intent-to-treat analysis of our pivotal
Phase 3 study, forty-six percent (46%) of patients receiving the lower dose of GATTEX (N=35) responded and achieved a highly statistically significant
reduction in PN compared to placebo (p=0.007).  Twenty-five percent (25%) of patients receiving the higher dose of GATTEX (N=32) responded and
showed a trend in the difference between the treatment group and placebo, but this did not reach statistical significance (p=0.161).  In this Phase 3 study,
there were no statistical differences in the incidence rates of adverse events or serious adverse events among the treatment groups when compared to
placebo.  Two low-dose patients gained independence from and discontinued PN by week 16 and a third high-dose patient discontinued PN at the end of
treatment. The study's criteria for conducting the statistical analysis of the primary endpoint required that the results for the high-dose group show statistical
significance before considering the results of the low-dose group.  Given GATTEX's orphan designation in SBS and the statistically strong (p=0.007) and
clinically meaningful findings in the low-dose group, we met with the FDA to discuss the regulatory requirements for the development of GATTEX for SBS.
During our meeting, the FDA recommended that we conduct a confirmatory Phase 3 study prior to submitting an NDA.  We plan to initiate this study and are
currently finalizing a protocol to address the FDA's comments and will incorporate results from our Phase 3 extension study

The process of structuring and commencing a second Phase 3 clinical study will require significant resources and could be time consuming and subject
to unanticipated delays and cost.  For example, the FDA may not concur with our proposed protocol for the study, which would delay and could increase the
cost of the study.  Even if the FDA concurs with our protocol, there are no assurances that the results of the second Phase 3 study based on the protocol will
show the required safety and efficacy data to support an NDA for GATTEX or regulatory approval of GATTEX by the FDA.

If we are ultimately unable to obtain regulatory approval to commercialize GATTEX in a timely manner, or at all, or if the FDA approved indication, side
effect and adverse events profile, and product distribution requirements are not competitive with existing competitor products, our ability to generate
revenues to sustain our operations will be substantially impaired, our business will be materially harmed and our stock price may be adversely affected.
Biotechnology stock prices, including our stock price, have declined significantly in certain instances where companies have failed to meet expectations with
respect to FDA approval or the timing for FDA approval.

If we do not receive regulatory approval to market NPSP558 for hypoparathyroidism in the U.S. in a timely manner, or at all, or if we obtain regulatory
approval to market NPSP558 for hypoparathyroidism but the approved label is not competitive with then existing competitive products, our business may be
materially harmed and our stock price may be adversely affected.

We are developing NPSP558 for hypoparathyroidism.  Historically, we have developed this compound as PREOS for osteoporosis.  We are currently
supporting an investigator-initiated trial to explore the use of NPSP558 as a hormone replacement therapy to treat hypoparathyroidism. The study calls for
50 patients, most of them already enrolled, to be dosed with NPSP558 every-other-day for a period of up to 24 months.  The objectives of this study
are to understand the effect of parathyroid hormone 1-84 on bone quality in hypoparathyroidism, and demonstrate the safety and efficacy

22

---



of NPSP558 in
this indication.  We are also initiating a pivotal registration study to demonstrate the safety and efficacy of NPSP558 as a potential therapy to treat
hypoparathyroidism.  This study would call for 75 to 100 patients to be dosed with NPSP558 for a period of 24 weeks.  Prior to commencement of dosing,
patients will complete an eight-to-ten week screening and stabilization process.

If we are unable to obtain U.S. regulatory approval for NPSP558 for hypoparathyroidism or PREOS for  osteoporosis, or if we receive regulatory
approval to market NPSP558 or PREOS in the U.S. but the FDA-approved indication, side effect and adverse events profile, and product distribution
requirements are not competitive with existing competitor products, our business may be materially harmed and our stock price may be adversely affected.
Biotechnology stock prices, including our stock price, have declined significantly in certain instances where companies have failed to meet expectations with
respect to FDA approval or the timing for FDA approval.



We may never develop any more commercial drugs or other products that generate revenues.

Sensipar (Mimpara in Europe) and Preotact are our only sources, to date, of commercial revenues.  We also expect to begin receiving royalty revenue
on Kirin's sales of REGPARA in Japan in the second half of 2008.  Our remaining product candidates will require significant additional development, clinical
trials, regulatory approvals and additional investment before their potential commercialization. As part of our corporate restructuring, we now outsource
substantially all of our research, and development activities. If we are unable to transition to an outsourcing company in an efficient and timely manner, the
development of our product candidates will be delayed.  Additionally, our product development efforts may not lead to commercial drugs for a number of
reasons, including the failure of our product candidates to be safe and effective in clinical trials or because we have inadequate financial or other resources
to pursue the programs through the clinical trial process.  Even if we are able to commercialize one or more of our product candidates, we cannot assure
you that such product candidates will find acceptance in the medical community.

We have limited internal capacity to conduct preclinical testing and clinical trials, and our dependence on contract research organizations could result in
delays in and additional costs for our drug development efforts.

We have historically had limited internal resources and capacity to perform preclinical testing and clinical trials. In addition, we restructured our
operations in 2007, which included reductions in our worldwide workforce as well as a transition to an outsourcing business strategy.  Because of these
reductions and our limited internal resources to perform preclinical and clinical testing, we rely almost entirely on contract research organizations, or CROs,
to perform preclinical testing and clinical trials for drug candidates that we choose to develop without a collaborator. If the CROs that we hire to perform our
preclinical testing and clinical trials or our collaborators or licensees do not meet deadlines, do not follow proper procedures, or a conflict arises between us
and our CROs, our preclinical testing and clinical trials may take longer than expected, may be delayed or may be terminated. If we were forced to find a
replacement CRO to perform any of our preclinical testing or clinical trials, we may not be able to find a suitable replacement on favorable terms, or at all.
Even if we were able to find another CRO to perform a preclinical test or clinical trial, the delay in the test or clinical trial may result in significant
expenditures.  Events such as these may result in delays in our obtaining regulatory approval for our drug candidates or our ability to commercialize our
products and could result in increased expenditures that would adversely affect our operating results.

In addition, for some of our drug candidates, we plan to contract with collaborators or licensees to advance those candidates through later-stage, more
expensive clinical trials, rather than invest our own resources to perform these clinical trials.  Depending on the terms of our agreements with these
collaborators or licensees, we may not have any control over the conduct of these clinical trials, and in any event we would be subject to the risks associated
with depending on collaborators or licensees to develop these drug candidates, as described below.

We have no internal manufacturing capabilities.  We depend on third parties, including a number of sole suppliers, for the manufacturing, supply, and
storage of our product candidates and drug delivery devices to be used for our commercial launch of products, our partner's commercial launch of products,
and in our clinical trials. We have experienced instances where our contract manufacturers have produced product and drug delivery devices, which have
not complied with our specifications and could not be used for commercial use or clinical trials. Product

23

---



introductions and clinical trials may be delayed or
suspended if the manufacture or supply of our products or drug delivery devices are delayed, interrupted or discontinued.

We do not have internal manufacturing capabilities to produce supplies of GATTEX, NPSP558 or any of our other product candidates to support clinical
trials or commercial launch of these products, if they are approved. We also do not have internal manufacturing capabilities to produce supplies of the
injection devices used to administer GATTEX and NPSP558.  We are dependent on third parties for manufacturing, supply, and storage of our product
candidates and injection devices. If we are unable to contract for a sufficient supply of our product candidates or injection devices on acceptable terms, or if
we encounter delays or difficulties in the manufacturing or supply process or our relationships with our manufacturers, we may not have sufficient product or
injection devices to conduct or complete our clinical trials or support preparations for the commercial launch of our product candidates, if approved.

We depend on a number of contract manufacturers to supply key components of GATTEX, NPSP558, and PREOS. For instance, we have entered into
an agreement with Boehringer Ingelheim Austria GmbH, or BI, to produce bulk supplies of the active pharmaceutical ingredients of GATTEX, NPSP558, and
PREOS for clinical use and our commercial requirements if we receive FDA approval.   We expect BI to be able to produce sufficient bulk supplies of
GATTEX NPSP558, and PREOS on a timely basis. Nevertheless, manufacturing biological products is complex and no assurances can be provided that BI
will be able to produce commercial quantities of bulk drug product in a timely manner or at all.

We have entered into a manufacturing agreement with Cangene Corporation, or Cangene, for the production of finished supplies of GATTEX.  Cangene
is currently our sole source for our fill and finish clinical supply requirements of GATTEX.  Although Cangene has only produced small quantities of GATTEX
for our clinical requirements, we anticipate that Cangene will be able to produce sufficient finished commercial supplies of GATTEX, if GATTEX receives
marketing approval from the FDA.  Nevertheless, the fill and finish aspect of the manufacturing process is complex and no assurances can be provided that
Cangene will be able to produce commercial quantities of GATTEX in a timely manner or at all.

We also depend on Vetter Pharma-Fertigung GmbH, or Vetter, for the production of finished supplies of NPSP558 for clinical use. Because the "fill
and finish" aspect of the manufacturing process for NPSP558 requires the use of Vetter's proprietary technology, Vetter is our sole source for finished
supplies of NPSP558. The fill and finish aspect of the manufacturing process for NPSP558 is complex and no assurances can be provided that Vetter will be
able to produce sufficient finished supplies of NPSP558 to satisfy our commercial requirements in a timely manner, or at all. Since we have not received
marketing approval for NPSP558 in the U.S., we currently do not have a formal manufacturing and supply agreement with Vetter for the production of
commercial quantities of finished supplies of NPSP558.  If we are unable to reach such an agreement on favorable terms, we may be required to seek
another manufacturing partner to produce finished supplies of NPSP558, which could result in significant added costs and delays.

We rely on Ypsomed AG, or Ypsomed, to manufacture clinical supplies of the injection pen device used for the administration of PREOS. Ypsomed is
our sole source for the pen and, absent the development of an alternative method of delivery of PREOS, we will remain dependent on Ypsomed's
technology to produce the pen in commercial quantities if the FDA approves PREOS. The pen has been specifically designed and developed for delivery of
PREOS. Manufacturing drug delivery devices such as the pen is a complex process and no assurances can be provided that Ypsomed will be able to
produce commercial quantities of the pen in a timely manner or at all. Since we have not received marketing approval for PREOS in the U.S., we currently
do not have a formal agreement with Ypsomed for the production of commercial quantities of injection pen devices.  If we are unable to reach such an
agreement on favorable terms, we may be required to seek another manufacturing partner to develop and produce a drug delivery device for the
administration of PREOS, which could result in significant added costs and delays.

We have experienced certain instances where our contract manufacturers have produced product and pens that have not met our required
specifications and could not be used in clinical trials or for commercialization. Any extended disruption or termination of our relationship with any of our
contract manufacturers could materially harm our business and financial condition and adversely affect our stock price.

Dependence on contract manufacturers for commercial production involves a number of additional risks, many of which are outside our control. These
additional risks include:

| | • |  | there may be delays in scale-up to quantities needed for clinical trials and commercial launch or failure to manufacture such quantities
to our specifications, or to deliver such quantities on the dates we require;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

24

---



| | • |  | our current and future manufacturers are subject to ongoing, periodic, unannounced inspection by the FDA and corresponding state
and international regulatory authorities for compliance with strictly enforced cGMP regulations and similar foreign standards, and we do not have control
over our contract manufacturers' compliance with these regulations and standards;                                        
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | • |  | our current and future manufacturers may not be able to comply with applicable regulatory requirements, which would prohibit them
from manufacturing products or drug delivery devices for us;                                                                                                                                                                                                                      
| | • |  | if we need to change to other commercial manufacturing contractors, the FDA and comparable foreign regulators must approve these
contractors prior to our use, which would require new testing and compliance inspections, and the new manufacturers would have to be educated in, or
themselves develop substantially equivalent processes necessary for, the production of our products and drug delivery devices;
| | • |  | our manufacturers might not be able to fulfill our commercial needs, which would require us to seek new manufacturing arrangements
that could result in substantial delays and higher costs; and                                                                                                                                                                                                                    
| | • |  | we may not have intellectual property rights, or may have to share intellectual property rights, to any improvements in the
manufacturing processes or new manufacturing processes for our products or drug delivery devices.                                                                                                                                                                                       

Any of these factors could cause us to delay or suspend clinical trials, regulatory submission, required approvals or commercialization of our products
under development, entail higher costs and result in our inability to commercialize our products effectively.

Clinical trials are long, expensive and uncertain processes and the FDA may ultimately not approve any of our product candidates. We cannot assure
you that data collected from preclinical and clinical trials of our product candidates will be sufficient to support approval by the FDA, the failure of which could
delay our profitability and adversely affect our stock price.

Before we receive regulatory approval for the commercial sale of our product candidates, our product candidates are subject to extensive preclinical
testing and clinical trials to demonstrate their safety and efficacy. Clinical trials are long, expensive and uncertain processes. Clinical trials may not be
commenced or completed on schedule, and the FDA may not ultimately approve our product candidates for commercial sale. Further, even if the results of
our preclinical studies or clinical trials are initially positive, it is possible that we will obtain different results in the later stages of drug development or that
results seen in clinical trials will not continue with longer-term treatment. Drugs in late stages of clinical development may fail to show the desired safety and
efficacy traits despite having progressed through initial clinical testing. For example, positive results in early Phase 1 or Phase 2 clinical trials may not be
repeated in larger Phase 2 or Phase 3 clinical trials. All of our potential drug candidates are prone to the risks of failure inherent in drug development. The
clinical trials of any of our drug candidates, including GATTEX and NPSP558, could be unsuccessful, which would prevent us from commercializing the
drug. Our failure to develop safe, commercially viable drugs would substantially impair our ability to generate revenues and sustain our operations and
would materially harm our business and adversely affect our stock price.

If we fail to maintain our existing or establish new collaborative relationships, or if our collaborators do not devote adequate resources to the
development and commercialization of our licensed drug candidates, we may have to reduce our rate of product development and may not see products
brought to market or be able to achieve profitability.

Our strategy for developing, manufacturing and commercializing our products includes entering into various relationships with other
pharmaceutical and biotechnology companies to advance many of our programs. We have granted development, commercialization and marketing rights to
a number of our collaborators for some of our key product development programs, including cinacalcet HCl, Preotact, GATTEX, calcilytics, and glycine
reuptake inhibitors.  Our collaborators typically have full control over those efforts in their territories and the resources they commit to the programs.
Accordingly, the success of the development and commercialization of product candidates in those programs depends on their efforts and is beyond our
control. For us to receive any significant milestone or royalty payments from our collaborators, they must advance drugs through clinical trials, establish the
safety and efficacy of our drug candidates, obtain regulatory approvals and achieve market acceptance of those products. As a result, if a collaborator elects
to terminate its agreement with us with respect to a research program, our ability to advance the program may be significantly impaired or we may elect to
discontinue funding the program altogether.  For example, in early 2002, Abbott terminated its agreement with respect to isovaleramide, and Forest
Laboratories terminated its agreement with us with respect to ALX-0646.  As a result, these programs were discontinued.

25

---



As part of our product development and commercialization strategy, we evaluate whether to seek collaborators for our product candidates. If we elect to
collaborate, we may not be able to negotiate collaborative arrangements for our product candidates on acceptable terms, if at all. If we are unable to
establish collaborative arrangements, we will either need to increase our expenditures and undertake the development and commercialization activities at
our own expense or delay further development of the affected product candidate.

Collaborative agreements, including our existing collaborative agreements, pose the following risks:

| | • |  | our contracts with collaborators may be terminated and we may not be able to replace our collaborators;                                                                                                                                                                           
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | • |  | the terms of our contracts with our collaborators may not be favorable to us in the future;                                                                                                                                                                                       
| | • |  | our collaborators may not pursue further development and commercialization of compounds resulting from their collaborations with us
or may pursue the same on a different regulatory pathway from us;                                                                             
| | • |  | a collaborator with marketing and distribution rights to one or more of our product candidates may not commit enough resources to the
marketing and distribution of such candidates;                                                                                              
| | • |  | disputes with our collaborators may arise, leading to delays in or termination of the research, development or commercialization of our
product candidates, or resulting in significant litigation or arbitration;                                                                
| | • |  | contracts with our collaborators may fail to provide significant protection if one or more of them fail to perform;                                                                                                                                                               
| | • |  | in some circumstances, if a collaborator terminates an agreement, or if we are found to be in breach of our obligations, we may be
unable to secure all of the necessary intellectual property rights and regulatory approval to continue developing the same compound or product;
| | • |  | our collaborators could independently develop, or develop with third parties, drugs that compete with our products; and                                                                                                                                                           
| | • |  | we may be unable to meet our financial or other obligations under our collaborative agreements.                                                                                                                                                                                   

We cannot assure you that our current or future collaborative efforts will be successful. If our collaborative efforts fail, our
business and financial condition would be materially harmed.

We have never marketed, sold or distributed a product and may need to rely on third parties to successfully market and sell our products and generate
revenues.

Due to the delay in obtaining regulatory approval of PREOS for osteoporosis, we have eliminated all commercial sales and related field operations. As a
result, if and when we receive regulatory approval to market and sell one or more of our product candidates we will have to either build a new commercial
organization or enter into agreements with contract sales organizations to provide sales, marketing, market research and product planning services. Our
ability to gain market acceptance and generate revenues will be substantially dependent upon our ability to build a commercial organization and/or enter into
such agreements on favorable terms and to manage the efforts of those service providers successfully. We may also benefit from establishing a relationship
with one or more companies with existing distribution systems and direct sales forces to market any or all of our product candidates; however, we cannot
assure you that we will be able to enter into or maintain agreements with these companies on acceptable terms, if at all.

Because of the uncertainty of pharmaceutical pricing, reimbursement and healthcare reform measures, we may be unable to sell our products profitably.

The availability of reimbursement by governmental and other third-party payers affects the market for any pharmaceutical product. These third-party
payers continually attempt to contain or reduce the costs of healthcare. There have been a number of legislative and regulatory proposals to change the
healthcare system and further proposals are likely. Medicare's policies may decrease the market for our products that are designed to treat patients with
age-related disorders, such as osteoporosis and hyperparathyroidism. Significant uncertainty exists with respect to the reimbursement status of newly
approved healthcare products.

In addition, third-party payers are increasingly challenging the price and cost-effectiveness of medical products and services. We might not be able to
sell our products profitably or recoup the value of our investment in product development if reimbursement is unavailable or limited in scope, particularly for
product candidates addressing small patient populations, such as GATTEX for the treatment of SBS and NPSP558 for hypoparathyroidism.

26

---



In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing
drug pricing vary widely from country to country. We expect that there will continue to be a number of federal and state proposals to implement
governmental pricing controls. While we cannot predict whether such legislative or regulatory proposals will be adopted, the adoption of such proposals
could have a material adverse effect on our business, financial condition and profitability.

Because of intense competition and technological change in the pharmaceutical industry, the marketplace may not accept our products, and we may not
be able to compete successfully against other companies in our industry and achieve profitability.

The pharmaceutical and biotechnology industries are intensely competitive. We have competitors in both the U.S. and internationally including major
multi-national pharmaceutical companies, chemical companies, biotech companies, universities and other research organizations. Many of our competitors
have drug products that have already been approved or are in development, and operate large, well-funded research and development programs in these
fields. Many of our competitors have substantially greater financial and management resources, superior intellectual property positions and greater
manufacturing, marketing and sales capabilities, areas in which we have limited or no experience. In addition, many of our competitors have significantly
greater experience than we do in undertaking preclinical testing and clinical trials of new or improved pharmaceutical products and obtaining required
regulatory approvals. Consequently, our competitors may obtain FDA and other regulatory approvals for product candidates sooner and may be more
successful in manufacturing and marketing their products than we or our collaborators, which could render our product candidates obsolete and non-
non-competitive.

Existing and future products, therapies and technological approaches will compete directly with the products we seek to develop. Current and
prospective competing products may provide greater therapeutic benefits for a specific problem, may offer easier delivery or may offer comparable
performance at a lower cost. Any product candidate that we develop and that obtains regulatory approval must then compete for market acceptance and
market share. Our product candidates may not gain market acceptance among physicians, patients, healthcare payers and the medical community. Further,
any products we develop may become obsolete before we recover any expenses we incurred in connection with the development of these products. As a
result, we may never achieve profitability.

We may be unable to obtain patents to protect our technologies from other companies with competitive products,

The patent positions of pharmaceutical and biotechnology firms are uncertain and involve complex legal and factual questions. The U.S. Patent and
Trademark Office has not established a consistent policy regarding the breadth of claims that it will allow in biotechnology patents. If it allows broad claims,
the number and cost of patent interference proceedings in the U.S. and the risk of infringement litigation may increase. If it allows narrow claims, the risk of
infringement may decrease, but the value of our rights under our patents, licenses and patent applications may also decrease. In addition, the scope of the
claims in a patent application can be significantly modified during prosecution before the patent is issued. Consequently, we cannot know whether our
pending applications will result in the issuance of patents or, if any patents are issued, whether they will provide us with significant proprietary protection or
will be circumvented, invalidated, or found to be unenforceable. Until recently, patent applications in the U.S. were maintained in secrecy until the patents
issued, and publication of discoveries in scientific or patent literature often lags behind actual discoveries. Patent applications filed in the U.S. after
November 2000 generally will be published 18 months after the filing date unless the applicant certifies that the invention will not be the subject of a foreign
patent application. We cannot assure you that, even if published, we will be aware of all such literature. Accordingly, we cannot be certain that the named
inventors of our products and processes were the first to invent that product or process or that we were the first to pursue patent coverage for our inventions.

Our commercial success depends in part on our ability to maintain and enforce our proprietary rights. If third parties engage in activities that infringe our
proprietary rights, our management's focus will be diverted and we may incur significant costs in asserting our rights. We may not be successful in asserting
our proprietary rights, which could result in our patents being held invalid or a court holding that the third party is not infringing, either of which would harm
our competitive position. In addition, we cannot assure you that others will not design around our patented technology.

Moreover, we may have to participate in interference proceedings declared by the U.S. Patent and Trademark Office or other
analogous proceedings in other parts of the world to determine priority of invention and the validity of

27

---



patent rights granted or applied for, which could result
in substantial cost and delay, even if the eventual outcome is favorable to us. We cannot assure you that our pending patent applications, if issued, would be
held valid or enforceable. Additionally, many of our foreign patent applications have been published as part of the patent prosecution process in such
countries. Protection of the rights revealed in published patent applications can be complex, costly and uncertain.

Additionally, under the Hatch-Waxman Act, a generic pharmaceutical manufacturer may file an Abbreviated New Drug Application, or ANDA, seeking
permission to market a generic version of one of our products prior to the expiration of our relevant patents. For example, a generic pharmaceutical
manufacturer could file an ANDA for cinacalcet HCl as early as March 2008.  Such a filing is an act of patent infringement and may result in our filing patent
infringement litigation to enforce our proprietary rights. There can be no assurance that we would prevail in such an action and our business may be
adversely affected should we fail to prevail in any such litigation.

In order to protect goodwill associated with our company and product names, we rely on trademark protection for our marks. We registered the
"PREOS" trademark with the U.S. Patent and Trademark Office.  A third party may assert a claim that the PREOS mark is confusingly similar to
its mark, and such claims or the failure to timely register the PREOS mark or objections by the FDA could force us to select a new name for PREOS, which
could cause us to incur additional expense or delay its introduction to market.

We also rely on trade secrets, know-how and confidentiality provisions in our agreements with our collaborators, employees and consultants to protect
our intellectual property. However, these and other parties may not comply with the terms of their agreements with us, and we might be unable to
adequately enforce our rights against these people or obtain adequate compensation for the damages caused by their unauthorized disclosure or use. Our
trade secrets or those of our collaborators may become known or may be independently discovered by others.

Our products and product candidates may infringe the intellectual property rights of others, which could increase our costs and negatively affect our
profitability.

Our success also depends on avoiding infringement of the proprietary technologies of others. In particular, there may be certain issued patents and
patent applications claiming subject matter that our collaborators or we may be required to license in order to research, develop or commercialize at least
some of our product candidates, including GATTEX, NPSP558 and PREOS.  In addition, third parties may assert infringement or other intellectual property
claims against us based on our patents or other intellectual property rights. An adverse outcome in these proceedings could subject us to significant
liabilities to third parties, require disputed rights to be licensed from third parties or require us to cease or modify our use of the technology. If we are
required to license such technology, we cannot assure you that a license under such patents and patent applications will be available on acceptable terms
or at all. Further, we may incur substantial costs defending ourselves in lawsuits against charges of patent infringement or other unlawful use of another's
proprietary technology.

We are subject to extensive government regulations that may cause us to cancel or delay the introduction of our products to market.

Our business is subject to extensive regulation by governmental authorities in the U.S. and other countries. Prior to marketing in the United States, a
drug must undergo rigorous testing and an extensive regulatory approval process implemented by the FDA under federal law, including the Federal Food,
Drug and Cosmetic Act. To receive approval, our collaborators or we must demonstrate, among other things, with substantial evidence from well-controlled
clinical trials that the product is both safe and effective for each indication where approval is sought. Depending upon the type, complexity and novelty of the
product and the nature of the disease or disorder to be treated, the approval process can take several years and require substantial expenditures. Data
obtained from testing are susceptible to varying interpretations that could delay, limit or prevent regulatory approvals of our products. Drug testing is subject
to complex FDA rules and regulations, including the requirement to conduct human testing on a large number of test subjects. Our collaborators, the FDA or
we may suspend human trials at any time if a party believes that the test subjects are exposed to unacceptable health risks. We cannot assure you that any
of our product candidates will be safe for human use. Other countries also have extensive requirements regarding clinical trials, market authorization and
pricing. These regulatory requirements vary widely from country to country, but, in general, are subject to all of the risks associated with U.S. approvals.

If any of our products receive regulatory approval, the approval will be limited to those disease states and conditions for which the product is safe and
effective, as demonstrated through clinical trials. In addition, results of preclinical studies and clinical trials with respect to our products could subject us to
adverse product labeling

28

---



requirements that could harm the sale of such products. Even if regulatory approval is obtained, later discovery of previously
unknown problems may result in restrictions of the product, including withdrawal of the product from the market. Further, governmental approval may subject
us to ongoing requirements for post-marketing studies. Even if we obtain governmental approval, a marketed product, its respective manufacturer and its
manufacturing facilities are subject to unannounced inspections by the FDA and must comply with the FDA's cGMP and other regulations. These regulations
govern all areas of production, record keeping, personnel and quality control. If a manufacturer fails to comply with any of the manufacturing regulations, it
may be subject to, among other things, product seizures, recalls, fines, injunctions, suspensions or revocations of marketing licenses, operating restrictions
and criminal prosecution. Other countries also impose similar manufacturing requirements. Our promotional materials and sales activities are governed by
FDA regulation. The FDA may require us to withdraw promotional material, to issue corrected material, or to cease promotion resulting in loss of credibility
with our customers, reduced sales revenue or increased costs.

Because of our restructuring initiatives and the related reductions in our workforce, we have reallocated certain employment responsibilities and have
increased our dependence on third parties to perform certain corporate functions.

We have restructured our operations, which included reductions in our workforce as well as a transition to an outsourcing business strategy. The
reductions have resulted in the loss of numerous long-term employees, the loss of institutional knowledge and expertise and the reallocation of certain
employment responsibilities, all of which could adversely affect operational efficiencies, employee performance and retention. In addition, because of these
reductions, we are outsourcing certain corporate functions, which makes us more dependent on third parties for the performance of these functions in
connection with our business and product candidates. To the extent that we are unable to effectively reallocate employee responsibilities, retain key
employees, establish and maintain agreements with competent third-party contractors on terms that are acceptable to us, or effectively manage the work
performed by any retained third-party contractors, our ability to advance our business or product candidates may be significantly impaired and our stock
price may be adversely affected.

If we fail to attract and retain key executives and employees, the development and commercialization of our products may be adversely affected.

We depend heavily on our executive, managerial and clinical personnel. To the extent that we lose any of these key personnel, our ability to develop
products and become profitable may suffer. The risk of being unable to retain key personnel may be increased by the fact that we have not entered into
long-term employment contracts with our executives or employees. Our future success will also depend in large part on our ability to attract and retain
qualified executives and employees in the future. We face competition for personnel from other companies, academic institutions, government entities and
other organizations.  In particular, we are highly dependent on members of our executive team to manage our business.  In connection with our restructuring
initiatives and our plan to transition the company to an outsourcing business strategy, certain members of our executive team are no longer with the
company and new executive team members have been hired.  Our transition in expertise, as with any company, will take time, resources and may result in
unexpected expense and delay to our business programs.  Each new member of our executive team is highly qualified, important to our business and would
be difficult to replace.  We are also dependent on several key employees who would also be difficult to replace.  If we are unable to retain our executives
and key employees, our ability to operate under the outsourcing business model and compete in our industry may be hindered and our business may suffer.
Each of our executives and key employees is an employee at will and, despite our retention efforts; we cannot assure you that they will remain with the
company.

We are involved in securities class action litigation and shareholder derivative litigation that could become expensive and divert management's attention
from operating our business.

NPS and certain of our officers have been named as defendants in a consolidated securities class action lawsuit.  In addition, certain of our officers,
directors and former officers and directors have been named as defendants in several shareholder derivative lawsuits.  The initial derivative litigation has
been dismissed, but the court has granted the plaintiff leave to amend and re-file the complaint.  Additional derivative actions have been filed as well, which
mimic the previously dismissed case but relate to GATTEX.  We believe that the claims in these lawsuits are without merit and intend vigorously to defend
our self and the other defendants against the claims.  We maintain insurance for claims of this nature, which we believe is adequate.  Moreover, we believe,
based on information currently available, that the filing and ultimate outcome of the lawsuits will not have a material impact on our financial position.
However, our extended involvement in these actions may become expensive and divert management's attention and resources from

29

---



operating our business.
Additionally, we may not be successful in having these lawsuits dismissed or settled within the limits of our insurance or at all.

If product liability claims are brought against us or we are unable to obtain or maintain product liability insurance, we may incur substantial liabilities that
could reduce our financial resources.

The clinical testing and commercial use of pharmaceutical products involves significant exposure to product liability claims.   We have obtained limited
product liability insurance coverage for our clinical trial in humans; however, our insurance coverage may be insufficient to protect us against all product
liability damages.  Further, liability insurance coverage is becoming increasingly expensive and we might not be able to obtain or maintain product liability
insurance in the future on acceptable terms or in sufficient amounts to protect us against product liability damages. Regardless of merit or eventual outcome,
liability claims may result in decreased demand for a future product, injury to reputation, withdrawal of clinical trial volunteers, loss of revenue, costs of
litigation, distraction of management and substantial monetary awards to plaintiffs. Additionally, if we are required to pay a product liability claim, we may not
have sufficient financial resources to complete development or commercialization of any of our product candidates and our business and results of
operations will be adversely affected.

Research and development involves hazardous materials and we must comply with environmental laws and regulations, which can be expensive and
restrict how we do business.

Research and development activities involve the controlled use of hazardous materials, radioactive compounds and other potentially dangerous
chemicals and biological agents. Although we believe our contractors' safety procedures for these materials comply with governmental standards, we cannot
eliminate the risk of accidental contamination or injury from these materials. We currently have insurance, in amounts and on terms typical for companies in
businesses that are similarly situated, that could cover all or a portion of a damage claim arising from our use of hazardous and other materials. However, if
an accident or environmental discharge occurs, and we are held liable for any resulting damages, the associated liability could exceed our insurance
coverage and our financial resources.

Risks Related to Our Common Stock and Notes Payable

Our stock price has been and will continue to be volatile and an investment in our common stock could suffer a decline in value.

You should consider an investment in our common stock as risky and invest only if you can withstand a significant loss and wide fluctuations in the
market value of your investment. We receive only limited attention by securities analysts and frequently experience an imbalance between supply and
demand for our common stock. The market price of our common stock has been highly volatile and is likely to continue to be volatile. Factors affecting our
common stock price include:

| | • |  | fluctuations in our operating results;                                                                                                                                                                                                                 
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | • |  | announcements of technological innovations or new commercial products by us, our collaborators or our competitors;                                                                                                                                     
| | • |  | published reports by securities analysts;                                                                                                                                                                                                              
| | • |  | the progress of our and our collaborators' clinical trials, including our and our collaborators' ability to produce clinical supplies of our
product candidates on a timely basis and in sufficient quantities to meet our clinical trial requirements;
| | • |  | governmental regulation and changes in medical and pharmaceutical product reimbursement policies;                                                                                                                                                      
| | • |  | developments in patent or other intellectual property rights;                                                                                                                                                                                          
| | • |  | publicity concerning the discovery and development activities by our licensees;                                                                                                                                                                        
| | • |  | public concern as to the safety and efficacy of drugs that we and our competitors develop;                                                                                                                                                             
| | • |  | our ability to meet market expectations with respect to FDA approval or the timing for FDA approval for our product candidates; and.                                                                                                                   
| | • |  | general market conditions.                                                                                                                                                                                                                             

Anti-takeover provisions in our Certificate of Incorporation, Bylaws, stockholder rights plan and under Delaware law
may discourage or prevent a change of control.

30

---



Provisions of our Certificate of Incorporation and Bylaws and Section 203 of the Delaware General Corporation Law could delay or prevent a
change of control of us.  For example, our Board of Directors, without further stockholder approval, may issue preferred stock that could delay or prevent a
change of control as well as reduce the voting power of the holders of common stock, even to the extent of losing control to others.  In addition, our Board of
Directors has adopted a stockholder rights plan, commonly known as a "poison pill," that may delay or prevent a change of control.

Substantial future sales of our common stock by us or by our existing stockholders could cause our stock price to fall.

Additional equity financings or other share issuances by us could adversely affect the market price of our common stock.  Sales by existing stockholders
of a large number of shares of our common stock in the public market and the sale of shares issued in connection with strategic alliances, or the perception
that such additional sales could occur, could cause the market price of our common stock to drop.

Royalty revenues received from Amgen on sales of cinacalcet HCl may not be sufficient to cover the interest and principal payments on the Secured
8.0% Notes and/or 15.5% Notes due March 30, 2017.  As a result, we would have to either voluntarily make such payments out of available cash
resources or risk forfeiture of certain royalty rights under the Amgen agreement.

In December 2004, we completed a private placement of $175.0 million in secured 8.0% Notes due March 30, 2017.  In August 2007, our
subsidiary completed a private placement of $100 million of secured 15.5% notes due March 30, 2017.  All of these secured notes are
non-recourse to us and are secured by certain royalty and our related rights under our agreement with Amgen.  Additionally, the sources for interest
payments and principal repayment of the secured notes are limited to royalty and milestone payments received from Amgen.  If the revenues received from
Amgen are insufficient to cover the interest and other payments due under the secured notes, we would have to forfeit our rights to future royalties and other
rights under the Amgen agreement unless we make the payments due out of our available cash resources.  If we make the payments, our cash resources
would be significantly reduced and we may not have sufficient cash resources to fund our programs and operations.  The principal amount of the secured
notes issued in August 2007 will increase through the issuance of additional notes in lieu of payment of cash interest until the initial class of secured notes is
paid in full.  If we do not make the payments due under the secured notes then we risk losing the future revenue stream from Amgen for sales of cinacalcet
HCl, which could adversely affect future cash resources and we would lose rights to the technology licensed to Amgen under the Amgen agreement.

Our liquidity and future cash flow may not be sufficient to cover interest payments on our 5.75% Convertible Notes due 2014 or to repay the notes at
maturity.

Our ability to make interest payments on and to repay at maturity or refinance our 5.75% convertible notes due 2014 will depend on our ability to
maintain sufficient cash and generate future cash flow.  Other than in 2007, we have never generated positive annual cash flow from our operating activities,
and we may not generate or sustain positive cash flows from operations in the future.  Our ability to generate sufficient cash flow will depend on our ability to
commercialize our proprietary product candidates in the U.S. and the ability of our partners to commercialize and successfully market our partnered
products throughout the world.  We cannot assure you that we, or our partners, will be successful in developing, commercializing and marketing our product
candidates.   Various factors such as general economic, financial, competitive, legislative and regulatory conditions may affect our and our partners' ability to
successfully commercialize our product candidates and thereby limit our ability to generate future cash flow to repay our 5.75% convertible notes.

Additionally, the 5.75% convertible notes provide for certain events of default, including payment defaults, breaches of covenants and certain events of
bankruptcy, insolvency and reorganization.  If any event of default occurs and is continuing, the principal amount of the notes, plus accrued and unpaid
interest, if any, may be declared immediately due and payable.   The notes also provide that if a fundamental change occurs to our business, as defined in
the note, at any time prior to the maturity of the note, then the holder shall have the right to require us to redeem the notes, or any portion thereof plus
accrued interest and liquidated damages.   There can be no assurance that, if any of the foregoing events were to occur, we would have the ability repay the
principal amount and interest accrued under the notes and/or any additional monies owed in connection with the acceleration of the notes.

Conversion of the 5.75% Convertible Notes will dilute the ownership interest of our existing stockholders, including holders who had previously
converted their notes.

31

---



The conversion of some or all of the 5.75% convertible notes will dilute the ownership interests of existing stockholders. Any sales in the public market
of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the
notes may encourage short selling by market participants.

Changes in interest rates can affect the fair value of our investment portfolio and the debt we have issued and its interest earnings.

Our interest rate risk exposure results from our investment portfolio and our secured notes.  Our primary objectives in managing our investment portfolio
are to preserve principal, maintain proper liquidity to meet operating needs and maximize yields.  The securities we hold in our investment portfolio are
subject to interest rate risk.  At any time, sharp changes in interest rates can affect the fair value of the investment portfolio and its interest earnings.
Currently, we do not hedge these interest rate exposures.  We have established policies and procedures to manage exposure to fluctuations in interest
rates.  We place our investments with high quality issuers, limit the amount of credit exposure to any one issuer, and do not use derivative financial
instruments in our investment portfolio.  Our 8.0% secured notes due March 30, 2017, our 15.5% secured notes due March 30, 2017, and our 5.75%
convertible notes due August 7, 2014 each have a fixed interest rate.  The fair value of the convertible notes is affected by changes in the interest rates and
by changes in the price of our common stock.  The fair values of the secured notes are affected by changes in the interest rates and by historical rates of
royalty revenues from cinacalcet HCl sales.

Our Auction Rate Securities (ARS) are currently illiquid and may never be saleable due to the recent deterioration of the U.S. credit and capital
markets.  If the U.S. capital markets, including the markets for our auction- rate securities, deteriorate further or adversely affect other investments
in our portfolio, our auction-rate securities may never be saleable and our financial condition and cash flow may be adversely impacted.

Our investment portfolio includes investments in certain auction rate securities or ARS.  ARS are variable interest rate securities tied to short-term
interest rates with nominal long-term maturities.  ARS have interest rate resets through a modified Dutch auction, at predetermined short-term intervals,
usually every 7, 28, 35, or 49 days.  With the liquidity issues experienced in global credit and capital markets, our ARS portfolio has recently experienced
multiple unsuccessful auctions as the amount of securities submitted for sale has exceeded the amount of purchase orders.  Given the unsuccessful
auctions, our ARS are illiquid until there is a successful auction for them and therefore, we have classified ARS marketable securities (except Sold ARS -
see below) to non-current assets as of December 31, 2007.

The estimated value of our ARS holdings at December 31, 2007, was $53.3 million, which reflects $2.4 million less than our carrying value of $55.7
million.  In establishing the estimated market value of our ARS, we have used the market value determined by our investment advisors.  The market values
were determined using a proprietary valuation model using the quality of the underlying securities or assets securing the ARS investments, the market
values of comparable securities, the quality of credit enhancement (if any) applicable to the specific security, estimated time to maturity or unwinding of the
arrangement, an analysis of the terms of the indentures and other factors depending on the individual ARS.

In March 2008, we agreed to sell certain of our ARS investments or the Sold ARS, to one of our investment advisors for $26.0 million.  The market value
as of December 31, 2007 and the principal value of the Sold ARS were $24.9 million and $30.1 million, respectively. For the year ended December 31,
2007, we recognized an other-than-temporary loss of $4.1 million on the Sold ARS in the Consolidated Statement of Operations and $1.1 million is recorded
as an unrealized loss in the Accumulated Other Comprehensive Loss section of the Consolidated Balance Sheet at December 31, 2007 on the Sold ARS.
Excluding the Sold ARS, we believe that the decrease in market value on our ARS is temporary in nature due to the underlying assets securing the ARS, the
AAA rating by Standard & Poors,  as of December 31, 2007 and February 28, 2008, our belief that historical liquidity will return to the global credit and
capital markets,  and our intent and ability to hold to recovery.   None of the ARS are backed by sub-prime mortgages.  Accordingly, a $1.3 million
unrealized loss was recorded at December 31, 2007 in Accumulated Other Comprehensive loss section of the Balance Sheet related to the ARS, excluding
the Sold ARS.  The market value of these ARS, excluding the Sold ARS,were estimated to be $28.4 million at December 31, 2007 and $26.4 million at
February 29, 2008.

If uncertainties in the credit and capital markets continue, these markets deteriorate further or if we experience rating downgrades on any investments in
our portfolio, including our ARS, the market value of our investment portfolio may decline further, which we may determine is an other-than-temporary
impairment.  This would result in a realized loss and would negatively affect our financial position, results of operations and liquidity.

32

---



We believe that based on our current cash, cash equivalents and marketable securities balances at December 31, 2007, the current lack of liquidity in
the credit and capital markets will not have a material impact on our liquidity, cash flow, financial flexibility or ability to fund its operations in 2008.

|ITEM 1B. | Unresolved Staff Comments.
|-------- | --------------------------

None.

|ITEM 2. | Properties.
|------- | -----------

During 2007, we consolidated our business operations into one facility in Bedminster, New Jersey.  In Bedminster, we lease approximately 33,500
square feet of administrative space.  The Bedminster lease will expire in February 2010.  Prior to entering into the Bedminster lease, we leased
approximately 76,500 square feet of administrative office space in Parsippany, New Jersey.  The Parsippany lease expired in October 2007.  Historically, we
have also maintained laboratory and administrative facilities in Toronto, Canada; Mississauga, Canada; and Salt Lake City, Utah.  During 2007, we closed
each of these facilities as part of our restructuring initiative. To facilitate the transition of our Canadian operations to New Jersey, we continue to lease
approximately 1,020 square feet of office space in Toronto.  The lease expires on August 31, 2008.

In July 2007, we entered into a lease termination agreement with the Mars Discovery District, pursuant to which our lease for laboratory and office space
located in Toronto, Canada was terminated.  Under the agreement, we sold our tenant improvements to a third party for $2.4 million.  Also in July 2007, we
sold our laboratory and office building located in Salt Lake City to the University of Utah for $21.0 million.  As part of the sale, the University of Utah released
us from all obligations under a 40-year ground lease for land upon which the facility is located. In June 2007, we sold our land, laboratory, and office building
located in Mississauga, Canada to Transglobe Property Management Services Ltd. in Trust for $4.4 million.

|ITEM 3. | Legal Proceedings.
|------- | ------------------

Securities Class Action.

A consolidated shareholders' securities class action lawsuit is currently pending against us and certain of our present and former officers and directors
in the U.S. District Court for the District of Utah, Central Division, as Case No. 2:06cv00570 DAK. By order dated September 14, 2006, the court
consolidated four separately filed lawsuits into this action. By order dated November 17, 2006, the court appointed lead plaintiff and counsel for the
proposed class. On January 16, 2007, the lead plaintiff and its counsel filed a consolidated amended complaint asserting two federal securities claims on
behalf of lead plaintiff and all other shareholders of NPS who purchased publicly traded shares of NPS between August 7, 2001, and May 2, 2006, which
period is referred to in this paragraph as the "class period." The consolidated complaint asserts two claims: a claim founded upon Section 10(b)
of the Securities Exchange Act of 1934, or the 1934 Act, and SEC Rule 10b-5 promulgated thereunder, which is asserted against all defendants, and a claim
founded upon Section 20(a) of the 1934 Act, which is asserted against the individual defendants.  Both claims are based on the allegations that, during the
class period, NPS and the individual defendants made false and misleading statements to the investing public concerning PREOS. The consolidated
complaint alleges that false and misleading statements were made during the class period concerning the efficacy of PREOS as a treatment for
postmenopausal osteoporosis, the potential market for PREOS, the dangers of hypercalcemic toxicity as a side effect of injectable PREOS, and the
prospects of FDA approval of our NDA for injectable PREOS. The complaint also alleges claims of option backdating and insider trading of NPS stock during
the class period.  The consolidated complaint seeks compensatory damages in an unspecified amount, unspecified equitable or injunctive relief, and an
award of an unspecified amount for plaintiff's costs and attorneys fees.

On March 19, 2007, Defendants filed a motion to dismiss the consolidated complaint, which the court denied on July 3, 2007. On August 1, 2007, the
court entered a scheduling order setting a trial date for the action on April 20, 2009. On November 1, 2007, lead plaintiff filed its motion to certify the class of
shareholders that it seeks to represent in the action. On January 30, 2008, defendants filed an opposition to this motion, and it is currently pending before
the court. Although defendants believe the motion should be denied, no assurances can be given in this regard.  If lead plaintiff's motion for class
certification is granted, the parties will continue to engage in the discovery process and prepare for trial.

33

---



We believe the claims are without merit and intend to vigorously defend NPS and the related defendants in this action.  We maintain insurance for
actions of this nature, which we believe is adequate.



On August 22, 2006, an NPS shareholder filed a shareholder derivative action against certain of our present and former officers and directors.  This
action, which names NPS as a nominal defendant but is asserted on NPS's behalf, is pending in the Third Judicial District Court of Salt Lake County, State
of Utah, as Case No. 060913838.  The complaint asserts allegations similar to those asserted in the securities class action described above and also
alleges that the defendant directors and officers violated their fiduciary duties by making the allegedly false and misleading statements to the investing public
concerning PREOS.  The derivative complaint seeks compensatory damages in an unspecified amount, unspecified equitable or injunctive relief and an
award of an unspecified amount for plaintiff's costs and attorneys fees.

Defendants filed a motion to dismiss the lawsuit, which the Court granted by order dated July 8, 2007.   In the order, the Court also granted plaintiff
leave to propound a books and records inspection demand under Utah law and to amend his shareholder derivative complaint.   Plaintiff served a books and
records inspection demand, in response to which NPS produced the requested documents.   On December 14, 2007, defendants filed a motion to stay the
lawsuit pending resolution of the securities class action and similar shareholder derivative lawsuits filed in U.S. District Court for the District of Utah, which is
described below.   Plaintiff has opposed defendants' motion to stay, which is currently pending before the court.   If the court does not grant defendants'
motion to stay, plaintiff will be permitted to file an amended shareholder derivative complaint.

Three additional shareholder derivative suits are pending against certain of our present and former officers and directors in the U.S. District Court for the
District of Utah.  These lawsuits are titled Wagner v. Tombros, et al. (filed July 24, 2007), Alvarez v. Jackson, et al. (filed August 17, 2007), and Sutton v.
Tombros, et al. (filed November 14, 2007).  These lawsuits also allege the defendants made false and misleading statements concerning PREOS, and that
because of these statements, the defendants breached their fiduciary duties.  In addition, the Sutton complaint alleges that the defendants made false and
misleading statements concerning GATTEX, and because of these statements, the defendants breached their fiduciary duties.  All three lawsuits seek
compensatory damages in an unspecified amount, unspecified equitable or injunctive relief and an award of an unspecified amount for plaintiff's costs and
attorneys fees.

The Wagner, Alvarez, and Sutton complaints have not yet been served on any of the defendants, and therefore the deadlines to respond to these
complaints have not been set.

We intend to vigorously defend against all the purported shareholder derivative actions, which we believe are without merit and were brought in the
name of the corporation in violation of controlling law.  We maintain insurance for actions of this nature, which we believe is adequate.

|ITEM 4. | Submission of Matters to a Vote of Security Holders.
|------- | ----------------------------------------------------



No matter was submitted to the stockholders during the fourth quarter of 2007.





34

---



PART II



|ITEM 5. | Market for Registrant's Common Equity and Related Stockholder Matters
|------- | ---------------------------------------------------------------------

Since May 26, 1994, our common stock has been quoted on the Nasdaq National Market under the symbol
"NPSP." In connection with NASDAQ's transition to a national securities exchange in October 2006, our common stock is now quoted on the
Nasdaq Global Market under the same symbol. The following table sets forth, for the periods indicated, the high and low closing sales prices for our
common stock, as reported on the Nasdaq Global Market.



|               |  | High |       | Low
|-------------- |  | ---- | ----- | ---
|2006           |  |      |       |    
|First Quarter  |  | $    | 15.35 |    
|Second Quarter |  |      | 9.13  |    
|Third Quarter  |  |      | 4.75  |    
|Fourth Quarter |  |      | 5.36  |    
|2007           |  |      |       |    
|First Quarter  |  | $    | 4.55  |    
|Second Quarter |  |      | 4.54  |    
|Third Quarter  |  |      | 6.00  |    
|Fourth Quarter |  |      | 5.68  |    

As of March 6, 2008, there were approximately 187 holders of record of our common stock.

We have never declared or paid cash dividends on capital stock. We intend to retain any future earnings to finance growth and development and
therefore do not anticipate paying cash dividends in the foreseeable future.

We have adopted a policy and implemented procedures allowing directors and officers to effect sales of the Company's securities under SEC Rule
10b5-1. Under this rule, directors and officers may adopt a prearranged contract, instructions, or written plan arranging for the sale of Company securities on
specified conditions. To this effect, prearranged plans have already been implemented and additional such plans may be adopted from time to time.

35

---



|ITEM 6. | Selected Financial Data.
|------- | ------------------------

The selected consolidated financial data presented below are for each fiscal year in the five-year period ended
December 31, 2007. This is derived from, and qualified by reference to, our audited consolidated financial statements and notes thereto appearing
elsewhere in this Form 10-K.

Consolidated Statements of Operations Data:

|                                                          |  |   | Years Ended December 31,
|--------------------------------------------------------- |  | - | ------------------------
|                                                          |  |   | 2007                    
|(in thousands, except per share amounts)                  |  |   | Restated (5)            
|Revenues:                                                 |  |   |                         
|Product sales                                             |  | $ | 20,310                  
|Royalties                                                 |  |   | 49,626                  
|Milestones and license fees                               |  |   | 16,312                  
|Total revenues                                            |  |   | 86,248                  
|                                                          |  |   |                         
|Operating expenses:                                       |  |   |                         
|Cost of goods sold                                        |  |   | 6,180                   
|Cost of royalties                                         |  |   | 4,659                   
|Cost of license fees                                      |  |   | 1,547                   
|Research and development                                  |  |   | 38,723                  
|Selling, general and administrative                       |  |   | 26,998                  
|Restructuring charges                                     |  |   | 13,386                  
|Total operating expenses                                  |  |   | 91,493                  
|                                                          |  |   |                         
|Other operating (gains) losses:                           |  |   |                         
|Gain on sale of assets held for sale                      |  |   | (1,826)                 
|Gain on sale of fixed assets                              |  |   | (6,384)                 
|Gain on sale of assets (2)                                |  |   | (30,000)                
|Write-down of long-lived assets                           |  |   | -                       
|Amortization of purchased intangibles                     |  |   | -                       
|Merger costs and termination fees (3)                     |  |   | -                       
|Total Other operating (gains) losses                      |  |   | (38,210)                
|Operating income (loss)                                   |  |   | 32,965                  
|Other income (expense), net                               |  |   | (36,467)                
|Income (loss) before income tax expense (benefit)         |  |   | (3,502)                 
|Income tax expense (benefit)                              |  |   | 780                     
|Net loss                                                  |  | $ | (4,282)                 
|                                                          |  |   |                         
|Basic and diluted net loss per share (4)                  |  | $ | (0.09)                  
|                                                          |  |   |                         
|                                                          |  |   |                         
|Basic and Diluted weighted average shares outstanding (4) |  |   | 46,804                  

________________

|(1) | We adopted the fair value recognition provisions of Statement of Financial Accounting Standards No. 123R, Share Based
Payment, or SFAS No. 123R, using the modified prospective method. The adoption of SFAS No. 123R increased our operating loss, loss
before income tax expense (benefit) and net loss for 2006 by $13.4 million and basic and diluted net loss per share by $0.29.
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|(2) | Amount relates to the sale of our mGluRs program to AstraZeneca.  See note 3 to the consolidated financial statements for information
concerning the AstraZeneca agreement.                                                                                                                                                                                                           
|(3) | Amount relates primarily to a June 2003 termination fee of $35.6 million relating to our proposed merger with Enzon Pharmaceuticals,
Inc and a December 2003 fee of $4.3 million relating to the termination of our contract with the Government of Canada under its Technology Partnerships
Canada program.                                                                          
|(4) | See note 1 to the consolidated financial statements for information concerning the computation of net income (loss) per
share.                                                                                                                                                                                                                                                        
|(5) | See note 2 to the consolidated financial statements for information concerning the restatement of the 2007 financial
data.                                                                                                                                                                                                                                                            

36

---

Consolidated Balance Sheets Data:

Years Ended December 31,2007


2006


2005


2004


2003(in thousands)


Restated (1)Cash, cash equivalents, and currentmarketable investment securities

$
133,331

$
146,152

$
258,967

$
329,685

$
303,874Working capital


102,921


145,222


233,907


306,349


283,906Total assets


231,853


224,740


331,052


397,485


327,508Long-term portion of lease financing, notes payableand other long-term liabilities


341,345


373,517


390,117


367,000


192,000Accumulated deficit


(873,154)


(868,872)


(756,204)


(586,481)


(418,230)Stockholders' equity (deficit)


(191,656)


(193,244)


(97,524)


(12,789)


112,785

(1)
See note 2 to the consolidated financial statements for information concerning the restatement of the 2007 financial
data.ITEM 7.
Management's Discussion and Analysis of Financial Condition and Results of Operations.SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

The following discussion should be read in conjunction with our consolidated financial statements and related notes appearing elsewhere in this Annual
Report.

This Annual Report on Form 10-K and the documents incorporated by reference into this report contain forward-looking statements made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management's judgment
regarding future events. In many cases, you can identify forward-looking statements by terminology such as "may," "will,"
"should," "plan," "expect," "anticipate," "estimate," "predict," "intend,"
"potential" or "continue" or the negative of these terms or other words of similar import, although some forward-looking statements
are expressed differently. All statements other than statements of historical fact included in this Annual Report on Form 10-K and the documents
incorporated by reference into this report regarding our financial position, business strategy and plans or objectives for future operations are forward-looking
statements. Without limiting the broader description of forward-looking statements above, we specifically note that statements regarding potential drug
candidates, their potential therapeutic effect, the possibility of obtaining regulatory approval, our ability or the ability of our collaborators to manufacture and
sell any products, market acceptance, or our ability to earn a profit from sales or licenses of any drug candidate are all forward-looking in nature. We cannot
guarantee the accuracy of the forward-looking statements, and you should be aware that results and events could differ materially and adversely from those
contained in the forward-looking statements due to a number of factors, including:

•

Our ability to outsource activities critical to the advancement of our product candidates and manage those companies to whom such
activities are outsourced;•

our ability to secure additional funds;•

the successful continuation of our strategic collaborations, our and our collaborators' ability to successfully complete clinical trials,
commercialize products and receive required regulatory approvals and the length, time and cost of obtaining such regulatory approvals;•

competitive factors;•

our ability to maintain the level of our expenses consistent with our internal budgets and forecasts;•

the ability of our contract manufacturers to successfully produce adequate supplies of our product candidates and drug delivery devices
to meet clinical trial and commercial launch requirements for us;•

changes in our relationships with our collaborators;•

variability of our royalty, license and other revenues;•

our ability to enter into and maintain agreements with current and future collaborators on commercially reasonable terms;37•

the demand for securities of pharmaceutical and biotechnology companies in general and our common stock in particular;•

uncertainty regarding our patents and patent rights;•

compliance with current or prospective governmental regulation;•

technological change; and•

general economic and market conditions.You should also consider carefully the statements set forth in Item 1A of this Annual Report entitled "Risk Factors" which addresses
these and additional factors that could cause results or events to differ materially from those set forth in the forward-looking statements. All subsequent
written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the applicable
cautionary statements. In addition, new risks emerge from time to time and it is not possible for management to predict all such risk factors or to assess the
impact of such risk factors on our business. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements.
We undertake no obligation to update or revise these forward-looking statements.

Restatement of Consolidated Financial Statements

During the preparation of the financial results for the quarter ended March 31, 2008, the Company identified an error in the
computation of the redemption premium interest expense, under the effective interest method, for the year ended December 31,
2007, associated with the Secured 8.0% Notes due on March 30, 2017 (Class A Notes).  Accordingly, the Company has restated its
Consolidated Balance Sheet as of December 31, 2007 to increase accrued interest expense related to the Class A Notes by $3.8
million.  Additionally, the Company discovered an error in computing interest expense, under the effective interest method, related to
the amortization of debt issuance costs, the correction of which increased debt issuance costs by $96,000.  The tax impact on both
entries resulted in a decrease of income taxes payable by $74,000.  The Company has also restated its Consolidated Statement of
Operations as of December 31, 2007 to increase interest expense related to the Class A notes by $3.8 million, decrease interest
expense related to reduced amortization of debt issuance costs by $96,000 and decrease income tax expense for the tax effect of
these entries by $74,000.This Amendment No. 1 on Form 10-K/A amends our Annual Report on Form 10-K for the year ended December 31, 2007,
as filed with the Securities and Exchange Commission on March 17, 2008, for the purpose of restating our audited consolidated
financial statements and related notes as of and for the year ended December 31, 2007 contained in Item 8 of Part II.See Notes 2, 11, 14 and 21 to the audited consolidated financial statements for further discussion of the restatement and
related disclosures.  All amounts included in this discussion and analysis reflect the effects of the restatement.Overview

We are a biopharmaceutical company engaged in the development of specialty therapeutics to treat gastrointestinal and endocrine disorders with high
unmet medical need.  Our lead clinical programs involve two proprietary proteins to restore or replace biological function, GATTEXTM
(teduglutide) and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection).  GATTEX is an analog of GLP-2, a protein involved in the regeneration and
repair of the intestinal lining, and is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome (SBS).  SBS affects patients
who have had 50% or more of their small intestine removed.  Given GATTEX's activity in promoting gastrointestinal repair, we are also evaluating its role in
treating other gastrointestinal conditions associated with intestinal failure, specifically gastrointestinal mucositis, necrotizing enterocolitis, and Crohn's
disease.  NPSP558 is in Phase 2 clinical testing as a hormone therapy for hypoparathyroidism, a disorder that decreases blood calcium due to an
insufficiency of parathyroid hormone.  We have historically developed NPSP558 for osteoporosis under the brand name PREOS®. In
addition to our proprietary clinical portfolio, we have a number of royalty-based clinical and commercial stage programs.

In 2007, we restructured our operations and implemented a new business strategy to focus our resources on developing GATTEX and NPSP558 for
specialty indications with high unmet medical need.  Previously, our strategic priority was to obtain U.S. regulatory approval of NPSP558 for the treatment of
osteoporosis under the brand name38PREOS.  While we continue to believe that the U.S. osteoporosis market remains a viable commercial opportunity for
this compound, after a detailed review, we determined that it was in the best interest of our business to focus our resources on specialty opportunities with
high unmet medical need within our pipeline and pursue osteoporosis only on a partnered, rather than proprietary basis.

During 2007, we took the following actions to support our business plan of developing specialty therapeutics to treat GI and endocrine disorders with
high unmet medical need:

Refocused our resources and implemented a clinical development strategy for GATTEX and NPSP558 for specialty indications with high unmet medical
need
Substantially reduced annual operating expenses and cash utilization, which included consolidating our operations into one facility in Bedminster,
NJ
Raised more than $275.0 million in capital through new financings and the monetization of assets that were no longer strategically aligned
Retired more than $191.0 million in convertible debt due in 2008
Completed a Phase 3 clinical study of GATTEX for the treatment of SBS
Secured an ex-North America partnership for GATTEX with Nycomed
Enhanced our leadership team with several key appointmentsWe have incurred cumulative losses from inception through December 31, 2007 of approximately $873.2 million. We expect to continue to incur
significant operating losses over at least the next several years as we continue our current and anticipated development projects. Activities that will increase
our future operating losses include activities to obtain FDA approval to market GATTEX and NPSP558 in the U.S.; current and future clinical trials with
GATTEX and NPSP558; and clinical and commercial manufacturing for GATTEX and NPSP558 in the U.S.

Royalty-based Products

Our royalty-based products consist of one product that has been granted marketing approval in the United States, Europe and Japan and another
product that has been granted marketing approval in Europe.  Amgen is marketing Cinacalcet HCl in the U.S. as Sensipar® and in the European Union
as Mimpara® for the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis and for the treatment of
elevated calcium levels in patients with parathyroid carcinoma.  In October 2007, our partner Kirin received approval from the Japanese Pharmaceuticals
and Medical Devices Agency to market cinacalcet HCl in Japan for the treatment of patients with secondary hyperparathyroidism during maintenance
dialysis.  Kirin began commercializing cinacalcet HC1 in Japan under the trade name REGPARA in the first quarter of 2008.

Nycomed is marketing PREOTACT in Europe for the treatment of postmenopausal women with osteoporosis at high risk for fracture.  To date, Nycomed
has launched PREOTACT in 12 markets, including Denmark, Germany, the United Kingdom, Italy, Spain, Greece, Netherlands and Austria.

Research and Development Projects
Our most advanced proprietary research and development projects involve GATTEX and NPSP558. We also have other royalty-based product
candidates including Ronacaleret (751689), a Phase 2 calcilytic compound that is being developed by our licensee, GlaxoSmithKline, for osteoporosis.
Proprietary Product Candidates

GATTEX. GATTEX is our brand name for glucagon-like peptide 2, a naturally occurring hormone that regulates proliferation of the cells
lining the small intestine. We are independently investigating GATTEX as a potential treatment for SBS, and other GI indications, including gastrointestinal
mucositis, necrotizing enterocolitis, and Crohn's disease.

In October 2007, we reported top-line results from a Phase 3 clinical study of GATTEX in adult patients with SBS.  As discussed elsewhere in this
report, including in Item 1 of this report entitled "Business", on the basis of our communication with the FDA concerning the results from this
study, we intend to commence a second Phase 3 confirmatory study with GATTEX.  We are finalizing a protocol for this study to address the FDA's
comments and will incorporate the results from a Phase 3-extension study into this confirmatory study.

39In September 2007, we signed a license agreement with Nycomed in which we granted Nycomed the right to develop and commercialize GATTEX
outside the United States, Canada and Mexico for the treatment of gastrointestinal disorders.  We received $35.0 million in up-front fees under the
agreement. Nycomed paid us $10.0 million upon signing the license agreement and paid us an additional $25.0 million in up-front license fees after
reviewing the GATTEX Phase 3 top-line clinical results released in the fourth quarter of 2007.  Under the terms of the agreement, we have the potential to
earn up to $190.0 million in development and sales milestone payments plus royalties on product sales. We are responsible to complete the on-going Phase
3 GATTEX clinical trials in SBS and Nycomed may elect to share future development costs 50:50 with us to advance and broaden the indications for
GATTEX.  Under a previously existing licensing agreement with a third party, we were required to pay $6.6 million to
the licensor and will be required to
make future payments based on GATTEX royalties and milestones earned.  This $6.6 million fee has been deferred and is being amortized over the
estimated performance period.  Due to our continuing involvement, we are recognizing revenue over the estimated performance period and for the year
ended December 31, 2007, we recognized $7.3 million in license fee revenue.  The balance of the up-front license fee has been deferred at December 31,
2007 and is estimated to be recognized as revenue in 2008.  We did not recognize any research and licensing revenue in 2006 and 2005.

During the years ended December 31, 2007, 2006 and 2005, we incurred expenses of $19.6 million, $15.5 million and $28.8 million, respectively,
in the research and development of this product candidate, including costs associated with the manufacture of clinical supplies of GATTEX. We have
incurred costs of approximately $130.5 million since
we assumed development obligations of this product candidate under our acquisition of Allelix
Biopharmaceuticals Inc., or Allelix, in December 1999.

Our development administration overhead costs are included in total research and development expense for each period, but are not allocated among
our various projects.
The goal of our GATTEX development program is to obtain marketing approval from the FDA and assist Nycomed in obtaining marketing approvals
from analogous international agencies. We will consider the project substantially complete if such marketing approvals are obtained even though
subsequent to that time we might incur additional expenses in conducting additional clinical trials and follow-up studies. Before the requisite marketing
approvals can be obtained, pivotal clinical trials must be completed with satisfactory results and marketing approvals must be submitted to applicable
regulatory agencies. We are unable to estimate the costs to completion or the completion date for the GATTEX program because of the on-going work
resulting from the results of our pivotal Phase 3 trial in adults with SBS, the early stage of the clinical trials for other indications such as gastrointestinal
mucositis, necrotizing enterocolitis, and Crohn's disease, the risks associated with the clinical trial process, including the risks that patient enrollment in the
clinical trials may be slow, that we may repeat, revise or expand the scope of future trials or conduct additional clinical trials not presently planned to secure
marketing approvals, and the additional risks identified herein. We cannot predict when material cash inflows from our GATTEX program will commence, if
ever, because of the many risks and uncertainties relating to the results of our Phase 3 clinical trial with SBS patients, completion of clinical trials, receipt of
marketing approval from the applicable regulatory agency, acceptance in the marketplace, and the availability of sufficient funds to complete development of
the product. To date, we have not received any revenues from product sales of GATTEX. The risks and uncertainties associated with completing the
development of GATTEX on schedule, or at all, include but are not limited to the following:

•

GATTEX may not be shown to be safe and efficacious in the pivotal and on-going clinical trials;•

We may be unable to obtain regulatory approval of the drug on a timely basis, or at all;•

We may be unable to secure adequate clinical and commercial supplies of GATTEX in order to complete preclinical studies, clinical
trials and initiate commercial launch upon approval; and•

We may not have adequate funds to complete the development of GATTEX.A failure to obtain marketing approval for GATTEX or to timely complete development and obtain regulatory approval would likely have
the following results on our operations, financial position and liquidity:


•

We would not earn any sales revenue from GATTEX, which would increase the likelihood that we would need to obtain additional
financing for our other development efforts;•

Our reputation among investors might be harmed, which might make it more difficult for us to obtain equity capital on attractive terms or
at all; and•

Our profitability would be delayed and our business and stock price may be adversely affected.40NPSP558. NPSP558 is our proprietary recombinant, full length (1-84), human parathyroid hormone that we are developing as a
potential treatment for hypoparathyroidism.

In September 2007, the FDA granted orphan drug status for NPSP558 as a treatment for hypoparathyroidism.  Also, in 2007, we continued supporting
an investigator initiated study to explore the use of NPSP558 as a hormone  therapy to treat hypoparathyroidism. We also plan to initiate a pivotal
registration studyto demonstrate the safety and efficacy of NPSP558 as a potential therapy to treat hypoparathyroidism.   The study preparation
has started and we expect top-line results by the second half of 2010.

In July 2007, we entered into a new license agreement with Nycomed, under which we granted to Nycomed the right to commercialize PREOTACT in all
non-U.S. territories, excluding Japan and Israel.  Nycomed's licensed rights in Canada and Mexico will revert back to us or our U.S. licensee for
commercialization, if and when NPSP558 receives regulatory approval in the U.S.  The 2007 license agreement contains milestone and royalty payment
obligations which are similar to those under our 2004 license agreement with Nycomed. Nycomed is required to pay us royalties on sales of PREOTACT
only in the European Union, the Commonwealth of Independent States and Turkey.  The 2007 license agreement provides for the assumption by Nycomed
of our manufacturing and supply obligations and patent prosecution and maintenance obligations under the 2004 license agreement.  As part of the
manufacturing and supply transfer, Nycomed paid us $11.0 million for a significant portion of our existing bulk drug inventory.  Also, in July 2007, we entered
into an agreement with DRI Capital, or DRI, pursuant to which we sold to DRI our right to receive
future royalty payments arising from sales of PREOTACT under our license agreement with Nycomed.

Although we are pursuing NPSP558 only for hypoparathyroidism at this time, our historical development efforts have focused on developing this
compound for osteoporosis using the brand name PREOS®.  The expenditures described as part of our results of operations and financial condition
relate primarily to expense incurred for the osteoporosis indication. As noted above, we have determined that we will pursue NPSP558 for osteoporosis only
on a partnered basis.  During the years ended December 31, 2007, 2006 and 2005 we incurred $5.4 million, $14.3 million and $54.4 million,
respectively, in the research and development of this product candidate, including costs associated with the manufacture of clinical and commercial supplies
of NPSP558. We have incurred costs of approximately $347.1 million since we assumed development obligations for this product candidate under our
acquisition of Allelix in December 1999.
Our development administration overhead costs are included in total research and development expense for each period, but are not allocated among
our various projects.
The goal of our NPSP558 development program is to obtain marketing approval from the FDA and assist Nycomed in obtaining marketing approval from
analogous international agencies. We will consider the project substantially complete if we obtain those approvals even though subsequent to that time we
might incur additional expenses in conducting additional clinical trials and follow-up studies. Because of the on-going work with respect to the NPSP558
program, the FDA review process, the risks associated with the drug approval process, including the risk that we may have to repeat, revise or expand the
scope of clinical trials or conduct additional clinical trials not presently planned to secure marketing approvals and the initiation of commercial manufacturing
activities, and the additional risks identified herein, we are unable to estimate the costs to completion or the completion date for the NPSP558 program.
Material cash inflows relating to our NPSP558 development program will not commence until after marketing approvals are obtained, and then only if
NPSP558 finds acceptance in the marketplace. Because of the many risks and uncertainties relating to the receipt of marketing approval from the applicable
regulatory agencies and acceptance in the marketplace and the availability of sufficient funds to complete development of the product, we cannot predict
when material cash inflows from our NPSP558 program will commence, if ever.

The risks and uncertainties associated with completing the development of NSP558 on a timely basis, or at all, and successfully commercializing
NSP558include but are not limited to the following:

•

We may be unable to obtain regulatory approval of the drug on a timely basis or at all;•

We may be unable to secure adequate commercial supplies of NSP558 and the injection delivery device in order to initiate commercial
launch when and if NSP558 is approved; and•

We may not have adequate funds to complete the development and prepare for the commercial launch of NSP558 when and if
approved.A failure to obtain marketing approval for NSP558, secure adequate commercial supplies of NSP558, or secure adequate funds to
complete development and prepare for commercial launch would likely have the following results on our operations, financial position and liquidity:

41•

We would not earn any sales revenue from NSP558, which would increase the likelihood that we would need to obtain additional
financing for our other development efforts;•

Our reputation among investors might be harmed, which might make it more difficult for us to obtain equity capital on attractive terms or
at all; and•

Our profitability would be delayed and our business and stock price may be adversely affected.Royalty-based Product Candidates

Ronacalaret (751689). Our partner GlaxoSmithKline is pursuing a treatment for osteoporosis that focuses on the development of an
orally administered drug, Ronacalaret (751689) which is a calcilytic compound. Calcilytic compounds are small molecule antagonists of the calcium
receptors that temporarily increase the secretion of the body's own parathyroid hormone, which may result in the formulation of new bone. In animal studies,
we determined that intermittent increases in circulating levels of parathyroid hormone can be obtained through use of calcilytics.
In 1993, we collaborated with GlaxoSmithKline for research, development and commercialization of calcium receptor active compounds from treatment
of osteoporosis and other bone metabolism disorders. We are not expending any significant resources in the program. In May 2007, GlaxoSmithKline
initiated a Phase 2 dose-range finding study with a compound identified under the collaboration in post-menopausal women with osteoporosis.

GlaxoSmithKline has paid us a total of $38.7 million for license fees, research support, milestone payments and equity purchases as part of our
collaboration. We will receive additional payments of up to an aggregate of $32.0 million, which includes additional milestones under the December 2006
amendment noted below, if certain clinical milestones are achieved. We will also receive royalties on sales of any commercialized products based on
compounds identified in the collaboration. In addition to the milestone and royalty payments, we have a limited right to co-promote any products that are
developed through our collaboration and to receive co-promotion revenue, if any.
In December 2006 we entered into an amendment to our agreement with GlaxoSmithKline under which we provided GlaxoSmithKline rights to additional
compounds discovered by us. In connection with such amendment GlaxoSmithKline paid us a one time licensing fee of $3.0 million and agreed to pay us
additional milestones payments for the achievement of certain clinical milestones with such compounds as well as royalties on sales of such compounds
should GlaxoSmithKline commercialize any of such compounds.
Glycine Reuptake Inhibitors. We collaborated with Janssen on glycine reuptake inhibitors to identify prospective drug candidates
for schizophrenia and dementia. Janssen has now assumed full responsibility for the development of product candidates identified under the collaboration.
We are not expending any significant resources in the program. Janssen has informed us that they plan to seek a third party to share in the future
development costs and risks of the program. Janssen has informed us that they plan to seek a third party to share in the future development costs and risks
of the program. In the event Janssen enters into a collaborative agreement with a third party or sublicenses the program, we will continue to be eligible to
receive additional milestone payments of up to $20.5 million from Janssen or a licensee, if certain milestones are met and royalties on sales of any drugs
developed or sold by Janssen or a licensee under this collaboration agreement.


42Results of Operations
The following table summarizes selected operating statement data for the years ended December 31, 2007, 2006 and 2005 (dollars in
thousands):

2007


2006


2005Revenues:Product Sales

$
20,310

$
2,662

$
-Royalties


49,626


32,078


12,533Milestones and license fees


16,312


13,762


292Total Revenues

$
86,248

$
48,502

$
12,825Operating expenses:Cost of good sold

$
6,180

$
1,413

$
-% of product sales


30
%

53
%

-
%Cost of royalties

$
4,659

$
2,980

$
1,144% of royalties


9
%

9
%

9
%Cost of license fees

$
1,547

$
-

$
-% of milestones and license fees


9
%

-
%

-
%Research and development

$
38,723

$
68,411

$
117,445% of revenues


45
%

141
%

916
%Selling, general and administrative

$
26,998

$
52,177

$
48,635% of revenues


31
%

108
%

379
%Restructuring charges

$
13,386

$
8,179

$
-Gain on sale of assets held for sale

$
(1,826)

$
-

$
-Gain on sale of fixed assets

$
(6,384)

$
-

$
-Gain on sale of assets held for sale

$
(30,000)

$
-

$
-Write-down of long-lived assets

$
-

$
8,297

$
-Years ended December 31, 2007 and 2006
Revenues. Substantially all our revenues relate to license fees, milestone payments, product sales and royalty payments from our
licensees and collaborators. These revenues fluctuate from year to year. Our revenues were $86.2 million in 2007 compared to $48.5 million in 2006. We
recognized revenue under our research and license agreements as follows:

•

Under our agreement with Amgen for Sensipar® in the U.S. and Mimpara® in Europe (cinacalcet
HCl), we recognized revenue of $46.4 million in 2007 and $31.9 million in 2006;•

Under our agreement with Nycomed for PREOTACT®(parathyroid hormone [rDNA origin] for injection), we
recognized revenue of $30.1 million in 2007 and $3.1 million in 2006;•

Under our agreement with Nycomed for GATTEXTM(teduglutide, recombinant GLP-2)), we recognized revenue of
$7.3 million in 2007 and zero in 2006;•

Under our agreement with Ortho-McNeil, we recognized revenue of zero in 2007 and $8.0 million in 2006;•

Under our agreement with Kirin, we recognized revenue of $2.0 million in 2007 and $2.0 million in 2006; and•

Under our agreement with GSK, we recognized revenue of zero in 2007 and $3.0 million in 2006.The increase in royalty revenue earned from Amgen is due to sales growth of Sensipar.  Amgen pays Sensipar royalties directly to a wholly owned
subsidiary of NPS and the royalties secure non-recourse debt that we issued in August 2007 and December 2004.

For the year ended December 31, 2007, our revenues related to our agreement with Nycomed for PREOTACT were comprised of (i) $20.3 million in
sales of bulk product and finished inventory; (ii) $6.5 million in milestone revenue; and (iii) $3.3 million in royalty revenue.  For the year ended December 31,
2006, our revenues related to our agreement with Nycomed for PREOTACT were comprised of (i) $2.7 million in sales of bulk product inventory; (ii) $0.3
million in milestone revenue; and (iii) $0.1 million in royalty revenue.   In April 2006, the European Medicines Agency or EMEA approved PREOTACT for the
treatment of postmenopausal women with osteoporosis at high risk for43fractures.  In July 2007, we sold our right to receive certain future royalty payments
from Nycomed's sale of Preotact in Europe to DRI Capital (previously Drug Royalty Corporation).

For the year ended December 31, 2007, we recognized $7.3 million in license fee revenue under our agreement with Nycomed for GATTEX. In
September 2007, we entered into an agreement with Nycomed for the rights to develop and commercialize GATTEX in territories outside of North America
for gastrointestinal disorders. In connection with this agreement, we received a $35.0 million up-front license fee under the Nycomed agreement but only
recognized $7.3 million in revenue due to our continuing involvement under the agreement we are recognizing revenue over the estimated performance
period and for the year ended December 31, 2007, we recognized $7.3 million in license fee revenue.  The balance of the up-front license fee has been
deferred at December 31, 2007 and is estimated to be recognized as revenue in 2008.

During each of the years ended December 31, 2007 and 2006 we recognized milestone revenue of $2.0 million and $2.0 million, respectively, from Kirin
Pharma.  The Japanese Pharmaceuticals and Medical Devices Agency's approval of Regpara in 2007 and Kirin's filing of a new drug application in 2006
triggered the milestone payments.  We are entitled to royalties on Kirin's future sales of Regpara.

We recognized an up-front license fee from Ortho-McNeil of $8.0 million for a commitment not to sue for patent infringement and we recognized an
up-front license free from GSK of $3.0 million for the addition of certain compounds to the collaboration during the year ended December 31, 2006.

See "Liquidity and Capital Resources" below for further discussion of payments that we may earn in the future under these agreements.

Cost of Goods Sold.  Our cost of goods sold consists of the cost of inventory, subsequent to the April 2006 approval of
PREOTACT® in the EU, for product sales to Nycomed.  Prior to the approval of PREOTACT in the EU, we expensed the costs
associated with inventory as research and development expense, which created an initial First In First Out (FIFO) inventory layer with a carrying value of
zero.  We recorded cost of goods sold of $6.2 million and $1.4 million, respectively, during the years ended December 31, 2007 and 2006.  The increase in
cost of goods sold is due to increased sales to Nycomed and the previous utilization of zero-costed inventory layers. As of December 31, 2007, we have
consumed all of our zero-costed inventory.
Cost of Royalties.  Our cost of royalties consists of royalties owed under our agreement with the Brigham and Women's Hospital on sales of
cinacalcet HCl.  We recorded cost of royalties of $4.7 million and $3.0 million, respectively, during the years ended December 31, 2007 and 2006.  The
increase in cost of royalties is due to increased sales of cinacalcet HCl by Amgen.

Cost of License Fees.  Our cost of license fees relate to fees and royalties owed to a third party upon the licensing of GATTEX to
Nycomed in September 2007.  We recorded cost of license fees of $1.5 million during the year ended December 31, 2007.  Under the third party licensing
agreement, we made a cash payment of $6.6 million related to the Nycomed GATTEX agreement.  The balance of the license fee payment cost has been
deferred at December 31, 2007 and is estimated to be recognized as expense in 2008.

Research and Development.  Our research and development expenses are primarily comprised of personnel-related costs for our
employees who are dedicated to development activities, and from the fees paid and costs reimbursed to outside professionals to conduct research, pre-
clinical and clinical trials, and to manufacture drug compounds and related supplies prior to FDA approval.  Historically, our research and development
expenses also included costs for our employees who performed research activities.  However, substantially all of our internal research functions were
eliminated in connection with our restructuring initiatives. During 2007, we restructured our business to focus our clinical development on specialty
indications with high unmet medical need.  As a result of this restructuring, our research and development expenses decreased to $38.7 million for the year
ended December 31, 2007 from $68.4 million for the year ended December 31, 2006.  The reduction in research and development expenses primarily
related to (i) a $22.0 million decrease in personnel-related costs primarily due to the 2007 and 2006 restructurings; (ii) a $3.9 million decrease in facilities
costs due to the consolidation of our facilities to New Jersey, and (iii) a $3.7 million decline in expenses due to the discontinuation of research and other
development activities that are no longer strategically aligned with our current business model; and (iv) other overall decreases in overhead.  The declines in
2007 research and development expenses were partially offset by a $4.1 million increase in costs associated with advancing our clinical program for
GATTEX for short bowel syndrome.

44Selling, General and Administrative.  Our selling, general and administrative expenses consist primarily of the costs of our management
and administrative staff, business insurance, property taxes, professional fees, legal fees and product planning activities, including the cost of our sales
force through June 2006.  Our selling, general and administrative expenses decreased to $27.0 million for the year ended December 31, 2007 from $52.2
million in 2006.  The decrease in selling, general and administrative expenses was primarily due to (i) a $14.0 million decrease in personnel and related
costs; (ii) a $9.9 million decline in costs due to the discontinuation of commercial activities associated with PREOS and the 2006 termination of our co-
promotional activities for Kineret® and Restasis®; and (iii) $1.0 million  decrease in other overall decreases in selling,
general and administrative overhead, including facility costs, information technology and depreciation.  The declines in selling, general and administrative
expenses were attributable to the restructuring of our business during 2007.

Restructuring Charges.  Our restructuring charges relate to our initiatives to restructure operations as announced on March 14, 2007
and June 12, 2006.  In connection with our restructuring initiatives, we reduced our worldwide workforce, including employees and contractors, eliminated all
commercial sales and related field-based activities, terminated certain collaboration agreements, and closed and sold facilities located outside of New
Jersey.  The reductions in workforce involved all functional disciplines, including selling, general and administrative employees as well as research and
development personnel.  Restructuring charges for the years ended December 31, 2007 and 2006 were $13.4 million and $8.2 million, respectively.
Restructuring charges were primarily comprised of employee termination benefits.

Gain on Sale of Assets Held for Sale.  Our gain on sale of assets held for sale of $1.8 million in 2007 relates to the sale of our laboratory
and administrative office building, including equipment, located in Mississauga,Canada.
Gain on Sale of Fixed Assets.  Our gain on sale of fixed assets of $6.4 million in 2007 relates primarily to the sale of our laboratory and
administrative office building, including equipment, located in Salt Lake City, Utah in July 2007, and the sale of our leasehold improvements and equipment
at a laboratory facility in Toronto, Canada in August 2007.

Gain on Sale of Assets.  During the year ended December 31, 2007, in connection with the restructuring of our business, we recorded a
gain of $30.0 million related to the sale of our interests in our metabotropic glutamate receptors or mGluRs, program to AstraZeneca, or AZ.

Write-down of Long-Lived Assets.  In connection with our decision to close our facilities in Salt Lake City, Utah and Toronto, Canada, we
determined that the fair value of the property and equipment located in Toronto was less than its carrying value at December 31, 2006.  Accordingly, during
the year ended December 31, 2006, we recorded an $8.3 million write-down of the assets.  We had no write-down during the year ended December 31,
2007.

Total Other Expense, Net.  Our total other expense, net, increased to $36.5 million for the year ended December 31, 2007 from $19.7
million for the prior year.  The increase in total other expense, net, is due primarily to a $11.8
million increase in interest expense, under the effective interest
method, on debt agreements entered into in 2007 (including the class B notes ($6.5 million increase), the 5.75% convertible notes ($1.2 million increase)
and, DRI Capital's purchase of our PREOTACT royalty, accounted for as debt, ($4.1 million).  The increase was also attributable to a $4.2 million increase in
interest expense, under the effective interest method, on the redemption premium associated with the Class A notes due to an increased forecast of sales of
Sensipar, a $4.1 million other than temporary impairment charge related to certain ARS, a $970,000 loss on the extinguishment of lease financing
obligations related to termination of the Salt Lake City building and $815,000 loss on foreign currency transactions.  The increase was partially offset by a
reduction in interest expense from our repayment of substantially all of our 3% convertible notes during the fourth quarter of 2007 ($1.5 million decrease), a
reduction in interest expense on the Class A notes due to a $19.3 million principal payment in April 2007 ($666,000 decrease), increased interest income of
$398,000 and a gain of $1.3 million on the extinguishment of our 3% convertible notes.

Income Taxes. Our income tax expense was $780,000 in 2007 related to United States Federal alternative minimum tax
compared to zero in 2006.

As of December 31, 2007, we had a United States federal and state income tax net operating loss carryforward of approximately $227.3 million
and $388.1 million, respectively, and a United States federal income tax research credit carryforward of approximately $7.0 million. We also had a Canadian
federal and provincial income tax net operating loss carryforward of approximately $646.3 million and $664.4 million, respectively, a Canadian research pool
carryforward of approximately $218.6 million and a Canadian investment tax credit carryforward of approximately $21.3 million. Our ability to utilize the
United States operating loss and credit carryforwards against future taxable45income will be subject to annual limitations in future periods pursuant to the
"change in ownership rules" under Section 382 of the Internal Revenue Code of 1986.Years ended December 31, 2006 and 2005

Revenues.

- Under our agreement with Amgen, we recognized revenue of $31.9 million in 2006 and $12.5 million in 2005;
- Under our agreement with Kirin, we recognized revenue of $2.0 million in 2006 and no revenue in 2005;
- Under our agreement with Nycomed, we recognized revenue of $3.1 million in 2006 and $234,000 in 2005;
- Under our agreement with Ortho-McNeil, we recognized revenue of $8.0 million in 2006 and no revenue in 2005; and
- Under our agreement with GSK, we recognized revenue of $3.0 million in 2006 and no revenue in 2005.

The increase in royalty revenue earned from Amgen is due to an increase in sales of cinacalcet HCl since launching in March 2004 and due to an
increase in the royalty rates earned on sales of cinacalcet HCl due to Amgen's achievement of certain cumulative annual sales thresholds. Additionally,
during 2006 we recognized milestone revenue of $2.0 million from Kirin for the filing of a new drug application with the Japanese Pharmaceuticals and
Medical Devices Agency in February 2006 for cinacalcet HCl; we recognized PREOTACT product sales revenue of $2.7 million, royalty revenue of $96,000
and milestone revenue of $360,000 from Nycomed; we recognized an up-front fee from Ortho-McNeil of $8.0 million for commitment not to sue for patent
infringement; and we recognized an up-front license fee from GSK of $3.0 million for the addition of certain compounds to the collaboration.

See "Liquidity and Capital Resources" below for further discussion of payments that we may earn in the future under these agreements.

Cost of Goods Sold.  We recorded cost of goods sold of $1.4 million and zero, respectively, during 2006 and 2005. The increase in cost of
goods sold is due to increased sales to Nycomed and the previous utilization of zero-costed inventory layers.

Cost of Royalties. We recorded cost of royalties of $3.0 million and $1.1 million, respectively, during 2006 and 2005. The increase in cost of
royalties is due to increased sales of cinacalcet HCl by Amgen.

Research and Development. Our research and development expenses are primarily comprised of personnel-related costs for our employees
who are dedicated to development activities, and from the fees paid and costs reimbursed to outside professionals to conduct research, preclinical and
clinical trials, and to manufacture drug compounds and related supplies prior to FDA approval.  Our research and development expenses decreased to $68.4
million in 2006 from $117.4 million in 2005. Research and development expenses decreased from 2005 to 2006 principally due to a $29.8 million
decrease in the costs associated with the manufacture of clinical and commercial supplies of PREOS and GATTEX, a $21.1 million decrease in the costs of
advancing our PREOS clinical program, a $6.9 million decrease in the development costs of advancing our central nervous system programs and a $4.5
million decrease in the development costs of advancing our GATTEX clinical program, offset by a $7.8 million increase in compensation cost related to
share-based compensation resulting from the adoption of SFAS No. 123R, including a charge of $1.0 million for accelerated vesting of stock options under
severance agreements and a $2.0 million increase for a licensing fee associated with intellectual property rights acquired.



Selling, General and Administrative. Our selling, general and administrative expenses consist primarily of the costs of our management
and administrative staff, business insurance, property taxes, professional fees, legal fees and product planning activities, including the cost of our sales
force through June 2006.  Our selling, general and administrative expenses increased to $52.2 million in 2006 from $48.6 million in 2005. The increase in
selling, general and administrative expenses from 2005 to 2006 is due primarily to a $5.4 million increase in compensation cost related to share-based
compensation resulting from the adoption of SFAS No. 123R, including a charge of $1.3 million for accelerated vesting of stock options under severance
agreements, a charge of $1.7 million in compensation expense due to severance agreements and a $1.0 million increase in other selling, general and
administrative  costs, offset by a $4.3 million decrease in market research, educational and commercial activities, including personnel costs, associated with
PREOS and our promotional activities around Kineret and Restasis

46

---



Write-Down of Long-Lived Assets. Our write-down of long-lived assets relates to our impairment testing of fixed assets located in
Toronto, Canada. We evaluated alternative courses of actions that were finalized with the decision in 2007 that our Salt Lake City, Utah and Toronto,
Canada sites would be closed. As a result, we determined that the fair value of the property and equipment located at Toronto, Canada was less than the
carrying value, resulting in a $8.3 million write-down of the assets during 2006. We had no write-down during the year ended December 31, 2005.

Restructuring Charges. Our restructuring charges relate to our initiative to restructure operations which was announced on June 12,
2006, referred to as our 2006 Restructuring Plan. Under the 2006 Restructuring Plan, we reduced our worldwide workforce, including employees and
contractors, by approximately 250 positions, eliminated all commercial sales and related field based activities, terminated our agreement with Allergan Inc.
to promote Restasis Ophthalmic Emulsion to rheumatologists and closed and planned to sell our technical operations facility in Mississauga, Ontario,
Canada. The reduction in workforce involved all functional disciplines including selling, general and administrative employees as well as research and
development personnel. The charge related to the 2006 Restructuring Plan during 2006 was $8.2 million and was comprised primarily of severance related
expenses.

Total Other Expense, Net. Our total other expense, net, increased from $15.4 million in 2005 to $19.7 million in 2006. The increase in
total other expense, net, from 2005 to 2006 is due primarily to a $3.9 million increase in interest expense related to increasing our estimate of the effective
interest rate on our Class A Notes for the cash sweep premium, a $734,000 decrease in foreign currency transaction gain, offset by a $500,000 increase in
interest income due to higher yields in 2006.

Income Taxes. Our income tax expense (benefit) was zero in 2006 compared to income tax benefit of

$55,000 in 2005. The income tax benefit recorded in 2005 relates to our estimates of refundable tax credits from the Canadian province of Quebec for
research and development activities performed.

Liquidity and Capital Resources

The following table summarizes selected financial data (amounts in the thousands):

|                                  |  |   | December 31, 2007 |  |   | December 31, 2006
|--------------------------------- |  | - | ----------------- |  | - | -----------------
|                                  |  |   | Restated (1)      |  |   |                  
|Cash, cash equivalents,           |  |   |                   |  |   |                  
|and current marketable securities |  | $ | 133,331           |  | $ | 146,152          
|Total assets                      |  |   | 231,853           |  |   | 224,740          
|Current debt                      |  |   | 24,992            |  |   | 19,044           
|Non-current debt                  |  |   | 336,449           |  |   | 365,533          
|Stockholders' deficit             |  | $ | (191,656)         |  | $ | (193,244)        



|(1) | See note 2 to the consolidated financial statements for information concerning the restatement of the 2007 financial data.
|--- | --------------------------------------------------------------------------------------------------------------------------

We require cash to fund our operating expenses, to make capital expenditures, acquisitions and investments and to service our debt. We have financed
operations since inception primarily through payments received under collaborative research and license agreements, the private and public issuance and
sale of equity securities, and the issuance and sale of secured debt, convertible debt and lease financing. Through December 31, 2007, we have
recognized $247.4 million of cumulative revenues from payments for research support, license fees, product sales, milestone and royalty payments, $563.0
million from the sale of equity securities for cash and $555.2 million from the sale of secured debt and convertible debt for cash.

Our principal sources of liquidity are cash, cash equivalents, and current marketable investment securities, which totaled $108.4 million at
December 31, 2007. The primary objectives for our marketable investment security portfolio are liquidity and safety of principal. Investments are
intended to achieve the highest rate of return to us, consistent with these two objectives. Our investment policy limits investments to certain types of
instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer.

Our investment portfolio includes investments in certain auction rate securities or ARS.  ARS are variable interest rate securities tied to short-term
interest rates with nominal long-term maturities.  ARS have interest rate resets through a modified Dutch auction, at predetermined short-term intervals,
usually every 7, 28, 35, or 49 days.  With the liquidity

47

---



issues experienced in global credit and capital markets, our ARS portfolio has recently experienced
multiple unsuccessful auctions as the amount of securities submitted for sale has exceeded the amount of purchase orders.  Given
the unsuccessful
auctions, our ARS are illiquid until there is a successful auction for them and therefore, we have classified ARS marketable securities (except Sold ARS -
see below) to non-current assets as of December 31, 2007.

The estimated value of our ARS holdings at December 31, 2007, was $53.3 million, which reflects $2.4 million less than our carrying value of $55.7
million.  In establishing the estimated market value of our ARS, we have used the market value determined by our investment advisors. The market values
were determined using a proprietary valuation model using the quality of the underlying securities or assets securing the ARS investments, the market
values of comparable securities, the quality of credit enhancement (if any) applicable to the specific security, estimated time to maturity or unwinding of the
arrangement, an analysis of the terms of the indentures and other factors depending on the individual ARS.

In March 2008, we agreed to sell certain of our ARS investments or the Sold ARS, to one of our investment advisors for $26.0 million.  The market value
as of December 31, 2007 and the principal value of the Sold ARS were $24.9 million and $30.1 million, respectively. For the year ended December 31,
2007, we recognized an other-than-temporary loss of $4.1 million on the Sold ARS in the Consolidated Statement of Operations and $1.1 million is recorded
as an unrealized loss in the Accumulated Other Comprehensive Loss section of the Consolidated Balance Sheet at December 31, 2007 on the Sold ARS.
Excluding the Sold ARS, we believe that the decrease in market value on our ARS is temporary in nature due to the underlying assets securing the ARS, the
AAA rating by Standard & Poors as of December 31, 2007 and February 29, 2008, our belief that historical liquidity will return to the global credit and
capital markets, and our intent and ability to hold to recovery.  None of the ARS are backed by sub-prime mortgages.  Accordingly, a $1.3 million unrealized
loss was recorded at December 31, 2007 in Accumulated Other Comprehensive loss section of the Balance Sheet related to the ARS, excluding the Sold
ARS.  The market value of these ARS, excluding the Sold ARS were estimated to be $28.4 million at December 31, 2007 and $26.4 million at February 29,
2008.

If uncertainties in the credit and capital markets continue, these markets deteriorate further or if we experience ratings downgrades on any investments
in our portfolio, including on ARS, the market value of our investment portfolio may decline further, which we may determine is an other-than-temporary
impairment.  This would result in a realized loss and would negatively affect our financial position, results of operations and liquidity.

We believe that based on our current cash, cash equivalents and marketable securities balances at December 31, 2007, the current lack of liquidity in
the credit and capital markets will not have a material impact on our liquidity, cash flow, financial flexibility or ability to fund our operations in 2008.

In August 2007, we repurchased and retired $20.2 million of our 3% Convertible Notes for $19.5 million plus accrued interest.  Additionally, in
October 2007, we closed a tender offer in which $171.2 million in 3% Convertible Notes were tendered to us for $169.1 million plus accrued interest.  After
acquiring these 3% Convertible Notes, we retired them in October 2007.  As of December 31, 2007, $598,000 in 3% Convertible Notes remain outstanding.
We plan to purchase and retire the remaining notes when they mature in June 2008.

In October 2007, we entered into an Asset Purchase Agreement with AZ in which we agreed to sell our rights, including intellectual property, in
drugs targeting mGluRs to AZ for $30.0 million.  Additionally, NPS and AZ agreed to terminate the collaborative research and development agreement
related to drugs targeting mGluRs that was entered into in 2001.  As a result of this termination, we are no longer required to provide research FTE support
or pay for an equal share of external discovery costs, including patent related costs.

In September 2007, we signed a license agreement with Nycomed in which we granted Nycomed the right to develop and commercialize
GATTEX outside the United States, Canada and Mexico for the treatment of gastrointestinal disorders. We received $35.0 million in up-front fees under the
agreement, of which $7.3 million was recognized as licensing revenue during the year ended December 31, 2007. Under the terms of the agreement, we
have the potential to earn up to $190.0 million in development and sales milestone payments and additional royalties on product sales. Under the terms of
the agreement, we are responsible to complete the first pivotal Phase 3 GATTEX clinical trial to support the registration of GATTEX for SBS in the US and
Nycomed may elect to share our future joint development costs 50:50 to advance and broaden the indications for GATTEX.  Additionally, under a previously
existing licensing agreement with a third party, we made a $6.6 million payment to the licensor and will be required to make future payments based on
GATTEX royalties and milestones earned, as a result of the $35.0 million license fee we received from Nycomed in 2007.

48

---



In August 2007, we completed a private placement of $50.0 million of our 5.75% Convertible Notes, or 5.75% Notes, due August 7, 2014. Interest on the
5.75% Notes is payable quarterly in arrears on the first day of the succeeding
calendar quarter commencing January 1, 2008. The holders may convert all or
a portion of the 5.75% Notes into common stock at any time, subject to certain milestones, on or before August 7, 2014. The 5.75% Notes are convertible
into our common stock at a conversion rate equal to approximately $5.44 per share, subject to adjustment in certain events. On or after August 7, 2012, we
may redeem any or all of the 5.75% Notes at a redemption price of 100% of their principal amount, plus accrued and unpaid interest to the day preceding
the redemption date. The 5.75% Notes are unsecured senior debt obligations and rank equally in right of payment with all existing and future unsecured
indebtedness. Neither we nor any of our subsidiaries are restricted under the indenture from paying dividends, incurring debt, or issuing or repurchasing our
securities.

In August 2007, our wholly owned subsidiary, Cinacalcet Royalty Sub LLC, closed a private placement of $100.0 million of its Pharmaceutical Royalty
Monetization AssetSM (PhaRMASM) Secured 15.5% Class B Notes due 2017, or Class B Notes. We received net proceeds
from the issuance of the Class B Notes of approximately $97.0 million, after deducting costs associated with the offering. The Class B Notes are secured by
certain royalty and related rights under our agreement with Amgen and are non-recourse to NPS Pharmaceuticals, Inc. The only source for interest
payments and principal repayment of the Class B Notes is limited to royalty and milestone payments received from Amgen and only after the Class A Notes,
as described in Note 11 to the consolidated financial statements in this report, are paid in full. Accrued interest on the Class B Notes was $6.2 million as of
December 31, 2007. We incurred related debt issuance costs of $3.6 million, which were deferred and are being amortized using the "effective
interest-rate" method. The effective interest rate on the Class B Notes, including debt issuance costs, is approximately 16.0%.

In July 2007, we entered into a Lease Termination Agreement with the Mars Discovery District, or MaRs, under which our operating lease for the office
and laboratory space in Toronto, Canada was terminated.  Pursuant to the Lease Termination Agreement, we sold our leasehold tenant improvements to a
third party for $2.4 million.  The termination of our operating lease and sale of our leasehold tenant improvements was part of our restructuring initiatives,
which included a plan to close our Mississauga and Toronto facilities and discontinue all operations in Canada.

In July 2007, we entered into an Agreement for the Sale and Assignment of Rights with DRI Capital (previously Drug Royalty Corporation), pursuant to
which we sold to DRI our right to receive future royalty payments arising from sales of PREOTACT under our license agreement with Nycomed.  Under the
agreement, DRI paid us an up-front purchase price of $50.0 million.  An additional $25.0 million will be due to us in 2010 if certain PREOTACT sales
thresholds are achieved.  If and when DRI receives two and a half times the amount of principal advanced, the agreement will terminate and the remainder
of the royalties, if any, will revert back to us.

In July 2007, we entered into a new License Agreement with Nycomed to allow Nycomed to commercialize PREOTACT in all non-U.S. territories,
excluding Japan and Israel, and amend certain rights and obligations of NPS and Nycomed under the 2004 license agreement.  The agreement provides for
the assumption by Nycomed of our manufacturing and supply obligations to Nycomed and patent prosecution and maintenance obligations under the 2004
License Agreement.  As part of the manufacturing and supply transfer, Nycomed paid us $11.0 million for a significant portion of our existing bulk drug
inventory.

In July 2007, we sold our 93,000 square foot laboratory and office building, including certain laboratory and office equipment and furnishings, located in
Salt Lake City, Utah for $21.0 million. The sale of this facility was part of our restructuring initiative which included a plan to close our Salt Lake City facility
and to discontinue all Salt Lake City operations.  We recorded a gain on the sale of these fixed assets of $3.3 million during the year ended December 31,
2007.

In June 2007, we closed on our Agreement of Purchase and Sale to sell our land and 85,795 square foot laboratory and office building located in
Mississauga, Ontario, Canada for $4.4 million.  The sale of this facility was also part of our restructuring initiatives, which included a plan to discontinue all
operations in Canada. We recorded a gain on the sale of these fixed assets of $1.8 million during the year ended December 31, 2007.

In March 2007, we announced that we were restructuring the company and decreased our employees from 196 to 35 as of December 31, 2007.  In
conjunction with the reduction in force we also closed our operations in Toronto, Canada and Salt Lake City, Utah.  We believe the restructuring will
enhance our ability to focus on our late stage product opportunities, including additional indications with our lead product candidates, preserve cash, allocate
resources rapidly to different programs, and reallocate internal resources more effectively.

49

---



In May 2007, we repurchased from BioMed Realty, L.P. our 93,000 square foot laboratory and office building located in Salt Lake City, Utah, for $20.0
million which extinguished the balance of our related 15-year lease
obligation.  The repurchase of the laboratory and office building is considered an early
extinguishment of debt and the amount paid to repurchase the building was in excess of the carrying value of the lease financing obligation. Accordingly, we
recorded a loss of $1.0 million during the year ended December 31, 2007 on such extinguishment. As discussed above, in July 2007 we closed our
transaction with the University of Utah and sold this building along with certain equipment and furnishings for $21.0 million.

In June 2006, as a result of the uncertainty with respect to the regulatory approval of PREOS by the FDA, we announced an initiative to restructure
operations, referred to as our 2006 Restructuring Plan. The primary objective of the 2006 Restructuring Plan was to maximize shareholder value by
significantly reducing cash burn, reprioritizing our development portfolio and leveraging our proprietary research and development assets. Under the 2006
Restructuring Plan, we reduced our worldwide workforce, including employees and contractors, by approximately 250 positions, eliminated all commercial
sales and related field based activities, terminated our agreement with Allergan, Inc. to co-promote its proprietary drug, Restasis

In December 2005, we completed a sale-leaseback transaction with BioMed Realty, L.P., a Maryland limited partnership, in which we agreed to sell our
93,000 square foot laboratory and office building located in Salt Lake City, Utah for $19.0 million and lease back the property under a 15-year lease with
BMR-383 Colorow Drive LLC, a subsidiary of BioMed Realty. Net proceeds from the sale were $19.0 million after deducting miscellaneous closing
expenses. As discussed above, we repurchased the building from BioMed Realty in May 2007 and in July 2007 sold the building to the University of Utah.

In September 2005, we completed a public offering of 7.0 million shares of our common stock at $11.35 per share, with net proceeds of
approximately $78.7 million, after deducting offering costs of $797,000.

The following table summarizes our cash flow activity for the years ended December 31, 2007, 2006 and 2005 (amounts in thousands):

|                                                    |  |   | 2007     |  |   | 2006      |  |   | 2005     
|--------------------------------------------------- |  | - | -------- |  | - | --------- |  | - | ---------
|Net cash provided by (used in) operating activities |  | $ | 27,602   |  | $ | (103,912) |  | $ | (161,414)
|Net cash provided by (used in) investing activities |  |   | 62,632   |  |   | 49,250    |  |   | (22,468) 
|Net cash provided by (used in) financing activities |  | $ | (35,484) |  | $ | (8,085)   |  | $ | 104,761  

Net cash provided by operating activities was $27.6 million in 2007 compared to cash used in operating activities of $103.9
million in 2006 and $161.4 million in 2005.  The swing to net cash provided by operating activities resulted primarily from the difference of recording  net loss
of $4.3 million in 2007 as compared to a $112.7 million net loss in 2006 (a $108.4 million difference) which included a gain on the sale of assets of $30.0
million to AZ; a $18.7 million increase in deferred revenue primarily due to the agreement with Nycomed for GATTEX ($35.0 million, partially offset by the
$7.3 million recognized in 2007), a $3.9 million decrease in operating assets due to lower accounts receivable in 2007 and a $13.7 million decrease in
accounts payable and other current accrued expenses.  The overall shift from a use
of cash in operating activities during the year ended December 31, 2006
to cash provided by operating activities is due to the restructuring activities undertaken during 2006 and 2007.  The decrease in cash used in operating
activities during 2006 compared to 2005 is primarily a result of a decreased net loss during 2006.  The net loss decreased $57.1 million in 2006 compared to
2005 due primarily to increased revenues recognized under license agreements and decreases in research and development expenses, offset by increased
selling, general and administrative expenses and a write down of long-lived assets of $8.3 million.  Additionally, we recorded greater non-cash compensation
expense of $11.4 million in 2006 related to all equity awards.

Net cash provided by investing activities was $62.6 million in 2007 compared to $49.3 million in 2006 and cash used by investing activities of $22.5
million in 2005.  Net cash provided by investing activities during 2007 and 2006 was primarily the result of selling marketable investment securities to fund
current operations.  Additionally, during 2007, we received proceeds from the sales of our assets held for sale and our fixed assets of $4.4 million and $24.7
million, respectively.  Net cash used in investing activities during 2005 was primarily the result of investing part of the proceeds from our Secured Notes.
Additionally, capital expenditures for 2007, 2006 and 2005 were $160,000, $1.3 million and $13.4 million, respectively.  Capital expenditures during 2005
relate primarily to the construction of leasehold improvements on laboratory and administrative space in the MaRS Discovery District in Toronto,
Canada.

Net cash used by financing activities was $35.5 million in 2007 compared to $8.1 million in 2006 and net cash provided by financing activities of $104.8
million in 2005.  Cash used in financing activities in 2007 primarily relates to

50

---



the repurchase and retirement of substantially all of our 3% convertible notes for
$189.3 million, principal payments of $19.3 million on our Class A notes; the purchase of our Salt Lake City administrative and office building and related
retirement of our lease financing obligations for $20.0 million in May 2007; and the payment of $4.7 million in debt issuance costs; and the $2.6 million
increase in our restricted cash balances related to our Class A notes.  Cash used in financing activities was partially offset by the issuance of $100.0 million
Class B notes, the $50.0 million issuance in 5.75% convertible notes, and the $50.0 million sale of Preotact royalties to DRI.  Cash used in financing
activities in 2006 primarily relates to principal payments of $1.3 million on our Class A Notes and increases in our restricted cash balances of $12.3 million
related to our Class A Notes.  Cash provided by financing activities in 2005 primarily relates to net proceeds of $78.7 million from the sale of 7.0 million
shares of NPS common stock, net proceeds of $19.0 million from the sale of our administrative office and laboratory building located in Salt Lake City, Utah
and the use of $4.9 million in restricted cash and cash equivalents to fund the interest expense shortfall on our Class A Notes and to pay long-term
manufacturing commitments.  Additionally, we received cash from the exercise of employee stock options and proceeds from the sale of stock by us
pursuant to the employee stock purchase plan.  Employee stock option exercises and proceeds from the sale of stock by us pursuant to the employee stock
purchase plan provided approximately $448,000, $1.1 million, and $2.3 million, respectively, of cash during 2007, 2006 and 2005.  Proceeds from the
exercise of employee stock options vary from period to period based upon, among other factors, fluctuations in the market value of NPS stock relative to the
exercise price of such options and the availability of stock to the employee stock purchase plan.

We could receive future milestone payments from all our agreements of up to $253.5 million in the aggregate if each of our current licensees
accomplishes the specified research and/or development milestones provided in the respective agreements.  In addition, all of the agreements require the
licensees to make royalty payments to us if they sell products covered by the terms of our license agreements.  However, we do not control the subject
matter, timing or resources applied by our licensees to their development programs.  Thus, potential receipt of milestone and royalty payments from these
licensees is largely beyond our control.  Further, each of these agreements may be terminated before its scheduled expiration date by the respective
licensee either for any reason or under certain conditions.

We have entered into certain research and license agreements that require us to make research support payments to academic or research institutions
when the research is performed.  Additional payments may be required upon the accomplishment of research milestones by the institutions or as license
fees or royalties to maintain the licenses.  As of December 31, 2007, we have a total commitment of up to $1.3 million for future research support and
milestone payments.  Further, depending on the commercial success of certain of our products, we may be required to pay license fees or royalties.  For
example, we are required to make royalty payments to certain licensors on GATTEX net sales and cinacalcet HCl royalty revenues.  We expect to enter into
additional sponsored research and license agreements in the future.

We have entered into long-term agreements with certain manufacturers and suppliers that require us to make contractual payment to these
organizations.  We expect to enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which
may require up-front payments and long-term commitments of cash.

The following represents our contractual obligations as of December 31, 2007 (in millions):

|                                      |  |   |       |  |   | Less than |  |   |           |  |   |           |  |   | More than
|------------------------------------- |  | - | ----- |  | - | --------- |  | - | --------- |  | - | --------- |  | - | ---------
|Contractual Obligations               |  |   | Total |  |   | 1 year    |  |   | 2-3 years |  |   | 4-5 years |  |   | 5 years  
|Operating Leases                      |  | $ | 1.0   |  | $ | 0.4       |  | $ | 0.6       |  | $ | -         |  | $ | -        
|Purchase Commitments (1)              |  |   | 21.4  |  |   | 21.3      |  |   | 0.1       |  |   | -         |  |   | -        
|Convertible Notes Payable             |  |   | 50.6  |  |   | 0.6       |  |   | -         |  |   | -         |  |   | 50.0     
|Interest on Convertible Notes Payable |  |   | 20.2  |  |   | 4.0       |  |   | 5.8       |  |   | 5.8       |  |   | 4.6      
|Secured Notes Payable (2)             |  |   | 310.8 |  |   | 24.3      |  |   | 84.1      |  |   | 157.0     |  |   | 45.4     
|Interest on Secured Notes Payable (2) |  |   | 241.0 |  |   | 27.4      |  |   | 63.0      |  |   | 125.6     |  |   | 25.0     
|Capital Lease Obligation              |  |   | 0.2   |  |   | 0.1       |  |   | 0.1       |  |   | -         |  |   | -        
|Royalty payment obligation            |  | $ | 5.8   |  | $ | 1.0       |  | $ | 2.0       |  | $ | 2.0       |  | $ | 0.8      

________________

|(1) | Purchase obligations primarily represent commitments for services ($17.2 million), manufacturing agreements ($2.8 million) and other
research and purchase commitments ($1.4 million).                                                                                                                                       
|--- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|(2) | Amounts shown as contractual commitments under our Secured Notes payable represent our estimate of expected principal repayment
based on anticipated cinacalcet HCl royalty income. Amounts shown in interest on Secured Notes include our expected premium redemption payment
based on cinacalcet HCl royalty income levels.

51

---

We expect that our existing capital resources excluding marketable investment securities classified as long-term, including interest earned thereon, will
be sufficient to allow us to maintain our current and planned operations through at least 2008. However, our actual needs will depend on numerous factors,
including the progress and scope of our internally funded research, development and commercialization activities; our ability to comply with the terms of our
research funding agreements; our ability to maintain existing collaborations; our decision to seek additional collaborators; the success of our collaborators in
developing and marketing products under their respective collaborations with us; our success in producing clinical and commercial supplies of our product
candidates on a timely basis sufficient to meet the needs of our clinical trials and commercial launch; the costs we incur in obtaining and enforcing patent
and other proprietary rights or gaining the freedom to operate under the patents of others; and our success in acquiring and integrating complementary
products, technologies or businesses. Our clinical trials may be modified or terminated for several reasons including the risk that our product candidates will
demonstrate safety concerns; the risk that regulatory authorities may not approve our product candidates for further development or may require additional
or expanded clinical trials to be performed; and the risk that our manufacturers may not be able to supply sufficient quantities of our drug candidates to
support our clinical trials or commercial launch, which could lead to a disruption or cessation of the clinical trials or commercial activities. We may also be
required to conduct unanticipated clinical trials to obtain regulatory approval of our product candidates, GATTEX and NPSP558.  If any of the events that
pose these risks comes to fruition, our actual capital needs may substantially exceed our anticipated capital needs and we may have to substantially modify
or terminate current and planned clinical trials or postpone conducting future clinical trials. As a result, our business may be materially harmed, our stock
price may be adversely affected, and our ability to raise additional capital may be impaired.

We will need to raise substantial additional funds to support our long-term research, product development, and commercialization programs. We
regularly consider various fund raising alternatives, including, for example, partnering of existing programs, monetizing of potential revenue streams, debt or
equity financing and merger and acquisition alternatives. We may also seek additional funding through strategic alliances, collaborations, or license
agreements and other financing mechanisms. There can be no assurance that additional financing will be available on acceptable terms, if at all. If adequate
funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research and development programs, or to obtain
funds through arrangements with licensees or others that may require us to relinquish rights to certain of our technologies or product candidates that we
may otherwise seek to develop or commercialize on our own.

Critical Accounting Policies and Estimates

Our discussion and analysis of our consolidated financial condition and results of operations are based upon our consolidated financial statements,
which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to
make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets
and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue and research and development costs.
We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form
the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from
these estimates under different assumptions or conditions.

We believe the following critical accounting policies affect the significant judgments and estimates used in the preparation of our consolidated financial
statements:


revenue recognition;accrual of research and development expenses;share based payments;marketable securities;accrued redemption premium and effective interest computation and;valuation of long-lived and intangible assets and goodwill.52Revenue Recognition. We earn our revenue from product sales, license fees, milestone payments, research
and development support payments and royalty payments. As described below, significant management judgment and estimates must be made and used in
connection with the revenue recognized in any accounting period. Material differences may result in the amount and timing of our revenue for any period if
our management made different judgments or utilized different estimates.We apply the provisions of Staff Accounting Bulletin No. 104, Revenue Recognition,or SAB No. 104, to
all of our revenue transactions and Emerging Issues Task Force, or EITF, Issue No. 00-21, Revenue Arrangements with Multiple Deliverables, to all
revenue transactions entered into in fiscal periods beginning after June 15, 2003. We recognize revenue from product sales when persuasive
evidence of an arrangement exists, title to product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection from
the customer is reasonably assured and we have no further performance obligations. All revenues from product sales are recorded net of the applicable
provision for returns in the same period the related sales are recorded. We recognize revenue from milestone payments as agreed upon events
representing the achievement of substantive steps in the development process are achieved and where the amount of the milestone payment approximates
the value of achieving the milestone. We recognize revenue from up-front nonrefundable license fees on a straight-line basis over the period we have
continuing involvement in the research and development project. Royalties from licensees are based on third-party sales of licensed products and are
recorded in accordance with the contract terms when third-party results are reliably measurable and collectability is reasonably assured. Cash received in
advance of the performance of the related research and development support and for nonrefundable license fees when we have continuing involvement is
recorded as deferred revenue. Where questions arise about contract interpretation, contract performance, or possible breach, we continue to recognize
revenue unless we determine that such circumstances are material and/or that payment is not probable.

We analyze our arrangements entered into after June 15, 2003 to determine whether the elements can be separated and accounted for
individually or as a single unit of accounting in accordance with EITF No. 00-21. Allocation of revenue to individual elements which qualify for
separate accounting is based on the estimated fair value of the respective elements.

Pursuant to the guidance in EITF Issues No. 99-19, "Reporting Revenue Gross as a Principal versus Net as an Agent,"and No. 01-14, "Income Statement Characterization of Reimbursements Received for 'Out-of-Pocket'
Expenses Incurred,"the Company analyzes whether to categorize reimbursed expenses from corporate partners as a) the gross
amount billed or b) the net amount retained, the Company will analyze the relevant facts and circumstances related to these expenses and considered the
factors, as specified in the EITF Issues noted above.

Accrual of Research and Development Expenses. Research and development costs are expensed as incurred and include salaries and
benefits; costs paid to third-party contractors to perform research, conduct clinical trials, develop and manufacture drug materials and delivery devices; and
associated overhead expenses and facilities costs. Clinical trial costs are a significant component of research and development expenses and include costs
associated with third-party contractors. Invoicing from third-party contractors for services performed can lag several months. We accrue the
costs of services
rendered in connection with third-party contractor activities based on our estimate of management fees, site management and monitoring costs and data
management costs. Differences between actual clinical trial costs from estimated clinical trial costs have not been material and are adjusted for in the period
in which they become known.
Share-Based Payments. We grant options to purchase our common stock to our employees and directors under our stock option plans. The
benefits provided under these plans are share-based payments subject to the provisions of revised SFAS No. 123R. Effective January 1, 2006,
we use the fair value method to apply the provisions of SFAS No. 123R with a modified prospective application which provides for certain changes to
the method for valuing share-based compensation. The valuation provisions of SFAS No. 123R apply to new awards and to awards that are
outstanding on the effective date and subsequently modified or cancelled. Under the modified prospective application, prior periods are not revised for
comparative purposes. Share-based compensation expense recognized under SFAS No. 123R during 2007 was $6.0 million, including $1.0 million for
accelerated vesting of stock options under the 2007 Restructuring. At December 31, 2007, total unrecognized estimated compensation expense
related to non-vested stock options, restricted stock and restricted stock units was $12.0 million, which is expected to be recognized over a weighted-
average period of 1.45 years.Upon adoption of SFAS No. 123R, we began estimating the value of stock option awards on the date of grant using a
Black-Scholes pricing model (Black-Scholes model). Similarly, prior to the adoption of SFAS No. 123R, the value of all share-based awards was
estimated on the date of grant using the Black-Scholes model for the pro forma information required to be disclosed under SFAS No. 123. The
determination of the fair value of share-based payment awards on the date of grant using the Black-Scholes model is affected by our stock price as well as assumptions53regarding a number of complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over
the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rate and expected dividends. If factors change and
we employ different assumptions in the application of SFAS No. 123R in future periods, the compensation expense that we record under SFAS
No. 123R may differ significantly from what we have recorded in the current period.

Estimates of share-based compensation expenses are significant to our financial statements, but these expenses are based on option valuation models
and will never result in the payment of cash by us.

The guidance in SFAS No. 123R and SAB 107 is relatively new, and best practices are not well established. The application of these principles
may be subject to further interpretation and refinement over time. There are significant differences among valuation models, and there is a possibility that we
will adopt different valuation models in the future. This may result in a lack of consistency in future periods and materially affect the fair value estimate of
share-based payments. It may also result in a lack of comparability with other companies that use different models, methods and assumptions.

For purposes of estimating the fair value of stock options granted during 2007 using the Black-Scholes model, we have made an estimate regarding our
stock price volatility. We used a combination of historical volatility and the implied volatility of market-traded options in our stock for the expected volatility
assumption input to the Black-Scholes model, consistent with the guidance in SFAS No. 123R and SAB No. 107. In calculating the estimated
volatility for 2007, we weighted implied volatility at zero percent and historical volatility at 100 percent. The risk-free interest rate is based on the yield curve
of U.S. Treasury strip securities for a period consistent with the expected life of the option in effect at the time of grant (weighted-average of 4.7% for 2007).
We do not target a specific dividend yield for our dividend payments, but we are required to assume a dividend yield as an input to the Black-Scholes model.
The dividend yield assumption is based on our history and expectation of dividend payouts (weighted-average of zero for 2007). The expected term is
estimated using historical option exercise information (weighted-average of 3.5 years for 2007).

Marketable Securities.  We account for our marketable securities in accordance with SFAS No. 115, Accounting for Certain
Investments in Debt and Equity Securities, and classify our marketable investment securities as available for sale.   Available for sale securities are
recorded at fair value. Unrealized holding gains and losses, net of the related tax effect, are excluded from earnings and are reported as a separate
component of stockholders' deficit until realized. A decline in the market value below cost that is deemed other than temporary is charged to results of
operations resulting in the establishment of a new cost basis for the security.  Our marketable securities consist primarily U.S. dollar denominated corporate
or government debt securities. Debt securities generally are long long-term securities with coupons that may or may not reset periodically against a
benchmark interest rate.

At December 31, 2007, we had approximately $53.3 million at fair value invested auction rate securities, or ARS.  ARS are variable interest rate
securities tied to short-term interest rates with nominal long-term maturities.  ARS have
interest rate resets through a modified Dutch auction, at
predetermined short-term intervals, usually every 7, 28, 35, or 49 days.   With the liquidity issues experienced in global credit and capital markets, our ARS
portfolio has recently experienced multiple unsuccessful auctions as the amount of ARS submitted for sale has exceeded the amount of purchase orders.
Given the unsuccessful auctions, certain of the Company's ARS are illiquid until there is a successful auction for them.

In establishing the estimated market value of our ARS, we have used the market value determined by our investment advisors. The market values were
determined using a proprietary valuation model using the quality of the underlying securities or assets securing the ARS investments, the market values of
comparable securities, the quality of credit enhancement (if any) applicable to the specific security, estimated time to maturity or unwinding of the
arrangement, an analysis of the terms of the indentures and other factors depending on the individual ARS.  Factors that may impact our valuation include
changes to credit ratings of the securities as well as to the underlying assets supporting those securities, rates of default of the underlying assets, underlying
collateral value, discount rates, counterparty risk and ongoing strength and quality of market credit and liquidity.

If uncertainties in the credit and capital markets continue, these markets deteriorate further or if the Company experiences ratings downgrades on any
investments in our portfolio, including on ARS, the market value of the Company's investment portfolio may decline further, which the Company may
determine is an other-than-temporary impairment.  This would result in a realized loss and would negatively affect the Company's financial position, results
of operations and liquidity.

54Accrued Redemption Premium and Effective Interest Computation.  We accrue for estimated redemption premiums on our Class A Notes as
provided for in our December 2004 loan agreement.  The Class A Notes accrue interest at an annual rate of 8.0%.  Additionally, in the event we receive
royalty and milestone payments under our agreement with Amgen above certain specified amounts, a redemption premium on principal payments is owed.
The redemption premium ranges from 0% to 41.5% of principal payments, depending on the annual net sales of Sensipar by Amgen.  We estimate future
net sales of Sensipar by Amgen, compare our estimate to specified amounts in the Class A Note agreement to determine estimated redemption premiums
over the life of the Class A Notes, and then calculate the effective interest-rate on the Class A Notes by including the forecasted redemption premiums.  As a
result, the effective interest-rate is comprised of the stated interest rate of 8.0% on Class A Notes plus the estimated redemption premiums on the Class A
Notes.  Changes to the future Sensipar net sales forecast may have a material impact on interest expense.  Management evaluates its future Sensipar net
sales estimates on a quarterly basis and adjusts the effective interest-rate and corresponding accrued redemption premium when information indicates that
the estimate is materially above or below the prior estimate.

In July 2007, we entered into an agreement with DRI Capital, or DRI, in which we sold to DRI our right to receive future royalty payments arising from
sales of PREOTACT under our licensing agreement with Nycomed.  We received an up-front purchase price of $50.0 million and may receive an additional
milestone if future sales thresholds are achieved.  If and when DRI receives two and a half times the principal advanced, the agreement will terminate and
the remainder of the royalties, if any, will revert back to us.  We have determined that we should classify the initial up-front purchase price as debt and
amortize this using the effective interest-rate method over the estimated period to recover two and a half times the initial principal advanced.  We estimate
future net sales of PREOTACT by Nycomed and then calculate the effective interest-rate on the DRI Secured Notes.  Changes to the future PREOTACT net
sales forecast may have a material impact on interest expense.  Management evaluates its future PREOTACT net sales estimates on a quarterly basis and
adjusts the effective interest-rate when information indicates that the estimate is materially above or below the prior estimate.

Valuation of Long-lived and Intangible Assets and Goodwill. We assess the impairment of long-lived assets and goodwill whenever
events or changes in circumstances indicate that the carrying value may not be recoverable. Factors we consider important which could trigger an
impairment review include the following:

•

significant underperformance relative to expected historical or projected future operating results;•

significant changes in the manner of our use of the acquired assets or the strategy for our overall business;•

significant negative industry or economic trends;•

significant decline in our stock price for a sustained period; and•

our market capitalization relative to net book value.Our balance sheet reflects net long-lived assets of $11.4 million, including goodwill of $11.1 million as of
December 31, 2007.

When we determine that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above
indicators of impairment, we measure any impairment based on a probability weighted projected discounted cash flow method using a discount rate
determined by our management to be commensurate with the risk inherent in our current business model. Provision has been made for any impairment
losses related to our long-lived assets.

Goodwill represents the excess of costs over fair value of assets of businesses acquired. Goodwill and intangible assets acquired in a purchase
business combination and determined to have an indefinite useful life are not amortized, but instead tested for impairment at least annually.

Recent Accounting Pronouncements

In September 2006, the Financial Accounting Standards Board, or FASB, issued Statement on Financial Accounting Standard No. 157, Fair Value
Measurements,or SFAS No. 157. SFAS No. 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting
principles and expands disclosures about fair value measurements. SFAS No. 157 applies under other accounting pronouncements that require or permit
fair value measurements, the FASB having previously concluded in those accounting pronouncements that fair value is the relevant measurement attribute.
Accordingly, SFAS No. 157 does not require any new fair value measurements. SFAS No. 157 is effective for fiscal years beginning after November 15,
2007 for financial assets and liabilities and fiscal years beginning after November 15, 2008 for non-financial assets and liabilities. We are currently evaluating the55impact, if any, the adoption of SFAS No. 157 will have on our consolidated financial position, results of operations and cash flows.

In February 2007, the FASB issued Statement on Financial Accounting Standard No. 159, *The Fair Value Option for Financial Assets and
Financial Liabilities-including an amendment of FASB Statement No. 115, or SFAS No 159.*SFAS No. 159 permits entities to choose to measure
many financial instruments and certain other items at fair value that are not currently required to be measured at fair value, with unrealized gains and losses
related to these financial instruments reported in earnings at each subsequent reporting date. SFAS No. 159 is effective for first fiscal years beginning after
November 15, 2007. We are currently evaluating the impact, if any, the adoption of SFAS No. 159 will have on our consolidated financial position, results of
operations and cash flows.

In June 2007, the FASB ratified the Emerging Issues Task Force, or EITF, consensus on EITF Issue No. 07-3, Advance Payments for Research and
Development Activities. EITF Issue No. 07-3 requires companies to record non-refundable advance research and development payments to acquire
goods and services as an asset if the contracted party has not yet performed the related activities.  The amount capitalized is then recognized as expense
when the research and development activities are performed.  EITF Issue No. 07-3 is effective for fiscal years beginning after December 15, 2008 and is to
be applied prospectively for new contractual agreements.  We are currently evaluating the impact, if any, the adoption of EITF Issue No. 07-3 will have on
our consolidated financial position, results of operations and cash flows.

At its December 2007 meeting, the FASB ratified the consensus reached by the EITF in EITF Issue No. 07-1, Accounting for Collaborative
Arrangements Related to the Development and Commercialization of Intellectual Property. The EITF concluded that a collaborative arrangement is one
in which the participants are actively involved and are exposed to significant risks and rewards that depend on the ultimate commercial success of the
endeavor. Revenues and costs incurred with third parties in connection with collaborative arrangements would be presented gross or net based on the
criteria in EITF Issue No. 99-19, Reporting Revenue Gross as a Principal versus Net as an Agent, and other accounting literature. Payments to or
from collaborators would be evaluated and presented based on the nature of the arrangement and its terms, the nature of the entity's business and whether
those payments are within the scope of other accounting literature. The nature and purpose of collaborative arrangements are to be disclosed along with the
accounting policies and the classification and amounts of significant financial statement amounts related to the arrangements. Activities in the arrangement
conducted in a separate legal entity should be accounted for under other accounting literature; however, required disclosure under EITF Issue No. 07-1
applies to the entire collaborative agreement. This issue is effective for fiscal years beginning after December 15, 2008, and is to be applied using a
modified retrospective method to all periods presented for all collaborative arrangements existing as of the effective date. We are currently evaluating the
impact, if any, the adoption of EITF Issue No. 07-1 will have on our consolidated financial position, results of operations and cash flows.

ITEM 7A.
Quantitative and Qualitative Disclosures About Market Risk.Interest Rate Risk. Our interest rate risk exposure results from our investment portfolio, our convertible notes, and our secured notes.
Our primary objectives in managing our investment portfolio are to preserve principal, maintain proper liquidity to meet operating needs and maximize yields.
The securities we hold in our investment portfolio are subject to interest rate risk. At any time, sharp changes in interest rates can affect the fair value of the
investment portfolio and its interest earnings. For certain securities, such as ARS, there are limits on the interest rate these securities can pay contractually.
Increases in interest rates in excess of these contractual limits could cause the value of our investments to decline.  After a review of our marketable
investment securities, we believe that in the event of a hypothetical ten percent increase in interest rates, the resulting decrease in fair market value of our
marketable investment securities would be insignificant to the consolidated financial statements. Currently, we do not hedge these interest rate exposures.
We have established policies and procedures to manage exposure to fluctuations in interest rates. We place our investments with high quality issuers and
limit the amount of credit exposure to any one issuer and do not use derivative financial instruments in our investment portfolio. We invest in highly liquid,
investment-grade securities and money market funds of various issues, types and maturities. These securities are classified as available for sale and,
consequently, are recorded on the balance sheet at fair value with unrealized gains or losses reported as accumulated other comprehensive income as a
separate component in stockholders' equity (deficit). Our 3.0 percent Convertible Notes in the principal amount of $598,000 due June 15, 2008, our
5.75 percent Convertible Notes in the principal amount of $50.0 million due 2014, our 8.0 percent Class A Notes in the principal amount of $154.5 million
due 2017, and our 15.5 percent Class B Notes in the principal amount of $106.2 million due 2017, each have a fixed interest rate. The fair value of the
Convertible Notes is affected by changes in the interest rates and by changes in the price of our common stock. The fair value of the Secured Notes is
affected by changes in the interest rates and by historical rates of royalty revenues from cinacalcet HCl sales.

56Marketable Securities Risk.  At December 31, 2007, included within our investment portfolio are investments in auction rate securities
(ARS) with a fair value of $53.3 million.  With the liquidity issues experienced in the global credit and capital markets, our ARS have experienced multiple
failed auctions.  While we continue to earn interest on these investments at the maximum contractual rate, the estimated market values of these ARS no
longer approximates the principal value.  As of December 2007, we have recorded an unrealized loss of $2.4 million in accumulated other comprehensive
income for auction rate securities with declines in value deemed to be temporary.  See Note 5 to the consolidated financial statements.
Foreign Currency Risk. We have significant clinical and commercial manufacturing agreements which are denominated in euros and
Canadian Dollars. As a result, our financial results could be affected by factors such as a change in the foreign currency exchange rate between the U.S.
dollar and the Canadian dollar or euro, or by weak economic conditions in Canada or Europe. When the U.S. dollar strengthens against the Canadian dollar
or euros, the cost of expenses in Canada or Europe decreases. When the U.S. dollar weakens against the Canadian dollar or euro, the cost of expenses in
Canada or Europe increases. The monetary assets and liabilities in our foreign subsidiary which are impacted by the foreign currency fluctuations are cash,
accounts receivable, accounts payable, and certain accrued liabilities. A hypothetical ten percent increase or decrease in the exchange rate between the
U.S. dollar and the Canadian dollar or euro from the December 31, 2007 rate would cause the fair value of such monetary assets and liabilities in our
foreign subsidiary to change by an insignificant amount. We are not currently engaged in any foreign currency hedging activities.


57ITEM 8.
Financial Statements and Supplementary Data.NPS PHARMACEUTICALS, INC. AND SUBSIDIARIES
Table of Contents

|                                                                                   |  | Page
|---------------------------------------------------------------------------------- |  | ----
|Reports of Independent Registered Public Accounting Firm                           |  | 59  
|                                                                                   | 
|Consolidated Balance Sheets(restated)                                              |  | 61  
|                                                                                   | 
|Consolidated Statements of Operations(restated)                                    |  | 62  
|                                                                                   | 
|Consolidated Statements of Stockholders' Deficit and Comprehensive Loss (restated) |  | 63  
|                                                                                   | 
|Consolidated Statements of Cash Flows(restated)                                    |  | 65  
|                                                                                   | 
|Notes to Consolidated Financial Statements                                         |  | 66  

58

---

Report of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders 
   NPS Pharmaceuticals, Inc.:
We have audited the accompanying consolidated balance sheets of NPS Pharmaceuticals, Inc. and subsidiaries as of December 31, 2007 and
2006, and the related consolidated statements of operations, stockholders' deficit and comprehensive loss, and cash flows for each of the years in the
three-year period ended December 31, 2007. These consolidated financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these consolidated financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An
audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe
that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of NPS
Pharmaceuticals, Inc. and subsidiaries as of December 31, 2007 and 2006, and the results of their operations and their cash flows for each of the
years in the three-year period ended December 31, 2007, in conformity with U.S. generally accepted accounting principles.
As discussed in Note 2, the Company's 2007 consolidated financial statements have been restated.
As discussed in Note 1 to the consolidated financial statements, the Company adopted the provisions of Statement of Financial Accounting Standards
No. 123R, "Share-Based Payment", effective January 1, 2006.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), NPS
Pharmaceuticals, Inc.'s internal control over financial reporting as of December 31, 2007, based on criteria established in Internal
Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our
report dated March 14, 2008, except for the fifth paragraph of Management's Report on Internal Control over Financial Reported (As
Restated), as to which the date is May 19, 2008, expressed an adverse opinion on the effectiveness of the Company's internal control
over financial reporting.


/s/ KPMG LLPPrinceton, New Jersey
   March 14, 2008, except for Note 2
   as to which the date is May 19, 200859Report of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders 
   NPS Pharmaceuticals, Inc.:

We have audited NPS Pharmaceuticals, Inc.'s internal control over financial reporting as of December 31, 2007,
based on criteria established in Internal Control—Integrated Frameworkissued by the Committee of Sponsoring Organizations of the
Treadway Commission (COSO). NPS Pharmaceuticals, Inc.'s management is responsible for maintaining effective internal control over financial
reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's
Report on Internal Control over Financial Reporting (As Restated) appearing under Item 9A(b). Our responsibility is to express an opinion
on the Company's internal control over financial reporting based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial
reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting,
assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on
the assessed risk.  Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that
our audit provides a reasonable basis for our opinion.
A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records
that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide
reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally
accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of
management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized
acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any
evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or
that the degree of compliance with the policies or procedures may deteriorate.
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a
reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a
timely basis. Management has identified and included in its assessment the following material weaknesses:  an ineffective control environment,
financial reporting risk assessment process, supervisory and monitoring activities, and policies and procedures with respect to share-based
compensation, accrued liabilities, and interest expense.  We also have audited, in accordance with the standards of the Public Company
Accounting Oversight Board (United States), the consolidated balance sheets of NPS Pharmaceuticals, Inc. as of December 31, 2007 and
2006, and the related consolidated statements of operations, stockholders' deficit and comprehensive loss, and cash flows for each of the years
in the three-year period ended December 31, 2007.  These material weaknesses were considered in determining the nature, timing, and
extent of audit tests applied in our audit of the 2007 consolidated financial statements, and this report does not affect our report dated March 14,
2008, except for Note 2, as to which the date is May 19, 2008, that expressed an unqualified opinion on those consolidated financial
statements.
In our opinion, because of the effect of the aforementioned material weaknesses on the achievement of the objectives of the control criteria,
NPS Pharmaceuticals, Inc. has not maintained effective internal control over financial reporting as of December 31, 2007, based on criteria
established in Internal Control—Integrated Framework issued by  COSO./s/ KPMG LLPPrinceton, New Jersey
March 14, 2008, except for the fifth paragraph of Management's Report on Internal Control over Financial Reporting (As
Restated), as to which the date is May 19, 2008


60NPS PHARMACEUTICALS, INC. AND SUBSIDIARIES
                                                       Consolidated Balance Sheets 
                                                       December 31, 2007 and 2006(In thousands, except share data)2007


2006RestatedAssets


(Note 2)Current assets:Cash and cash equivalents

$
91,682

$
36,244Marketable investment securities


41,649


109,908Restricted cash and cash equivalents


24,560


21,921Accounts receivable


19,518


15,534Inventory


-


363Prepaid expenses


1,239


1,989Assets held for sale, net of accumulated depreciation of zero and $2,988, respectively


-


2,327Other current assets


6,437


1,403Total current assets


185,085


189,689Plant and equipment, net


309


19,849Goodwill


11,088


9,333Marketable investment securities


28,357


-Debt issuance costs, net of accumulated amortization of $10,011 and $6,660, respectively


7,014


5,569Other assets


-


300$
231,853

$
224,740Liabilities and Stockholders' DeficitCurrent liabilities:Accounts payable

$
3,369

$
2,057Accrued expenses and other current liabilities


4,931


6,224Accrued research and development expenses


5,128


2,020Accrued severance expenses


-


2,516Accrued interest expense


12,387


11,241Accrued restructuring charges


2,337


607Deferred revenue


29,020


758Current installments of notes payable, lease financingand capital lease obligations


24,992


19,044Total current liabilities


82,164


44,467Notes payable, less current portion


336,357


346,690Capital lease and lease financing obligations, less current portion


92


18,843Deferred revenue


-


5,045Other liabilities


4,896


2,939Total liabilities


423,509


417,984Commitments and contingencies (notes 3, 9, 10, 11, 13, and 19)Stockholders' deficit:Preferred stock, $0.001 par value. Authorized 5,000,000 shares; issued and outstanding no shares


-


-Common stock, $0.001 par value. Authorized 105,000,000 shares; issued and outstanding46,834,216 shares and 46,223,649 shares, respectively


47


46Additional paid-in capital


683,955


677,474Accumulated other comprehensive loss


(2,504)


(1,892)Accumulated deficit


(873,154)


(868,872)Total stockholders' deficit


(191,656)


(193,244)$
231,853

$
224,740See accompanying notes to consolidated financial statements.


61NPS PHARMACEUTICALS, INC. AND SUBSIDIARIES
Consolidated Statements of Operations 
                   Years ended December 31, 2007, 2006, and 2005 
                   (In thousands, except per share data)


2007


2006


2005RestatedRevenues:


(Note 2)Product sales

$
20,310

$
2,662

$
-Royalties


49,626


32,078


12,533Milestones and license fees


16,312


13,762


292Total revenues


86,248


48,502


12,825Operating expenses:Cost of goods sold


6,180


1,413


-Cost of royalties


4,659


2,980


1,144Cost of license fees


1,547


-


-Research and development


38,723


68,411


117,445Selling, general and administrative


26,998


52,177


48,635Restructuring charges


13,386


8,179


-Total operating expenses


91,493


133,160


167,224Other operating (gains) losses:Gain on sale of assets held for sale


(1,826)


-


-Gain on sale of fixed assets


(6,384)


-


-Gain on sale of assets


(30,000)


-


-Write down of long-lived assets


-


8,297


-Total other operating (gains) losses


(38,210)


8,297


-Operating income (loss)


32,965


(92,955)


(154,399)Other income (expense):Interest income


9,518


9,120


8,639Interest expense


(41,397)


(28,970)


(25,119)Loss on marketable investment securities


(4,113)


(156)


(13)Gain on extinguishment of debt


1,315


-


-Loss on extinguishment of lease financing obilgation


(970)


-


-Foreign currency transaction gain (loss)


(815)


170


904Other


(5)


123


210Total other expense, net


(36,467)


(19,713)


(15,379)Income (loss) before income tax expense (benefit)


(3,502)


(112,668)


(169,778)Income tax expense (benefit)


780


-


(55)Net loss

$
(4,282)

$
(112,668)

$
(169,723)Basic and Diluted net loss per common and potential common share

$
(0.09)

$
(2.43)

$
(4.14)Weighted average common and potential commonshares outstanding—basic and diluted


46,804


46,374


41,036See accompanying notes to consolidated financial statements.


62NPS PHARMACEUTICALS, INC. AND SUBSIDIARIES
Consolidated Statements of Stockholders' Deficit and Comprehensive Loss 
                   Years ended December 31, 2007, 2006 and 2005 
                   (In thousands, except share data)


Accumulated


Accumulated


Total stock-Additional





Comprehensive


other


deficit,


holders' deficitPreferred


Common


paid-in


Deferred


loss, Restated


comprehensive


Restated


Restatedstock


stock


capital


compensation


(Note 2)


loss


(Note 2)


(Note 2)Balances, December 31, 2004

$
-

$
39

$
578,268

$
(2,527)




$
(2,088)

$
(586,481)

$
(12,789)Issuance of 7,000,000 shares ofcommon stock for cash (note 10)


-


7


78,646


-





-


-


78,653Issuance of 132,173 shares of commonstock for cash under option plans


-


-


1,136


-





-


-


1,136Issuance of 151,962 shares ofdeferred stock for services


-


-


1,707


-





-


-


1,707Issuance of 103,575 shares of commonstock for cash under employeepurchase plan


-


-


1,151


-





-


-


1,151Compensation expense on stockoptions and stockappreciation rights


-


-


1,334


-





-


-


1,334Deferred compensation, net ofcurrent year expense


-


-


1,800


(593)





-


-


1,207Gross unrealized losses onmarketable securities













$
(572)Reclassification for realized losseson marketable securities














13Net unrealized losses on marketableinvestment securities


-


-


-


-


(559)


(559)


-


(559)Foreign currency translation gain


-


-


-


-


359


359


-


359Net loss


-


-


-


-


(169,723)


-


(169,723)


(169,723)Comprehensive loss


-


-


-


-

$
(169,923)


-


-


-Balances, December 31, 2005


-


46


664,042


(3,120)





(2,288)


(756,204)


(97,524)Issuance of 8,662 shares of commonstock for cash under option plans


-


-


73


-





-


-


73Issuance of 37,703 shares of commonstock for deferred stock units


-


-


-


-





-


-


-Issuance of 169,712 shares of commonstock for cash under employeepurchase plan


-


-


1,036


-





-


-


1,036Reversal of deferred compensationupon adoption of SFAS123R (note 11)


-


-


(3,120)


3,120





-


-


-Compensation expense on restrictedstock, deferred stock units andrestricted stock units


-


-


2,011


-





-


-


2,011Compensation expense on stockoptions and stockappreciation rights


-


-


13,432


-





-


-


13,432Gross unrealized gains onmarketable securities













$
406Reclassification for realized losseson marketable securities














156Net unrealized gains on marketableinvestment securities


-


-


-


-


562


562


-


562Foreign currency translation gain


-


-


-


-


(166)


(166)


-


(166)Net loss


-


-


-


-


(112,668)


-


(112,668)


(112,668)Comprehensive loss


-


-


-


-

$
(112,272)


-


-


-Balances, December 31, 2006

$
-

$
46

$
677,474

$
-




$
(1,892)

$
(868,872)

$
(193,244)63NPS PHARMACEUTICALS, INC. AND SUBSIDIARIES
Consolidated Statements of Stockholders' Deficit and Comprehensive Loss-(Continued) 
                   Years ended December 31, 2007, 2006 and 2005 
                    (In thousands, except share data)


Accumulated


Accumulated


Total stock-Additional





Comprehensive


other


deficit,


holders' deficitPreferred


Common


paid-in


Deferred


loss, Restated


comprehensive


Restated


Restatedstock


stock


capital


compensation


(Note 2)


loss


(Note 2)


(Note 2)Balances, December 31, 2006

$
-

$
46

$
677,474

$
-




$
(1,892)

$
(868,872)

$
(193,244)Issuance of 10,386 shares of commonstock for cash under option plans


-


-


52


-





-


-


52Issuance of 247,347 shares of commonstock for deferred and restrictedstock units


-


1


-


-





-


-


1Issuance of 229,733 shares of commonstock for services rendered





-


942














942Issuance of 123,101 shares of commonstock for cash under employeepurchase plan


-


-


395


-





-


-


395Compensation expense on restrictedstock, deferred stock units andrestricted stock units


-


-


1,509


-





-


-


1,509Compensation expense on stockoptions, stock appreciation rightsand employee stock purchase plan


-


-


3,583


-





-


-


3,583Gross unrealized loss onmarketable securities













$
(2,118)Reclassification for realized losseson marketable securities














49Net unrealized losses on marketableinvestment securities


-


-


-


-


(2,069)


(2,069)


-


(2,069)Foreign currency translation gain


-


-


-


-


1,457


1,457


-


1,457Net loss


-


-


-


-


(4,282)


-


(4,282)


(4,282)Comprehensive loss


-


-


-


-

$
(4,894)


-


-


-Balances, December 31, 2007

$
-

$
47

$
683,955

$
-




$
(2,504)

$
(873,154)

$
(191,656)See accompanying notes to consolidated financial statements.

64NPS PHARMACEUTICALS, INC. AND SUBSIDIARIES
Consolidated Statements of Cash Flows 
                   Years ended December 31, 2007, 2006 and 2005 
                   (In thousands)


2007


2006


2005RestatedCash flows from operating activities:


(Note 2)Net loss

$
(4,282)

$
(112,668)

$
(169,723)Adjustments to reconcile net loss to net cashprovided by (used in) operating activities:Depreciation and amortization


3,984


6,487


5,921Realized gain on disposition of assets held for sale


(1,826)


-


-(Gain) loss on sale of fixed assets


(6,384)


16


-Interest expense on notes payable


9,179


-


-Realized gain on extinguishment of debt andlease financing obligation


(345)


-


-Write down of long-lived assets


-


8,297


-Realized loss on marketable investment securities


4,113


156


13Bad debt expense


-


50


-Compensation expense on deferred stock units, restricted stock unitsand restricted stock


2,452


2,011


1,564Compensation expense on stock options and stock appreciation rights


3,583


13,432


2,439Decrease (increase) in operating assets:Accounts receivable


(4,645)


(11,313)


(2,849)Prepaid expenses, other current assets and other assets


(3,786)


(223)


58Inventory


396


(374)


-Increase (decrease) in operating liabilities:Accounts payable and accrued expenses


587


(13,136)


(1,888)Deferred revenue


22,581


3,902


2,115Other liabilities


1,995


(549)


936Net cash provided by (used in) operating activities


27,602


(103,912)


(161,414)Cash flows from investing activities:Sales and maturities of marketable investment securities


423,734


159,306


223,297Purchases of marketable investment securities


(389,975)


(108,765)


(232,406)Acquisitions of equipment and leasehold improvements


(160)


(1,302)


(13,359)Proceeds from sale of assets held for sale


4,371


-


-Proceeds from sale of fixed assets


24,662


11


-Net cash provided by (used in) investing activities


62,632


49,250


(22,468)Cash flows from financing activities:Proceeds from lease financing obligations


-


-


19,000Proceeds from issuance of notes payable


200,000


-


-Principal payments on notes payable and lease financing obligation


(228,546)


(1,266)


-Principal payments under lease financing obligations


-


(105)


(52)Payment of debt issuance costs


(4,747)


(434)


(32)Proceeds from issuance of common stock


448


1,109


80,940Decrease (increase) in restricted cash and cash equivalents


(2,639)


(7,389)


4,905Net cash (used in) provided by financing activities


(35,484)


(8,085)


104,761Effect of exchange rate changes on cash


688


279


617Net increase (decrease) in cash and cash equivalents


55,438


(62,468)


(78,504)Cash and cash equivalents at beginning of year


36,244


98,712


177,216Cash and cash equivalents at end of year

$
91,682

$
36,244

$
98,712See accompanying notes to consolidated financial statements.

65NPS PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements 
                  December 31, 2007, 2006, and 2005

(1) Organization and Summary of Significant Accounting Policies

The consolidated financial statements are comprised of the financial statements of NPS Pharmaceuticals, Inc. and its subsidiaries (NPS), collectively
referred to as the Company. The Company is developing specialty therapeutics for gastrointestinal (GI) and endocrine disorders with high unmet medical
need.  Its lead clinical programs involve two proprietary proteins to restore or replace biological function, GATTEXTM (teduglutide) and
NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection).  GATTEX is an analog of GLP-2, a protein involved in the regeneration and repair of the
intestinal lining, and is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome or SBS.  SBS affects patients who have
had 50% or more of their small intestine removed.  Given GATTEX's activity in promoting gastrointestinal repair, the Company is also evaluating GATTEX's
role in treating other gastrointestinal conditions associated with intestinal failure, specifically gastrointestinal mucositis, necrotizing enterocolitis, and Crohn's
disease.  NPSP558 is in Phase 2 clinical testing as a hormone replacement therapy for hypoparathyroidism, a disorder that decreases blood calcium due to
an insufficiency of parathyroid hormone.  In addition to the Company's proprietary clinical portfolio, the Company has a number of royalty-based clinical- and
commercial-stage programs.

In 2006 and 2007, the Company announced plans to restructure operations and in 2007 implemented a new business strategy to focus resources on
developing GATTEX and NPSP558 for specialty indications with high unmet medical need.  Previously, the Company's strategic priority was to obtain U.S.
regulatory approval of PREOS® (parathyroid hormone 1-84 [rDNA origin] injection) for the treatment of osteoporosis.  In connection with the
implementation of its new plan, during 2007 the Company suspended or monetized programs within its product portfolio that were no longer deemed
strategic and discontinued investment in discovery and early stage research.  Since inception, the Company's principal activities have been performing
research and development, raising capital and establishing research and license agreements.  All monetary amounts are reported in U.S. dollars unless
specified otherwise.

The following significant accounting policies are followed by the Company in preparing its consolidated financial statements:

(a) Cash Equivalents

The Company considers all highly liquid investments with maturities at the date of purchase of three months or less to be cash equivalents. Cash
equivalents at December 31, 2007 and 2006 consist of commercial paper, money market funds, debt securities and other highly liquid instruments of
approximately $85.7 million and $25.2 million, respectively. At December 31, 2007 and 2006, the book value of cash equivalents approximates fair
value.

Total restricted cash and cash equivalent balances at December 31, 2007 and 2006 were $24.6 million and $21.9 million, respectively. The
restricted amount at December 31, 2007 and 2006 consists of amounts for estimated redemption premiums, interest and principal on the Class A
Notes (see Note 11), and is classified as current.
(b) Marketable Investment Securities

The Company classifies its marketable investment securities as available for sale. Available for sale securities are recorded at fair value. Unrealized
holding gains and losses, net of the related tax effect, are excluded from earnings and are reported as a separate component of stockholders' deficit until
realized. A decline in the market value below cost that is deemed other than temporary is charged to results of operations resulting in the establishment of a
new cost basis for the security. Premiums and discounts are amortized or accreted into the cost basis over the life of the related security as adjustments to
yield using the effective-interest method. Interest income is recognized when earned. Realized gains and losses from the sale of marketable investment
securities are based on the specific identification method and are included in results of operations and are determined on the specific-identification basis.

66(c) Trade Accounts Receivable

Trade accounts receivable are recorded for research and development support performed; for license fees, milestone payments and royalty income
earned; and, for product sales and do not bear interest. The Company determines an allowance for doubtful accounts based on assessed customers' ability
to pay, historical write-off experience, and economic trends. Such allowance for doubtful accounts is the Company's best estimate of the amount of probable
credit losses in the Company's existing accounts receivable. The Company reviews its allowance for doubtful accounts monthly. The Company recorded
bad debt expense of zero, $50,000, and zero for the years ended December 31, 2007, 2006 and 2005, respectively. At December 31, 2007 and
2006 the allowance for bad debts was zero.

(d) Inventory

Inventory is recorded at the lower of cost or market and only capitalized once compounds have been approved by the appropriate regulatory agencies.
Cost, which includes amounts related to materials, labor and overhead, is determined using the first-in, first-out (FIFO) method.

(e) Plant and Equipment

Plant and equipment are stated at cost. Depreciation of plant was calculated on the straight-line method over its estimated useful life of 25 years in
Mississauga, Ontario, Canada and 39 years in Salt Lake City, Utah. Depreciation and amortization of equipment are calculated on the straight-line method
over estimated useful lives of 3 to 5 years. Leasehold improvements are amortized using the straight-line method over the shorter of the life of the asset or
remainder of the lease term. Assets held for sale, if any, are reported at the lower of the carrying amount, or fair value, less cost to sell. Depreciation is no
longer recorded once management has identified an asset as held for sale.
(f) Goodwill

Goodwill represents the excess of costs over fair value of assets of businesses acquired. Goodwill and intangible assets acquired in a purchase
business combination and determined to have an indefinite useful life are not amortized, but instead tested for impairment at least annually.
(g) Income Taxes

The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are
recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and
their respective tax bases, operating loss, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to
apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The
Company evaluates the need for a valuation allowance based on historical and projected income and whether the realizability of a deferred tax asset is
deemed to be more likely than not.
(h) Revenue Recognition

The Company analyzes its revenue arrangements to determine whether the elements should be separated and accounted for individually or as a single
unit of accounting.  Allocation of revenue to individual elements which qualify for separate accounting is based on the estimated fair value of the respective
elements.
The Company earns revenue from license fees, milestone payments, royalty payments, research and development support payments and
product sales. The Company recognizes revenue from up-front nonrefundable license fees on a straight-line basis over the period wherein the Company has
continuing involvement in the research and development project. The Company recognizes revenue from up-front nonrefundable license fees upon receipt
when there is no continuing involvement in the research and development project. The Company recognizes revenue from its milestone payments as
agreed-upon events representing the achievement of substantive steps in the development process are achieved and where the amount of the milestone
payment approximates the value of achieving the milestone. Royalties from licensees are based on third-party sales of licensed products and are recorded
in accordance with contract terms when sales results are reliably measurable and collectibility is reasonably assured. The Company recognizes revenue
from product sales when persuasive evidence of an arrangement exists, title to product and associated risk of loss has67passed to the customer, the price is
fixed or determinable, collection from the customer is reasonably assured and the Company has no further performance obligations. All revenues from
product sales are recorded net of the applicable provision for returns in the same period the related sales are recorded. Cash received for nonrefundable
licensee fees in which the Company has continuing involvement is recorded as deferred revenue.

The Company analyzes whether to categorize reimbursed expenses from corporate partners as a) the gross amount billed or b) the net amount
retained, the Company will analyze the relevant facts and circumstances related to these expenses and considered the factors noted above.

(i) Research and development expenses

Research and development expenses, are expensed as incurred and are primarily comprised of the following types of costs incurred in performing
research and development activities: salaries and benefits, overhead and occupancy costs, clinical trial and related clinical manufacturing costs, contract
services, and other outside costs.
(j) Selling, general and administrative expenses

Selling, general and administrative expenses are primarily comprised of salaries and benefits associated with sales and marketing, finance, legal, and
other administrative personnel; outside marketing expenses; overhead and occupancy costs; and other general and administrative costs.
(k) Income (Loss) per Common Share

Basic income (loss) per common share is the amount of income (loss) for the period applicable to the weighted average shares of common stock
outstanding during the reporting period. Diluted income (loss) per common share is the amount of income (loss) for the period plus interest expense
applicable to weighted average shares of common stock outstanding during the reporting period and weighted average share that would have been
outstanding assuming the issuance of common shares for all dilutive potential common shares.

(l) Share-Based Compensation

Prior to January 1, 2006, the Company employed the footnote disclosure provisions of Statement of Financial Accounting Standards (SFAS)
No. 123, Accounting for Stock-Based Compensation,and SFAS No. 148,Accounting for Stock-Based Compensation-
Transition and Disclosure, an amendment of SFAS No. 123. SFAS No. 123 encouraged entities to adopt a fair-value-based method of
accounting for stock options or similar equity instruments. However, it also allowed an entity to continue measuring compensation cost for stock-based
compensation using the intrinsic-value method of accounting prescribed by the Accounting Principles Board (APB) Opinion No. 25, Accounting for
Stock Issued to Employees. The Company had elected to continue to apply the provisions APB Opinion No. 25, under which no compensation
cost was recognized when the exercise price of the option equaled the market price of the stock on the date of grant for options granted to employees.

Effective January 1, 2006, the Company adopted the fair value recognition provision of SFAS No. 123R, share Based Payment,using the modified prospective method. Under this method, compensation cost during the years ended December 31, 2007 and 2006 includes the
portion vesting during the year for (1) all share-based payments granted prior to, but not vested as of December 31, 2005, based on the grant
date fair value estimated in accordance with the original provision of SFAS No. 123 and (2) all share-based payments granted subsequent to
December 31, 2005, based on the grant date fair value estimated using the Black-Scholes option-pricing model. The Company uses the straight-line
method of amortization for stock-based compensation.
(m) Use of Estimates

Management of the Company has made estimates and assumptions relating to reporting of assets and liabilities and the disclosure of contingent assets
and liabilities to prepare these consolidated financial statements in conformity with U.S. generally accepted accounting principles. Actual results could differ
from those estimates.
(n) Principles of Consolidation

The consolidated financial statements include the accounts of the Company, all subsidiaries in which it owns a majority voting interest including a
variable interest entity in which the Company is the primary beneficiary. The68Company eliminates all intercompany accounts and transactions in
consolidation. The Company reports all monetary amounts in U.S. dollars unless specified otherwise.

(o) Accounting for Impairment of Long-Lived Assets

The Company reviews its long-lived assets, excluding goodwill, for impairment whenever events or changes in circumstances indicate that the carrying
amount of an asset may not be recoverable. Recoverability of assets held and used is measured by a comparison of the carrying amount of an asset to
future net cash flows (undiscounted) expected to be generated by the asset. In addition, future events impacting cash flows for existing assets could render
write-down necessary where, previously, no such write-down was required. If such assets are considered to be impaired, the impairment to be recognized is
measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets held for sale are reported at the lower of
the carrying amount, or fair value, less costs to sell.(p) Foreign Currency Translation

The local foreign currency is the functional currency for the Company's foreign subsidiaries. Assets and liabilities of foreign operations are translated to
U.S. dollars at the current exchange rates as of the applicable balance sheet date. Revenues and expenses are translated at the average exchange rates
prevailing during the period. Adjustments resulting from translation are reported as a separate component of stockholders' deficit. Certain transactions of the
foreign subsidiaries are denominated in currencies other than the functional currency, including transactions with the parent company. Transaction gains
and losses are included in other income (expense) for the period in which the transaction occurs. The Company's subsidiaries operating in Canada had net
liabilities of approximately $37.4 million as of December 31, 2007 and net assets of approximately $4.3 million as of December 31, 2006.
(q) Operating Segments
The Company is engaged in the development and commercialization of pharmaceutical products, and in its current state of
development, considers its operations to be a single reportable segment. Financial results of this reportable segment are presented in the accompanying
consolidated financial statements. The Company's subsidiaries operating outside of the United States had long-lived assets, including goodwill, of
approximately $11.1 million and $9.8 million as of December 31, 2007 and 2006, respectively. The Company recognized non-United States revenue
of $39.4 million, $5.5 million and $269,000, respectively, during the years ended December 31, 2007, 2006 and 2005. Substantially all of the
Company's revenues for the years ended December 31, 2007 and 2006 were from five licensees of the Company. The majority of the Company's
revenue for the year ended December 31, 2005 were from two licensees. As of December 31, 2007 and 2006, the majority of the Company's
accounts receivable balances were from two licensees and four licensees, respectively.
(r) Comprehensive Income (Loss)

Comprehensive income (loss) consists of net income (loss) and other gains and losses affecting stockholders' equity (deficit) that, under U.S. generally
accepted accounting principles, are excluded from net income (loss).  For the Company, these consist of net unrealized gains or losses on marketable
investment securities and foreign currency translation gains and losses. Accumulated other comprehensive loss as of December 31, 2007 and 2006
consists of accumulated net unrealized losses on marketable investment securities of $2.4 million and $326,000, respectively, and foreign currency
translation losses of $109,000 and $1.6 million, respectively.
(s) Concentration of Suppliers

The Company has entered into agreements with contract manufacturers to manufacture clinical and commercial supplies of its product candidates. In
some instances, the Company is dependent upon a single supplier. The loss of one of these suppliers could have a material adverse effect upon the
Company's operations.

(t) Leases
The Company leases its facility under terms of a lease agreement which provides for rent holidays and escalating payments. Rent
under operating leases is recognized on a straight-line basis beginning with lease commencement through the end of the lease term. The Company records
deferred lease payments in other long-term liabilities.

69(u) Reclassifications

Certain prior year amounts have been reclassified to conform with the current year presentation.

(v) Deferred Financing Costs


Costs incurred in issuing the 3% and 5.75% convertible notes are amortized using the straight-line method over the shorter of the term of the
related instrument or the initial date on which the holders can require repurchase of the notes. The amortization of deferred financing costs is included in
Interest expense in the Consolidated Statements of Operations.
(w) Deferred License Fees

Cost of license fees are deferred if they are a direct cost of a revenue generating activity and that revenue is being deferred.  These deferred costs are
amortized over the same period and in the same manner as the related deferred revenue.  The amortization of deferred license fees is included in Cost of
license fees in the Consolidated Statements of Operations.

(x) Legal Defense Costs
Legal defense costs are expensed as incurred.

(2) Restatement of Consolidated Financial Statements


During the preparation of the financial results for the quarter ended March 31, 2008, the Company identified an error in the
computation of the redemption premium interest expense, under the effective interest method, for the year ended December 31,
2007, associated with the Secured 8.0% Notes due on March 30, 2017 (Class A Notes).  Accordingly, the Company has restated its
Consolidated Balance Sheet as of December 31, 2007 to increase accrued interest expense related to the Class A Notes by $3.8
million.  Additionally, the Company discovered an error in computing interest expense, under the effective interest method, related to
the amortization of debt issuance costs, the correction of which increased debt issuance costs by $96,000.  The tax impact on both
entries resulted in a decrease of income taxes payable by $74,000.  The Company has also restated its Consolidated Statement of
Operations as of December 31, 2007 to increase interest expense related to the Class A notes by $3.8 million, decrease interest
expense related to reduced amortization of debt issuance costs by $96,000 and decrease income tax expense for the tax effect of
these entries by $74,000.The following tables present the effects of all restatement adjustments on the consolidated financial statements reconciling
the "as previously reported" data to the "as restated" data for the Consolidated Balance Sheet as of December 31, 2007, and the
Consolidated Statement of Operations for the year ended December 31, 2007.December 31, 2007As PreviouslyConsolidated Balance Sheets





Reported

As RestatedDebt issuance costs, net





$
6,918

$
7,014Total assets






231,757


231,853Accrued expenses and other current liabilities






5,005


4,931Accrued interest expense






8,592


12,387Total current liabilities






78,443


82,164Total liabilities






419,788


423,509Accumulated deficit






(869,529)


(873,154)Total stockholders' deficit






(188,031)


(191,656)Total liabilities and stockholders' deficit





$
231,757

$
231,85370Year ended December 31, 2007As PreviouslyConsolidated Statement of Operations





Reported

As RestatedInterest expense





$
(37,698)

$
(41,397)Total other expense, net






(32,768)


(36,467)Income (loss) before income tax expense (benefit)






197


(3,502)Income tax expense (benefit)






854


780Net loss






(657)


(4,282)Net loss per share





$
(0.01)

$
(0.09)The restatement did not impact the amounts presented in the 2007 Consolidated Statements of Cash Flows as net cash flows from operating,
investing or financing activities, although it did impact certain components of cash flows from operating activities.  The restatement of the consolidated
financial statements also affected footnotes 11, 14 and 21.
(3) Collaborative and License Agreements

The Company is pursuing product development both on an independent basis and in collaboration with others. Because the Company has granted
exclusive development, commercialization, and marketing rights under certain of the below-described collaborative research, development, and license
agreements, the success of each program is dependent upon the efforts of the licensees. Each of the respective agreements may be terminated early. If any
of the licensees terminates an agreement, such termination may have a material adverse effect on the Company's operations. Following is a description of
significant current collaborations and license agreements:
(a) Amgen Inc.

The Company has a development and license agreement with Amgen to develop and commercialize compounds for the treatment of
hyperparathyroidism and indications other than osteoporosis. Amgen also acquired an equity investment in the Company in 1995. Amgen paid the Company
a $10.0 million nonrefundable license fee and agreed to pay up to $400,000 per year through 2000 in development support, potential additional development
milestone payments totaling $26.0 million, and royalties on any future product sales. To date, Amgen has paid the Company $19.0 million in milestone
payments. Amgen is incurring all costs of developing and commercializing these products. Amgen received exclusive worldwide rights excluding Japan,
China, Korea, and Taiwan. The Company recognized research and licensing revenue and royalties from product sales of $46.4 million, $31.9 million and
$12.5 million in 2007, 2006 and 2005, respectively, under the contract.
(b) AstraZeneca AB

In 2001, the Company entered into a collaborative effort with AstraZeneca AB (AstraZeneca) to discover, develop, and market new small molecule
therapies for the treatment of various disorders of the central nervous system. Under the terms of the agreement, the Company licensed to AstraZeneca its
proprietary technology related to protein structures known as metabotropic glutamate receptors (mGluRs). Additionally, the Company granted AstraZeneca
exclusive rights to commercialize mGluRs subtype-selective compounds. The Company was required to co-direct the research and pay for an equal share of
the preclinical research costs, including capital and a minimum number of personnel, through March 2009 unless terminated earlier by AstraZeneca or the
Company upon six months advance written notice. During 2007, 2006 and 2005, the Company incurred $2.3 million, $4.8 million and $4.7 million,
respectively in research and development expenses under the agreement while all other collaboration costs were borne by AstraZeneca.

On October 9, 2007, the Company entered into an Asset Purchase Agreement with Astra Zeneca in which the Company agreed to sell its rights,
including intellectual property, in drugs targeting mGluRs to AstraZeneca for $30.0 million.  As the net assets sold had no book basis, the Company
recorded a gain of $30 million.  Additionally, the Company and AstraZeneca agreed to terminate the collaborative research and development agreement
related to drugs targeting mGluRs that was entered into in 2001.  As a result of this termination, the Company is no longer required to provide research FTE
support or pay for an equal share of external discovery costs, including patent related costs.


71(c) GlaxoSmithKline

In 1993, the Company entered into an agreement with GlaxoSmithKline (GSK) to collaborate on the research, development and commercialization of
calcium receptor active compounds to treat osteoporosis and other bone metabolism disorders, excluding hyperparathyroidism. GSK also acquired an equity
investment in the Company in 1993. Under the terms of the agreement, the Company may receive milestone payments of up to $23.0 million and royalties
from any product sales under the license. To date, GSK has paid the Company $12.0 million in milestone payments. A total of $5.0 million in milestone
payments may still be earned under the agreement. The Company granted GSK the exclusive license to develop and market worldwide compounds
described under the GSK agreement, subject to the Company's right to co-promote in the United States. Once compounds have been selected for
development, GSK has agreed to conduct and fund all development of such products, including all human clinical trials and regulatory submissions. In
December 2006, the Company entered into an amendment to the agreement with GSK that permits GSK to develop additional compounds.  In consideration
for this amendment, the Company received a $3.0 million fee and GSK agreed to pay up to an additional $27.0 million upon achievement of certain
milestones for these compounds.

Under the GSK agreement, the Company recognized research and licensing revenue of $3.0 million in 2006. The Company recognized no research and
licensing revenue in 2007 and 2005. The Company is entitled to receive additional payments upon the achievement of specific development and regulatory
milestones. The Company is entitled to receive royalties on sales of such compounds by GSK and a share of the profits from co-promoted products.
(d) Janssen Pharmaceutica N.V.

In 1998, Allelix entered into a collaborative agreement with Janssen Pharmaceutica N.V. (Janssen), a wholly owned subsidiary of Johnson &
Johnson, for the research, development, and marketing of new drugs for neuropsychiatric disorders. Johnson & Johnson Development
Corporation also acquired an equity investment in Allelix in 1998. Under the terms of the agreement, the Company may receive royalties from any product
sales under this license.  Janssen has the right to market products worldwide, subject to a company option for co-promotion in Canada. Janssen is incurring
all costs of developing and commercializing products. Janssen has informed the Company that they plan to seek a third party to share in the future
development costs and risks of the program. In the event Janssen enters into a collaborative agreement with a third party or sublicenses the program, we
will continue to be eligible to receive additional milestone payments of up to $20.5 million from Janssen or a licensee, if certain milestones are met and
royalties on sales of any drugs developed or sold by Janssen or a licensee under this collaboration agreement. Under the Janssen agreement, the Company
recognized no research and licensing revenue in 2007, 2006 and 2005.
(e) Kirin Brewery Company, Ltd.

In 1995, the Company entered into an agreement with the pharmaceutical division of Kirin Brewery Company, Ltd. (Kirin), a Japanese company, to
develop and commercialize compounds for the treatment of hyperparathyroidism in Japan, China, Korea, and Taiwan. Kirin paid the Company a $5.0 million
license fee and agreed to pay up to $7.0 million in research support, potential additional milestone payments totaling $13.0 million and royalties on product
sales.  Kirin is incurring all costs of developing and commercializing products. Any payments subsequent to June 2000 represent milestone and royalty
payments. To date, Kirin has paid the Company $13.0 million in milestone payments. In October 2007, Kirin received approval from the Japanese
Pharmaceuticals and Medical Devices Agency to market cinacalcet HCl in Japan for the treatment of patients with secondary hyperparathyroidism during
maintenance dialysis, where the Company achieved the 2007 milestone.  The parties participate in a collaborative research program utilizing the Company's
parathyroid calcium receptor technology. The Company recognized research and licensing revenue of $2.0 million and $2.0 million in 2007 and 2006,
respectively. The Company did not recognize any research and licensing revenue in 2005 under the agreement.
(f) Nycomed Danmark ApS

GATTEX

In September 2007 the Company entered into a license agreement with Nycomed Danmark ApS (Nycomed) in which the Company
granted Nycomed the right to develop and commercialize GATTEX, or teduglutide, outside the United States, Canada and Mexico for the treatment of
gastrointestinal disorders. The Company received $35.0 million in up-front fees under the agreement. Nycomed paid the Company $10.0 million upon
signing the license agreement and paid the Company an additional $25.0 million in up-front license fees in the fourth quarter of 2007.  Under the terms of
the agreement, the Company has the potential to earn up to $190.0 million in development and sales milestone payments plus royalties on product sales.
Under the terms of the agreement, the Company is responsible to complete the72on-going Phase 3 GATTEX clinical trials in SBS and Nycomed may elect to
share future development costs 50:50 with NPS to advance and broaden the indications for GATTEX.  Under a previously existing licensing agreement with
a third party, the Company was required to pay $6.6 million to the licensor and will be required to make future payments based on GATTEX royalties and
milestone payments earned.  Due to the Company's continuing involvement, the Company is recognizing revenue over the estimated performance period
and for the year ended December 31, 2007, the Company recognized $7.3 million in license fee revenue.  The balance of the up-front license fee has been
deferred at December 31, 2007 and is estimated to be recognized as revenue in 2008.  The Company did not recognize any research and licensing revenue
in 2006 and 2005.

PREOTACT®

In 2004, the Company signed a distribution and license agreement with Nycomed in which the Company granted Nycomed the right to develop and
market PREOTACT® in Europe. Nycomed also acquired an equity investment in the Company of $40.0 million through the purchase of
1.33 million shares of the Company's common stock. The agreement requires Nycomed to pay the Company up to 20.8 million euros in
milestone payments upon regulatory approvals and achievement of certain sales targets and pay the Company royalties on product sales. In July 2007, the
Company entered into a new license agreement with Nycomed, pursuant to which the Company granted to Nycomed the right to commercialize PREOS in
all non-U.S. territories, excluding Japan and Israel.  Nycomed's licensed rights in Canada and Mexico, however, revert back to the Company if PREOS
receives regulatory approval in the U.S.  The 2007 license agreement contains milestone and royalty payment obligations which are similar to those under
the 2004 distribution and license agreement. Nycomed is required to pay the Company royalties on sales of PREOTACT only in the European Union, the
Commonwealth of Independent States and Turkey.  The 2007 license agreement provides for the assumption by Nycomed of NPS' manufacturing and
supply obligations and patent prosecution and maintenance obligations under the 2004 license agreement.  As part of the manufacturing and supply
transfer, Nycomed paid the Company $11.0 million for a significant portion of the Company's existing bulk drug inventory.  To date, the Company has
received 5.6 million euros in milestone payments from Nycomed.  The Company recognized revenue in 2007, 2006 and 2005 of $30.1 million, $3.1
million and $234,000, respectively.

(g) Ortho-McNeil Pharmaceuticals, Inc.

In December 2006, the Company entered into an agreement with Ortho-McNeil Pharmaceuticals, Inc. (Ortho), a wholly owed subsidiary of
Johnson & Johnson, pertaining to certain NPS patents. Ortho paid the Company an $8.0 million fee and agreed to pay royalties on product sales.
NPS will not incur any development or commercialization costs for these products. The Company recognized revenue of $8.0 million in 2006. The Company
did not recognize any research and licensing revenue in 2007 and 2005.
(h) In-License and Purchase Agreements

The Company has entered into certain sponsored research, license, and purchase agreements that require the Company to make research support and
milestone payments to academic or commercial research institutions. During 2007, 2006, and 2005, the Company paid to these institutions $239,000, $1.2
million, and $2.6 million, respectively, in sponsored research payments and license fees. As of December 31, 2007, the Company had a total
commitment of up to $1.3 million for future research support. Depending on the commercial success of certain products, the Company may be required to
pay license fees or royalties. Additionally, the Company is required to pay royalties on sales of cinacalcet HCl up to a cumulative maximum of $15.0 million.
To date, $10.0 million has been accrued for related royalties payable on sales of cinacalcet HC1, of which, $4.2 million has been paid.(4) Income (loss) Per Common Share

Basic income (loss) per common share is the amount of income (loss) for the period applicable to the weighted average shares of common stock
outstanding during the reporting period. Diluted income (loss) per common share is the amount of income (loss) for the period plus interest expense
applicable to weighted average shares of common stock outstanding during the reporting period and weighted average shares that would have been
outstanding assuming the issuance of common shares for all dilutive potential common shares.

Potential common shares of approximately 13.1 million, 11.8 million and 11.4 million during the years ended December 31,
2007, 2006, and 2005, respectively, that could potentially dilute basic earnings per share in the future were not included in the computation of diluted income
(loss) per share because to do so would have been anti-dilutive for the periods presented. Potential dilutive common shares for the years ended
December 31, 2007, 2006 and 200573include approximately 7.8 million, 5.2 million and 5.2 million, common shares related to convertible
debentures, respectively, and 5.3 million, 6.5 million, and 6.2 million shares, respectively, related to stock options, stock appreciation
rights, and restricted stock units.

(5) Marketable Investment SecuritiesThe Company's investment portfolio includes investments in certain auction rate securities or ARS.  ARS are variable interest
rate securities tied to short-term interest rates with nominal long-term maturities.  ARS have interest rate resets through a modified Dutch auction, at
predetermined short-term intervals, usually every 7, 28, 35, or 49 days.   With the liquidity issues experienced in global credit and capital markets, the
Company's ARS portfolio has recently experienced multiple unsuccessful auctions as the amount of securities submitted for sale has exceeded the amount
of purchase orders.  Given the unsuccessful auctions, the Company's ARS are illiquid until there is a successful auction for them and therefore, the
Company has classified ARS marketable securities (except Sold ARS - see below) to non-current assets as of December 31, 2007.

The estimated value of the Company's ARS holdings at December 31, 2007, was $53.3 million, which reflects $2.4 million less than the its carrying
value of $55.7 million.  In establishing the estimated market value of its ARS, the Company has used the market value determined by its investment
advisors. The market values were determined using a proprietary valuation model using the quality of the underlying securities or assets securing the ARS
investments, the market values of comparable securities, the quality of credit enhancement (if any) applicable to the specific security, estimated time to
maturity or unwinding of the arrangement, an analysis of the terms of the indentures and other factors depending on the individual ARS.In March 2008, the Company agreed to sell certain of its ARS investments or the Sold ARS, to one of the Company's
investment advisors for $26.0 million.  The market value as of December 31, 2007 and the principal value of the Sold ARS were $24.9 million and $30.1
million, respectively. For the year ended December 31, 2007, the Company recognized an other-than-temporary loss of $4.1 million on the Sold ARS in the
Consolidated Statement of Operations and $1.1 million is recorded as an unrealized loss in the Accumulated Other Comprehensive Loss section of the
Consolidated Balance Sheet at December 31, 2007 on the Sold ARS.  Excluding the Sold ARS, the Company believes that the decrease in market value on
its ARS is temporary in nature due to the underlying assets securing the ARS, the AAA ratings by Standard & Poors as of December 31, 2007 and
February 29, 2008, the Company's belief that historical liquidity will return to the global credit and capital markets, and the Company's intent and ability to
hold to recovery.   None of the ARS are backed by sub-prime mortgages.  Accordingly, a $1.3 million unrealized loss was recorded at December 31, 2007 in
Accumulated Other Comprehensive Loss section of the Balance Sheet related to the ARS, excluding the Sold ARS.  The market value of these ARS,
excluding the Sold ARS, was estimated to be $28.4 million at December 31, 2007 and $26.4 million at February 29, 2008.If uncertainties in the credit and capital markets continue, these markets deteriorate further or if the Company experiences
ratings downgrades on any investments in our portfolio, including on ARS, the market value of the Company's investment portfolio may decline further,
which the Company may determine is an other-than-temporary impairment.  This would result in a realized loss and would negatively affect the Company's
financial position, results of operations and liquidity.

Investment securities available for sale as of December 31, 2007 are summarized as follows (in thousands):

Gross


Grossunrealized


unrealizedAmortized


holding


holding


Faircost


gains


losses


valueDebt securities:Corporate

$
11,845

$
49

$
(31)

$
11,863Government agency


4,870


3


(16)


4,857Auction rate securities


26,036


-


(1,107)


24,929Total investments in marketable securites-current

$
42,751

$
52

$
(1,154)

$
41,649Debt securities:Auction rate securities


29,650


-


(1,293)


28,357Total investments in marketable securites-noncurrent

$
29,650

$
-

$
(1,293)

$
28,35774Investment securities available for sale as of December 31, 2006 are summarized as follows (in thousands):

Gross


Grossunrealized


unrealizedAmortized


holding


holding


Faircost


gains


losses


valueDebt securities:Corporate

$
46,973

$
1

$
(46)

$
46,928Municipal


23,850


-


-


23,850Government agency


39,411


5


(286)


39,130$
110,234

$
6

$
(332)

$
109,908Investment securities available for sale in an unrealized loss position as of December 31, 2007 are summarized as follows (in thousands):

Held for less than 12 months


Held for more than 12 months


TotalUnrealized





Unrealized





UnrealizedFair value


losses


Fair value


losses


Fair value


lossesDebt securities:Auction Rate

$
51,536

$
2,400

$
-

$
-

$
51,536

$
2,400Corporate


7,821


31


-


-


7,821


31Government agency


-


-


2,210


16


2,210


16$
59,357

$
2,431

$
2,210

$
16

$
61,567

$
2,447All securities in an unrealized loss position as of December 31, 2007 are debt securities and the decline in fair value is
due primarily to liquidity issues experienced in global credit and capital markets and the resulting failures in auction of our auction rate securities.

Maturities of investment securities available for sale are as follows at December 31, 2007 (in thousands):

Amortizedcost


Fair valueDue within one year


$
8,226

$
8,197Due after one year through five years



8,489


8,523Due after five years through ten years



-


-Due after ten years



55,686


53,286Total debt securities


$
72,401

$
70,006(6) Inventory

Inventory consists of material purchased and manufactured subsequent to the April 2006 approval of PREOTACT in the European Union (EU). Costs
associated with inventory production that were incurred prior to EU approval of PREOTACT have been previously expensed as research and development
expense, creating an initial FIFO inventory layer with a carrying value of zero. The Company does not have any inventory as of December 31, 2007 because
the Company sold its entire inventory on hand to Nycomed pursuant to the July 2007 license agreement with Nycomed (see Note 3(f)) which provided for
the assumption by Nycomed of the Company's manufacturing and supply obligations to Nycomed.


75The following table summarizes the Company's inventory as of December 31, 2007 and 2006 (in thousands):

December 31,2007


2006Work-in process


$
-

$
300Raw materials and supplies



-


63Total inventory


$
-

$
363(7) Plant and Equipment

Plant and equipment are recorded at cost and consist of the following (in thousands):

December 31,2007


2006Building




$
-

$
15,010Equipment





582


16,567Leasehold improvements





-


3,029Total cost





582


34,606Less accumulated depreciation and amortization





(273)


(14,757)Total plant and equipment




$
309

$
19,849In July 2007, the Company entered into a Lease Termination Agreement with the Mars Discovery District, or MaRs, under which the Company's
operating lease for the office and laboratory space in Toronto, Canada was terminated.  Pursuant to the Lease Termination Agreement, the Company sold
its leasehold tenant improvements to a third party for $2.4 million.  In August 2007, the Company auctioned off the remaining Toronto facility equipment for
$1.1 million. The Company recognized a gain on sale of fixed assets during the year ended December 31, 2007 of $3.2 million on these transactions.
The termination of the Company's operating lease and sale of its leasehold tenant
improvements was part of the Company's restructuring initiatives, which included a plan to close its Mississauga and Toronto facilities and discontinue all
operations in Canada.

In May 2007, the Company closed an Agreement of Purchase and Sale to repurchase its 93,000 square foot laboratory and office building located in Salt Lake City, UT, for $20.0
million. Under the terms of the agreement, the Company's 15-year lease obligation was extinguished. The repurchase of the laboratory and office building is
considered an early extinguishment of debt. The amount paid to repurchase the laboratory and office building was in excess of the carrying value of the
lease financing obligation. Accordingly, the Company recorded a loss of $1.0 million during the year ended December 31, 2007 on such
extinguishment.

In July 2007, the Company sold its 93,000 square foot laboratory and office building, including certain laboratory and office equipment and furnishings,
located in Salt Lake City, Utah for $21.0 million. As part of the sale, the University of Utah agreed to release the Company from all obligations under a 40
year ground lease for land upon which the building is located. The Company recognized a gain on sale of fixed assets during the year ended
December 31, 2007 of $3.3 million on this transaction. The sale of this facility was part of the Company's restructuring initiative which included a plan
to close its Salt Lake City facility and to discontinue all Salt Lake City operations.

During the fourth quarter of 2006, the Company performed impairment testing of its fixed assets located in Salt Lake City, Utah and Toronto, Canada.
The Company evaluated alternative courses of action that were finalized with the decision in 2007 that operations at these sites would be closed. As a
result, the Company determined that no impairment
charge was required for the property, plant and equipment located at Salt Lake City, Utah. The
Company, however, determined that the fair value of the property and equipment and leasehold improvements located at Toronto, Canada was less than
the carrying value, resulting in an $8.3 million write-down of the assets. The Company estimated fair value based on a combination of present value
techniques and market value of assets.


76An analysis of the assets held for sale as of December 31, 2006 are summarized as follows (in thousands):

Assets held for sale, net:Land

$
558Building


1,338Equipment


431Total assets held for sale, net

$
2,327In June 2007, the Company sold its land and 85,795 square foot laboratory and office building, including certain equipment and furnishings, located in
Mississauga, Ontario, Canada for $4.4 million. The Company recognized a gain on sale of assets held for sale during the year ended December 31, 2007 of
$1.8 million on this transaction.
(8) Goodwill
The cost of acquired companies in excess of the fair value of the net assets and purchased intangible assets at acquisition date was recorded
as goodwill. As of December 31, 2007 and 2006 the Company had goodwill of $11.1 million and $9.3 million from the acquisition of Allelix in
December 1999. As a result of the annual impairment test performed by management at year-end, it was noted that fair value exceeded the carrying value
of the reporting unit.  The change in goodwill in the current year is due to the change in foreign currency exchange rates.
(9) Leases
The Company has a non-cancelable operating lease for its office space in Bedminster, New Jersey that expires in 2010 and non-cancelable
operating leases for certain equipment that expire between 2006 and 2009.  Rent-free periods and other incentives granted under the lease and
scheduled rent increases are charged to rent expense on a straight-line basis over the related terms of the lease. Rental expense for operating leases was
approximately $2.4 million, $1.2 million, and $1.6 million for 2007, 2006, and 2005, respectively. The future lease payments under noncancelable operating
leases as of December 31, 2007 are as follows (in thousands):

OperatingleasesYear ending December 31:2008





$
4262009






4572010






782011






12012






-Thereafter






-Total minimum lease payments





$
962(10) Restructuring Charges

In June 2006, as a result of the uncertainty with respect to the regulatory approval of PREOS for osteporosis, the Company began an initiative to
restructure operations (the 2006 Restructuring Plan).  Under the 2006 Restructuring Plan, NPS reduced its worldwide workforce, including employees and
contractors, by approximately 250 positions, eliminated all commercial sales and related field based activities, terminated its agreement with Allergan Inc. to
promote Restasis® Ophthalmic Emulsion to rheumatologists and closed and planned to sell the Company's technical operations facility in Mississauga,
Ontario, Canada. The reduction in workforce involved all functional disciplines including selling, general and administrative employees as well as research
and development personnel.

The charges related to the 2006 Restructuring Plan during the year ended December 31, 2007 and 2006 were $476,000 and $8.2 million, respectively.
Associated severance payments related to the 2006 Restructuring Plan were paid primarily in the second and third quarters of 2006 for severed United
States employees and are anticipated to be paid by January 31, 2008 for severed Canadian employees. The cumulative restructuring charges through
December 31, 2007 related to the 2006 Restructuring Plan were $8.7 million.


77In March 2007, the Company announced an initiative to restructure operations and to reduce its work force from 196 employees to approximately 35
employees by the end of 2007 (the 2007 Restructuring Plan). Under the 2007 Restructuring Plan, the Company closed its operations in Toronto, Canada
and Salt Lake City, Utah. These steps are part of the Company's strategy to transition to an organization that will rely primarily on outsourcing research,
development activities and manufacturing operations, as well as other functions critical to its business. The Company believes this approach enhances its
ability to focus on late stage product opportunities, preserve cash, allocate resources rapidly to different projects and reallocate internal resources more
effectively.

The charge related to the 2007 Restructuring Plan during the year ended December 31, 2007 was $12.9 million. The charge during the year ended
December 31, 2007 was comprised of $8.7 million in severance related cash expenses, $1.0 million for accelerated vesting of options under existing
employee severance agreements and retirement plan, $2.7 million for accelerated vesting of restricted stock units under employee retention plans and
$485,000 for stock awards under employee severance enhancement agreements. Associated severance payments were substantially paid by February 28,
2008 for severed US employees and are anticipated to be paid by December 31, 2008 for severed Canadian employees. The cumulative restructuring
charges through December 31, 2007 related to the 2007 Restructuring Plan were $12.9 million. Total anticipated restructuring charges as a result of the
2007 Restructuring Plan are estimated to be approximately $13.0 million.

A summary of accrued restructuring costs is as follows (in thousands):

December 31,











December 31,2005


Charges


Cash


Non-Cash


20062006 Restructuring Plan:Severance

$
-

$
7,606

$
(6,772)

$
(227)

$
607Contract Termination Costs


-


573


(573)


-


-$
-

$
8,179

$
(7,345)

$
(227)

$
607


December 31,











December 31,2006


Charges


Cash


Non-Cash


20072006 Restructuring Plan:Severance

$
607

$
476

$
(1,076)

$
-

$
72007 Restructuring Plan:Severance


-


12,910


(7,143)


(3,437)


2,330$
607

$
13,386

$
(8,219)

$
(3,437)

$
2,337(11) Long-term Debt Obligations

The following table reflects the carrying value of our long-term debt obligations under our various financing arrangements as of December 31,
2007 and 2006 (in thousands):

December 31,2007


2006Convertible notes

$
50,598

$
192,000Secured notes


310,697


173,734Capital lease


146


-Lease financing obligation


-


18,843Total borrowings


361,441


384,577Less current position


24,992


19,044Total long-term debt obligations

$
336,449

$
365,533(a) Convertible Notes

In August 2007, the Company completed a private placement of $50.0 million in 5.75% Convertible Notes due August 7, 2014 (5.75% Convertible
Notes). The Company received net proceeds from the 5.75% Convertible Notes of approximately $49.4 million, after deducting costs associated with the
offering. The 5.75% Convertible Notes accrue78interest at an annual rate of 5.75% payable quarterly in arrears on the first day of the succeeding calendar
quarter commencing January 1, 2008. Accrued interest on the 5.75% Convertible Notes was approximately $1.2 million as of December 31,
2007. The holders may convert all or a portion of the 5.75% Convertible Notes into common stock at any time, subject to certain milestones, on or before
August 7, 2014. The 5.75% Convertible Notes are convertible into common stock at a conversion price of $5.44 per share, subject to adjustments in
certain events. The 5.75% Convertible Notes are unsecured debt obligations and rank equally in right of payment with all existing and future unsecured
senior indebtedness. On or after August 7, 2012, the Company may redeem any or all of the 5.75% Convertible Notes at a redemption price of 100%
of their principal amount, plus accrued and unpaid interest to the day preceding the redemption date. The 5.75% Convertible Notes provide for certain
events of default, including payment defaults, breaches of covenants and certain events of bankruptcy, insolvency and reorganization. The 5.75 %
Convertible Notes also provide that if there shall occur a fundamental change, as defined, at any time prior to the maturity of the Note, then the holder shall
have the right, at the Holder's option, to require the Company to redeem the notes, or any portion thereof plus accrued interest and liquidated damages, if
any. If a change of control, as defined, occurs and if the holder converts notes in connection with any such transaction, the Company will pay a make whole
premium by increasing the conversion rate applicable to the notes. If any event of default occurs and is continuing, the principal amount of the 5.75%
Convertible Notes, plus accrued and unpaid interest, if any, may be declared immediately due and payable. The Company has filed a registration statement
with the SEC, which has been declared effective, covering the common stock issuable upon conversion of the 5.75% Convertible Notes.  The Company
incurred debt issuance costs of approximately $600,000, which have been deferred and which are being amortized over a seven-year period. The effective
interest rate on the 5.75% Convertible Notes, including debt issuance costs, is 6.0%.

Pursuant to the Registration Rights Agreement, the Company has fileda shelf registration
statement with the SEC, covering resales of the common stock
issuable upon conversion of the 5.75% Convertible Notes.  The
registration statement has been declared effective. The Company agreed to use its reasonable best efforts to keep the registration statement effective until
the earlier of (i) the date as of which holders may sell all of the securities covered by the registration statement without restriction pursuant to Rule 144(k)
promulgated under the Securities Act of 1933 or (ii) the date on which holders shall have sold all of the securities covered by the registration statement.  If
the Company fails to comply with these covenants or suspends use of the registration statement for periods of time that exceed what is permitted under the Registration Rights Agreement, the Company is required to pay liquidated damages in an amount equivalent to 1% per annum of
(a) the principal amount of the notes outstanding, or (b) the conversion price of each underlying share of common stock that has been issued upon conversion of a note, in each case, until the Company
is in compliance with these covenants The Company believes the likelihood of such an event occurring is remote and, as such, the Company has not
recorded a liability as of December 31, 2007.In July 2003, the Company completed a private placement of $192.0 million in 3.0% Convertible Notes due June 15,
2008 (3% Convertible Notes). The Company received net proceeds from the 3% Convertible Notes of approximately $185.9 million, after deducting costs
associated with the offering. The 3% Convertible Notes accrue interest at an annual rate of 3.0% payable semiannually in arrears on June 15 and
December 15 of each year, beginning December 15, 2003. Accrued interest on the 3% Convertible Notes was approximately zero as of
December 31, 2007. The holders may convert all or a portion of the 3% Convertible Notes into common stock at any time on or before June 15,
2008. The 3% Convertible Notes are convertible into common stock at a conversion price of $36.59 per share, subject to adjustment in certain events. The
3% Convertible Notes are unsecured senior debt obligations and rank equally in right of payment with all existing and future unsecured senior indebtedness.
On or after June 20, 2006, the Company may redeem any or all of the 3% Convertible Notes at redemption prices of 100% of their principal amount,
plus accrued and unpaid interest through the day preceding the redemption date. Upon the occurrence of a "fundamental change," as defined in
the indenture governing the 3% Convertible Notes, holders of the 3% Convertible Notes may require the Company to redeem all or a part of the 3%
Convertible Notes at a price equal to 100% of the principal amount, plus accrued and unpaid interest and liquidated damages, if any. The Company has filed
a registration statement with the United States Securities and Exchange Commission covering the resale of the 3% Convertible Notes and common stock
issuable upon conversion of the 3% Convertible Notes. The Company incurred debt issuance costs of $6.1 million, which have been deferred and are being
amortized over a five-year period. The effective interest rate on the 3% Convertible Notes, including debt issuance costs, is 3.6%.

In August 2007 the Company repurchased $20.2 million par value of outstanding 3% Convertible Notes in the open market at a price of $19.5
million plus accrued interest. Additionally, in October 2007, the Company closed a tender offer in which $171.2 million of the 3.0% Convertible Notes were
tendered to the Company for $169.1 million plus accrued interest.  These 3% Convertible Notes were subsequently retired during the year ended December
31, 2007. As of December 31, 2007, the Company had $598,000 of the 3% Convertible Notes outstanding. The repurchase and subsequent
retirement of the 3% Convertible Notes is considered an early extinguishment of debt. The amount paid79to repurchase the 3% Convertible Notes was less
than the carrying value of the 3% Convertible Notes. Accordingly, the Company recorded a gain of $1.3 million, which is net of the write-off of $823,000 of
deferred financing costs, during the year ended December 31, 2007 on such extinguishment in accordance with the provisions of Accounting
Principles Board Opinion No. 26, Early Extinguishment of Debt(APB No. 26).

(b) Secured Notes Payable
In December 2004, the Company completed a private placement of $175.0 million in Class A Notes. The Company received net
proceeds from the issuance of the Class A Notes of approximately $169.3 million, after deducting costs associated with the offering. The Class A Notes
accrue interest at an annual rate of 8.0% payable quarterly in arrears on March 30, June 30, September 30 and
December 30 of each year (Payment Date). The Class A Notes are secured by certain royalty and related rights of the Company under its agreement
with Amgen. Additionally, the only source for interest payments and principal repayment of the Class A Notes is limited to royalty and milestone payments
received from Amgen plus any amounts available in the restricted cash reserve account and earnings thereon as described later. The Class A Notes are
non-recourse to NPS Pharmaceuticals, Inc. Payments of principal will be made on March 30 of each year commencing March 30, 2006, to the
extent there is sufficient revenue available for such principal payment. As of December 31, 2007, the outstanding principal balance on the Class A
Notes was $154.5 million. In connection with the issuance of the Class A Notes, the Company was required to place $14.2 million of the Class A Notes
proceeds into a restricted cash reserve account to pay any shortfall of interest payments through December 30, 2006. All remaining amounts of this
$14.2 million were used to repay principal in March 2007. In the event the Company receives royalty and milestone payments under its agreement with
Amgen above certain specified amounts, a redemption premium on principal repayment will be owed. The redemption premium ranges from 0% to 41.5% of
principal payments, depending on the annual net sales of Sensipar by Amgen. As of December 31, 2007, the Company classified $24.3 million of the
Class A Notes as current based on royalty payments accrued during the year ended December 31, 2007 plus available balances in the restricted cash
reserve account less estimated redemption premiums. The Company may repurchase, in whole but not in part, the Class A Notes on any Payment Date at a
premium ranging from 0% to 41.5% of outstanding principal, depending on the preceding four quarters' sales of Sensipar by Amgen. The Company is
accruing the estimated redemption premiums over the estimated life of the debt of six years using the "effective interest-rate" method. Accrued
interest on the Class A Notes was approximately $8.8 million as of December 31, 2007 which includes the Company's estimate of the redemption
premium.  The Company incurred debt issuance costs of $5.7 million, which are also being amortized using the "effective interest-rate" method.
The current effective interest rate on the Class A Notes, including debt issuance costs and estimated redemption premiums, is approximately 24.8%.

In July 2007, the Company entered into an agreement with DRI Capital, or DRI, formerly Drug Royalty L.P.3, in which the Company sold to DRI its
right to receive future royalty payments arising from sales of PREOTACT under its license agreement with Nycomed. Under the agreement, DRI paid the
Company an up-front purchase price of $50.0 million. An additional $25.0 million will be due to the Company in 2010 if certain PREOTACT sales thresholds
are achieved. If and when DRI receives two and a half times the principal advanced, the agreement will terminate and the remainder of the royalties, if any,
will revert back to the Company. The Company has determined that it should classify the initial up-front purchase price as debt and amortize using the
effective interest rate method over an estimated life of 11 years.  The repayment of the $50.0 million is secured solely by future royalty payments arising
from sales of PREOTACT by Nycomed.  The effective interest rate under the agreement, including issuance costs, is approximately 17.8%.

In August 2007, the Company completed a private placement of $100.0 million in Secured 15.5% Notes due March 30, 2017 (Class B Notes). The
Company received net proceeds from the issuance of the Class B Notes of approximately $97.0 million, after deducting costs associated with the offering.
The Class B Notes accrue interest at an annual rate of 15.5% payable quarterly in arrears on March 30, June 30, September 30 and December 30 of each
year. The Class B Notes are secured by certain royalty and related rights of the Company under its agreement with Amgen. Additionally, the only source for
interest payments and principal repayment of the Class B Notes is limited to royalty and milestone payments received from Amgen and only after the Class
A Notes are paid in full. Prior to repayment in full of the Class A Notes, interest on the Class B Notes will be paid in kind through the issuance of notes (the PIK
Notes) which will be part of the same class and have the same terms and rights as the Class B Notes, except that interest on the PIK Notes will
begin to accrue from the date that such PIK Notes are issued.  The Class B Notes are non-recourse to NPS Pharmaceuticals, Inc.  The Company may
repurchase, in whole but not in part, the Class B Notes at a calculated Redemption Price based on the timing of repurchase and the source of proceeds for
the repurchase.  The Redemption Price varies between 100.0% and 107.75% depending on these variables.  PIK Notes were issued on September 30,
2007 and December 31, 2007 in the amount of $2.3 million and $3.9 million, respectively. The Company80incurred debt issuance costs of $3.6 million, which
are being amortized using the "effective interest-rate" method. The effective interest rate on the Class B Notes, including debt issuance costs, is
approximately 16.0%.

(c) Lease Financing Obligations

In December 2005, the Company completed a sale-leaseback transaction with BioMed Realty, in which the Company sold its 93,000 square foot
laboratory and office building located in Salt Lake City, Utah for $19.0 million and leased back the property under a 15-year lease. Net proceeds from the
sale were $19.0 million. Because the lease agreement in the sale-leaseback transaction contained a purchase option by the Company, the Company
accounted for the transaction as a financing arrangement where the gain on the sale of $4.3 million was deferred.

In May 2007, the Company closed an Agreement of Purchase and Sale to repurchase from BioMed Realty its 93,000 square foot laboratory and office
building for $20.0 million. Under the terms of the agreement, the Company's 15-year lease obligation was extinguished. The repurchase of the laboratory
and office building is considered an early extinguishment of debt. The amount paid to repurchase the laboratory and office building was in excess of the
carrying value of the lease financing obligation. Accordingly, the Company recorded a loss of $1.0 million during the year ended December 31, 2007 on such
extinguishment.  See Note 7

(d) Contractual maturities of long-term debt obligations
The aggregate contractual maturities of long-term debt obligations, including estimated maturities of the Secured Notes, due
subsequent to December 31, 2007 are as follows (in thousands):

Year ending December 31:2008




$
24,9922009





36,3162010





47,9122011





101,0152012





54,923Thereafter





96,283Total long-term debt obligations




$
361,441(12) Capital Stock

(a) Stockholder Rights Plan

In December 1996, the board of directors approved the adoption of a Stockholder Rights Plan (the Rights Plan). The Rights Plan was subsequently
amended on December 31, 2001 to increase the purchase price of a share of Series A Junior Participating Preferred Stock and to extend the
expiration date of the Rights Plan. The Rights Plan provides for the distribution of a preferred stock purchase right (Right) as a dividend for each outstanding
share of the Company's common stock. This Right entitles stockholders to acquire stock in the Company or in an acquirer of the Company at a discounted
price in the event that a person or group acquires 20% or more of the Company's outstanding voting stock or announces a tender or exchange offer that
would result in ownership of 20% or more of the Company's stock. Each right entitles the registered holder to purchase from the Company 1/100th of a
share of Series A Junior Participating Preferred Stock, par value $0.001 per share at a price of $300 per 1/100th of a preferred share, subject to adjustment.
The Rights may only be exercised on the occurrence of certain events related to a hostile takeover of the Company as described above. In any event, the
Rights will expire on December 31, 2011. The Rights may be redeemed by the Company at $0.01 per right at any time prior to expiration or the
occurrence of an event triggering exercise. At December 31, 2007, the Rights were not exercisable.

(b) Capital Stock Transactions

In September 2005, the Company completed a public offering of 7.0 million shares of our common stock at $11.35 per share, with net proceeds of
approximately $78.7 million, after deducting offering costs of $797,000.

81

---



(13) Share-Based Compensation Plans

As of December 31, 2007, the Company has five equity incentive plans: the 1987 Stock Option Plan (the 1987 Plan), the 1994 Equity Incentive
Plan (the 1994 Plan), the 1994 Nonemployee Directors' Stock Option Plan (the Directors' Plan), the 1998 Stock Option Plan (the 1998 Plan), and the 2005
Omnibus Incentive Plan (the 2005 Plan). An aggregate of 8,203,593 shares are authorized for future issuance under the five plans.

As of December 31, 2007, there are no shares reserved for future grant under the 1987 Plan, the 1994 Plan and the Directors' Plan. As of
December 31, 2007, there are 735,218 and 1,787,547 shares reserved for future grant under the 2005 Plan and 1998 Plan, respectively. The
Company's 2005 Plan provides for the grant of nonqualified stock options, incentive stock options, stock appreciation rights, restricted stock, restricted stock
units, performance shares, cash-based awards and other stock-based awards. The Company's 1998 Plan provides for the grant of nonqualified stock
options and incentive stock options.  Under the Company's 2005 Plan, the exercise price of stock options, the grant price of stock appreciation rights and the
initial value of performance awards, must be equal to at least 100% of the fair market value of the Company's common stock on the date of grant. Stock
options generally vest 28% after year one and 2% per month thereafter. During 2007 and 2006, directors of the Company were granted 197,357 and
178,836, respectively, in deferred stock units for services that were recorded at fair value. During 2006, certain employees and executive officers of the
Company were granted 835,798 restricted stock units which vest subject to continued employment over a two or three year period. Under the Company's
1998 Plan, the exercise price of options is generally not less than the fair market value of the Company's common stock on the date of grant. The number of
shares, terms, and exercise period are determined by the board of directors on a grant-by-grant basis, and the exercise period does not extend beyond ten
years from the date of the grant. Stock options generally vest 28% after one year and 2% to 3% per month thereafter.

The Company also had an Employee Stock Purchase Plan (the Purchase Plan) whereby qualified employees were allowed to purchase limited amounts
of the Company's common stock at the lesser of 85% of the market price at the beginning or end of the offering period or purchase period. The Company
authorized 685,000 shares for purchase by employees. Employees purchased 123,101, 169,712 and 103,575 shares under the Purchase Plan in the years
ended December 31, 2007, 2006, and 2005, respectively, and 13 shares remain available for future purchase.  The Purchase Plan has been
discontinued until additional shares are made available.



|                                                                             |  | Year Ended       
|---------------------------------------------------------------------------- |  | -----------------
|Net loss:                                                                    |  | December 31, 2005
|As reported                                                                  |  | $                
|Add: Stock-based employee compensation expense included in reported net loss |  |                  
|Deduct: Total stock-based employee compensation expense determined under     |  |                  
|fair value-based method for all awards                                       |  |                  
|Pro forma                                                                    |  | $                
|                                                                             |  |                  
|Net loss per share as reported:                                              |  |                  
|Basic and diluted                                                            |  | $                
|Pro forma:                                                                   |  |                  
|Basic and diluted                                                            |  | $                

82

---



Net loss, as reported, in 2005 also includes compensation cost of $2,000 for stock-based compensation awards for nonemployees.

The pro forma disclosure shown above reflected the fair value of each option grant estimated on the date of grant using the
Black-Scholes option-pricing model with the following weighted-average assumptions for stock options granted during the year ended December 31, 2005:

|                         |  |  | Year ended        |  
|------------------------ |  |  | ----------------- | -
|                         |  |  | December 31, 2005 |  
|Dividend yield           |  |  | -                 |  
|Expected volatility      |  |  | 66.0              | %
|Risk-free interest rate  |  |  | 4.1               | %
|Expected term (in years) |  |  | 4.6               |  

Under SFAS No. 123 with the Black-Scholes option-pricing model, the Company estimated volatility using only its
historical share price performance over the expected life of the option. Under SFAS No. 123R, however, the Company estimates expected volatility
using a blend of implied volatility based on market-traded options on the Company's common stock and historical volatility of the Company's common stock
over the expected life of the options. In calculating the estimated volatility for the years ended December 31, 2007 and 2006, the Company weighted
implied volatility at zero percent and historical volatility at 100%. Results of prior periods do not reflect any restated amounts and the Company had no
cumulative effect adjustment upon adoption of SFAS No. 123R under the modified prospective method. The Company's policy is to recognize
compensation cost for awards with only service conditions and a graded vesting schedule on a straight-line basis over the requisite service period for the
entire award. Additionally, the Company's policy is to issue new shares of common stock to satisfy stock option and stock appreciation right exercises or
grants of restricted shares or deferred stock units.

The compensation expense under SFAS No. 123R is recorded in cost of goods sold, research and development expense, selling, general and
administrative expense and restructuring charges based on the specific allocation of employees receiving the awards. Additionally, the Company eliminated
the January 1, 2006 deferred compensation balance against additional paid-in capital upon adoption of SFAS No. 123R.

The following table summarizes the effect of compensation cost arising from share-based payment arrangements on the Company's statements of
operations for the years ended December 31, 2007 and 2006 for the Company's stock option plans, the employee stock purchase plan and other
share-based awards: (in thousands)

|                                                                           |  | Year Ended        |       | Year Ended       
|-------------------------------------------------------------------------- |  | ----------------- | ----- | -----------------
|                                                                           |  | December 31, 2007 |       | December 31, 2006
|Research and development                                                   |  | $                 | 1,000 |                  
|Selling, general and administrative                                        |  |                   | 4,005 |                  
|Restructuring charges                                                      |  |                   | 1,030 |                  
|Total cost of share-based compensation                                     |  |                   | 6,035 |                  
|Amount capitalized in inventory during the year                            |  |                   | -     |                  
|Amount recognized in income for amount previously capitalized in inventory |  |                   | (18)  |                  
|Amounts charged against income, before income tax expense (benefit)        |  | $                 | 6,017 |                  

The fair value of each option award is estimated, on the date of grant using the Black-Scholes option-pricing valuation model, which incorporates ranges
of assumptions for inputs as shown in the following table. The assumptions are as follows:

| | • |  | The expected volatility is a blend of implied volatility based on market-traded options on the Company's common stock and historical
volatility of the Company's stock over the expected life of the options.                                                                                                             
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | • |  | The Company uses historical data to estimate the expected life of the option; separate groups of employees that have similar historical
exercise behavior are considered separately for valuation purposes. The expected life of options granted represents the period of time the options are
expected to be outstanding.
| | • |  | The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected life of
the option.                                                                                                                                                                  

83

---



| | • |  | The expected dividend yield is based on the Company's current dividend yield as the best estimate of projected dividend yield for
periods within the expected life of the option.
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|                              |  |  | Years ended December 31,
|----------------------------- |  |  | ------------------------
|                              |  |  | 2007                    
|Dividend yield range          |  |  | —                       
|Expected volatility range     |  |  | 58.5% — 62.4%           
|Risk-free interest rate range |  |  | 4.3% — 5.0%             
|Expected term (in years)      |  |  | 3.2 — 4.1               

A summary of activity related to aggregate stock options and stock appreciation rights under all plans is indicated in the
following table (in thousands, except per share amounts):

|                                   |  | Year ended December 31, 2007
|---------------------------------- |  | ----------------------------
|                                   |  |                             
|                                   |  | Number                      
|                                   |  | of                          
|                                   |  | options                     
|                                   |  |                             
|Options outstanding at beginning   |  |                             
|of year                            |  | 5,498                       
|Options granted                    |  | 1,821                       
|Options exercised                  |  | 12                          
|Options canceled                   |  | 2,417                       
|Options outstanding at end of year |  | 4,890                       
|                                   |  |                             
|Vested and expected to vest        |  | 4,498                       
|                                   |  |                             
|Options exercisable at end of year |  | 3,005                       

The weighted-average grant-date fair value of options granted during the years ended December 31, 2007, 2006 and
2005 was $2.05, $3.87 and $6.85, respectively. The intrinsic value for stock options is defined as the difference between the current market value and the
grant price. The total intrinsic value of stock options exercised during the years ended December 31, 2007, 2006 and 2005 was $9,000, $25,000 and
$390,000, respectively.

Restricted stock, restricted stock units and deferred stock unit grants consist of the Company's common stock. The fair value of each restricted stock
grant, restricted stock unit and deferred stock unit is equal to the market price of the Company's stock at the date of grant. Restricted stock and restricted
stock unit grants are time vested. During 2006 certain grants of restricted stock units to employees contained performance vesting criteria. During the years
ended December 31, 2007, 2006 and 2005, the Company granted 197,357, 178,836 and 151,962 deferred stock units, respectively, which did not
contain any vesting restrictions. A summary of activity related to aggregate restricted stock and restricted stock units as of December 31, 2007, is
indicated in the following table (shares in thousands):

|                               |  | Number of |  |   | Weighted-average     
|------------------------------ |  | --------- |  | - | ---------------------
|                               |  | shares    |  |   | grant date fair value
|Nonvested at beginning of year |  | 1,016     |  | $ | 5.69                 
|Granted                        |  | 442       |  |   | 4.18                 
|Vested                         |  | (561)     |  |   | 4.47                 
|Forfeited                      |  | (690)     |  |   | 4.76                 
|Nonvested at December 31, 2007 |  | 207       |  | $ | 4.99                 

As of December 31, 2007, there was $12.0 million of total unrecognized compensation cost related to all unvested
share-based compensation arrangements that is expected to be recognized over a weighted-average period of 1.45 years. During the year ended
December 31, 2007, cash received from stock options exercised was $52,000.

84

---



(14) Income Taxes

The Company has recorded income tax expense (benefit) for the years ended December 31, 2007, 2006 and 2005 of $780,000,
zero and $(55,000), respectively.

Income tax differed from the amounts computed by applying the U.S. federal income tax rate of 34% to income (loss) before income tax expense
(benefit) as a result of the following (in thousands):

|                                                                |  |   | Years ended December 31,
|--------------------------------------------------------------- |  | - | ------------------------
|                                                                |  |   | 2007                    
|                                                                |  |   | Restated                
|Computed "expected" tax expense                                 |  | $ | (1,191)                 
|Expiration of tax attributes                                    |  |   | 6,025                   
|Foreign tax rate differential                                   |  |   | (812)                   
|Change in the valuation allowance for deferred tax assets       |  |   |                         
|attributable to operations and other adjustments                |  |   | (48,407)                
|Adjustment to deferred tax assets for changes in foreign taxes, |  |   |                         
|laws and rates                                                  |  |   | 38,478                  
|U.S. and foreign credits                                        |  |   | -                       
|State income taxes, net of federal tax effect                   |  |   | 2,083                   
|Foreign R&D wage tax credits (recoverable) payable              |  |   | -                       
|Equity based compensation expense                               |  |   | 58                      
|Other                                                           |  |   | 4,546                   
|                                                                |  | $ | 780                     

The Company recorded income tax expense of $780,000 during the year ended December 31, 2007 for U.S. alternative
minimum tax.  The Company recorded income tax benefit of $55,000 during the year ended December 31, 2005 for refundable income tax credits
relating to research and development activities in the province of Quebec.

Domestic and foreign components of income (loss) before taxes are as follows (in thousands):

|                        |  |   | Years ended December 31,
|----------------------- |  | - | ------------------------
|                        |  |   | 2007                    
|                        |  |   | Restated                
|Domestic                |  | $ | 34,806                  
|Foreign                 |  |   | (38,308)                
|Total loss before taxes |  | $ | (3,502)                 

85

---



The tax effects of temporary differences that give rise to significant portions of the deferred tax assets at
December 31, 2007 and 2006 are presented below (in thousands):

|                                                        |  |   | 2007     |  |   | 2006     
|------------------------------------------------------- |  | - | -------- |  | - | ---------
|                                                        |  |   | Domestic |  |   | Foreign  
|                                                        |  |   | Restated |  |   |          
|Deferred tax assets:                                    |  |   |          |  |   |          
|Stock compensation expense                              |  | $ | 5,362    |  | $ | -        
|Accrued compensation                                    |  |   | 69       |  |   | -        
|Equipment and leasehold improvements, principally due   |  |   |          |  |   |          
|to differences in depreciation and write down of assets |  |   | (40)     |  |   | -        
|Other accrued expenses                                  |  |   | 45       |  |   | -        
|Intangible assets                                       |  |   | -        |  |   | 5,039    
|Research and development pool carryforward              |  |   | -        |  |   | 63,389   
|Net operating loss carryforward                         |  |   | 82,211   |  |   | 189,966  
|Research credit carryforward                            |  |   | 7,021    |  |   | -        
|Minimum tax credit                                      |  |   | 780      |  |   | -        
|Capital loss carryfroward                               |  |   | 1,915    |  |   | -        
|Investment tax credit carryforward                      |  |   | -        |  |   | 18,080   
|State credits                                           |  |   | -        |  |   | -        
|Deferred royalty income                                 |  |   | -        |  |   | 16,207   
|Other                                                   |  |   | -        |  |   | 210      
|Total gross deferred tax assets                         |  |   | 97,363   |  |   | 292,891  
|Less valuation allowance                                |  |   | (97,363) |  |   | (292,891)
|Deferred tax assets                                     |  |   | -        |  |   | -        
|Deferred tax liabilities                                |  |   | -        |  |   | -        
|Net deferred tax asset (liability)                      |  | $ | -        |  | $ | -        

Subsequently recognized tax benefits relating to the valuation allowance for deferred tax
assets as of December 31, 2007 will be allocated as follows: 1) To the extent that the Allelix acquired net deferred tax assets are recognized, the tax
benefit will be applied to reduce any remaining unamortized goodwill. At December 31, 2007, the remaining unamortized goodwill equaled $11.1
million. 2) Tax benefits in excess of the acquired goodwill related to the acquisition will be reported as a reduction of income tax expense. The valuation
allowance includes the benefit for stock option exercises which increased the domestic net operating loss carryforwards. Future reductions to the domestic
valuation allowance will be allocated $87.5 million to operations and $9.9 million to paid-in capital.

The net change in the Company's total valuation allowance for the years ended December 31, 2007, 2006, and 2005 was an increase of $4.8
million, $23.0 million and $59.9 million, respectively. The Company has a cumulative loss for the previous three years and projects losses into the future.
Accordingly, as of December 31, 2007, the Company believes that it is not more likely than not that results of future operations will generate sufficient
income to realize any of our gross deferred tax assets and has recorded a 100%

86

---



At December 31, 2007, the Company had domestic and foreign net operating loss and credit carryforwards available to
offset future income for tax purposes approximately as follows (in thousands):

|          |  |   | Domestic net 
operating loss
carryforward
for regular income |  |   | Domestic    
research  
credit
carry- |  |   | Canadian net operating loss
carryforward for regular
income tax purposes |  |   | Canadian     
research
pool
carry- |  |   | Canadian     
investment 
tax credit
carry-
|--------- |  | - | ------------------------------------------------------------ |  | - | ------------------------------------- |  | - | ------------------------------------------------------------------------ |  | - | ---------------------------------- |  | - | -------------------------------------------
|          |  |   | tax purposes                                                 |  |   | forward                               |  |   | Federal                                                                  |  |   | Provincial                         |  |   | forward                                    
|          |  |   | Restated                                                     |  |   |                                       |  |   |                                                                          |  |   |                                    |  |   |                                            
|Expiring: |  |   |                                                              |  |   |                                       |  |   |                                                                          |  |   |                                    |  |   |                                            
|2008      |  | $ | -                                                            |  | $ | 334                                   |  | $ | 63,523                                                                   |  | $ | 68,463                             |  |   |                                            
|2009      |  |   | -                                                            |  |   | 317                                   |  |   | 97,569                                                                   |  |   | 101,586                            |  |   |                                            
|2010      |  |   | -                                                            |  |   | 166                                   |  |   | 129,284                                                                  |  |   | 132,631                            |  |   |                                            
|2011      |  |   | -                                                            |  |   | 360                                   |  |   | -                                                                        |  |   | -                                  |  |   |                                            
|2012      |  |   | -                                                            |  |   | 846                                   |  |   | -                                                                        |  |   | -                                  |  |   |                                            
|2013      |  |   | -                                                            |  |   | -                                     |  |   | -                                                                        |  |   | -                                  |  |   |                                            
|2014      |  |   | -                                                            |  |   | -                                     |  |   | 154,409                                                                  |  |   | 157,194                            |  |   |                                            
|2015      |  |   | -                                                            |  |   | -                                     |  |   | 109,309                                                                  |  |   | 109,600                            |  |   |                                            
|2016      |  |   | -                                                            |  |   | -                                     |  |   | -                                                                        |  |   | -                                  |  |   |                                            
|2017      |  |   | -                                                            |  |   | -                                     |  |   | -                                                                        |  |   | -                                  |  |   |                                            
|2018      |  |   | 2,858                                                        |  |   | 1,035                                 |  |   | -                                                                        |  |   | -                                  |  |   |                                            
|2019      |  |   | 18,695                                                       |  |   | 989                                   |  |   | -                                                                        |  |   | -                                  |  |   |                                            
|2020      |  |   | 16,136                                                       |  |   | 722                                   |  |   | -                                                                        |  |   | -                                  |  |   |                                            
|2021      |  |   | 3,951                                                        |  |   | 240                                   |  |   | -                                                                        |  |   | -                                  |  |   |                                            
|2022      |  |   | 16,083                                                       |  |   | 363                                   |  |   | -                                                                        |  |   | -                                  |  |   |                                            
|2023      |  |   | 66,194                                                       |  |   | 296                                   |  |   | -                                                                        |  |   | -                                  |  |   |                                            
|2024      |  |   | 34,616                                                       |  |   | 412                                   |  |   | -                                                                        |  |   | -                                  |  |   |                                            
|2025      |  |   | 60,688                                                       |  |   | 511                                   |  |   | -                                                                        |  |   | -                                  |  |   |                                            
|2026      |  |   | 8,107                                                        |  |   | 430                                   |  |   | 92,239                                                                   |  |   | 94,922                             |  |   |                                            
|2027      |  |   | -                                                            |  |   | -                                     |  |   | -                                                                        |  |   | -                                  |  |   |                                            
|Total     |  | $ | 227,328                                                      |  | $ | 7,021                                 |  | $ | 646,333                                                                  |  | $ | 664,396                            |  | $ | 218,581                                    

The Company also has domestic state net operating loss carryovers and tax credit carryforwards in varying amounts depending on the different state
laws. The Company's domestic tax loss carryover for alternative minimum tax purposes is approximately the same as the Company's regular tax loss
carryover. For the year ended December 31, 2007, certain Canadian research pool carryforward amounts were reclassified to Canadian net operating
loss carryforwards as a result of audit by Canadian and Quebec tax authorities. The remaining Canadian research pool carryforward of $218.6 million
carries forward indefinitely.

As measured under the rules of the Tax Reform Act of 1986, the Company has undergone one or more greater than 50% changes of ownership since
1986. Consequently, use of the Company's domestic net operating loss carryforward and research credit carryforward against future taxable income in any
one year may be limited. The maximum amount of carryforwards available in a given year is limited to the product of the Company's fair market value on the
date of ownership change and the federal long-term tax-exempt rate, plus any limited carryforward not utilized in prior years.

Effective January 1, 2007, the Company adopted FIN 48, Accounting for Uncertainty in Income Taxes - an interpretation of FAS 109,
which was issued in July 2006. FIN 48 clarifies the accounting for uncertainty in income taxes and prescribes a recognition threshold and measurement
attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.  The Company
adopted FIN 48-1, Definition of Settlement in FASB Interpretation No. 48, retroactive to the adoption of FIN 48. FIN 48-1 provides guidance on how
an enterprise should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits.

87

---

A reconciliation of the unrecognized tax benefits for the year ended December 31, 2007 is as follows (in thousands):

UnrecognizedTax ExpenseBalance as of January 1, 2007




$
5,148Additions for current year tax positions





-Reductions for prior year tax positions





(280)Balance as of December 31, 2007




$
4,868Unrecognized tax benefits amounted to $4.9 million at December 31, 2007, and did not include any accrued potential penalties or interest.
The Company does not expect unrecognized tax benefits to change significantly over the next 12 months.

The Company accounts for penalties or interest related to uncertain tax positions as part of its provision for income taxes. Due to the Company's
net operating loss carryforwards the adjustment related to the FIN 48 liability would not expect to result in a cash tax liability. Accordingly, the Company has
not accrued for penalties or interest for both the U.S. (both Federal and State) and Canada as of December 31, 2007 and 2006. Also, due to the Company's
net operating loss carryforwards, the Company does not believe any of its unrecognized tax benefits would have an impact on the effective tax rate

The Company files income tax returns in various jurisdictions with varying statutes of limitations. As of December 31, 2007, the statute of limitations for
income tax audits in Canada remains open for the tax years ended on or after December 31, 2002. The statute of limitations for income tax audits in the US
remains open for the tax years ended on or after December 31, 2002.
(15) Employee Benefit Plan
The Company maintains a tax-qualified employee savings and retirement plan (401(k) Plan) covering all of the Company's
employees in the United States. Pursuant to the 401(k) Plan, employees may elect to reduce their current compensation up to the maximum percent
allowable, not to exceed the limits of code section 401(k), 403(b), 404 and 415, of eligible compensation or the prescribed IRS annual limit and have the
amount of such reduction contributed to the 401(k) Plan. The 401(k) Plan permits, but does not require, additional matching contributions to the 401(k) Plan
by the Company on behalf of all participants. During the years ended December 31, 2007 and 2006, the Company matched 100% of employee
contributions up to 3% of employee pre-tax contributions and 50% of employee contribution on the next 3% of employee pre-tax contributions. During the
year ended December 31, 2005 the Company matched one-half of employee contributions up to a maximum contribution from the Company of the
lesser of 3% of employee compensation or $6,300. The Company recorded an expense associated with these matching contributions for the years ended
December 31, 2007, 2006, and 2005 of $602,000, $927,000 and $607,000, respectively.
Additionally, the Company maintains a tax-qualified defined contribution pension plan for its Canadian employees. Employees may elect to reduce their
current compensation by 2% or 4% of eligible compensation up to a maximum of Cnd. $9,000 per year in 2007, and have the amount of such reduction
contributed to the pension plan. The Company matches 100% of such contributions. The Company recorded an expense associated with these matching
contributions for the years ended December 31, 2007, 2006, and 2005 of Cnd. $137,000, Cnd. $328,000, and Cnd. $342,000, respectively.
(16) Disclosure about the Fair Value of Financial Instruments
The carrying value for certain short-term financial instruments that mature or reprice frequently at market rates approximates fair value. Such
financial instruments include: cash and cash equivalents, accounts receivable, accounts payable, and accrued and other liabilities. The fair values of
marketable investment securities are based on quoted market prices at the reporting date or other methods as more fully described in Note 11. The fair
value of the Company's Convertible Notes are estimated to be approximately $586,000 and $169.9 million as of December 31, 2007 and 2006
respectively for the outstanding 3% convertible notes and $51.5 million as of December 31, 2007 for the 5.75% convertible notes. The fair value of the
Company's Secured Notes was estimated to be $156.0 million and $198.0 million as of December 31, 2007 and 2006, respectively for
the Class A Notes and $106.2 million as of December 31, 2007 for the Class B Notes. The Company does not invest in derivatives.

88(17) Recent Accounting Pronouncements

In September 2006, the Financial Accounting Standards Board, or FASB, issued Statement on Financial Accounting Standard No. 157, Fair Value
Measurements,or SFAS No. 157. SFAS No. 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting
principles and expands disclosures about fair value measurements. SFAS No. 157 applies under other accounting pronouncements that require or permit
fair value measurements, the FASB having previously concluded in those accounting pronouncements that fair value is the relevant measurement attribute.
Accordingly, SFAS No. 157 does not require any new fair value measurements. SFAS No. 157 is effective for fiscal years beginning after November 15,
2007 for financial assets and liabilities and fiscal years beginning after November 15, 2008 for non-financial assets and liabilities. We are currently
evaluating the impact, if any, the adoption of SFAS No. 157 will have on our consolidated financial position, results of operations and cash flows.

In February 2007, the FASB issued Statement on Financial Accounting Standard No. 159, *The Fair Value Option for Financial Assets and
Financial Liabilities-including an amendment of FASB Statement No. 115, or SFAS No 159.*SFAS No. 159 permits entities to choose to measure
many financial instruments and certain other items at fair value that are not currently required to be measured at fair value, with unrealized gains and losses
related to these financial instruments reported in earnings at each subsequent reporting date. SFAS No. 159 is effective for first fiscal years beginning after
November 15, 2007. We are currently evaluating the impact, if any, the adoption of SFAS No. 159 will have on our consolidated financial position, results of
operations and cash flows.

In June 2007, the FASB ratified the Emerging Issues Task Force, or EITF, consensus on EITF Issue No. 07-3, Advance Payments for Research and
Development Activities.  EITF Issue No.  07-3 requires companies to record non-refundable advance research and development payments to acquire
goods and services as an asset if the contracted party has not yet performed the related activities.  The amount capitalized is then recognized as expense
when the research and development activities are performed.  EITF Issue No. 07-3 is effective for fiscal years beginning after December 15, 2008 and is to
be applied prospectively for new contractual agreements.  The Company is currently evaluating the impact, if any, the adoption of EITF Issue No. 07-3 will
have on the Company's consolidated financial position, results of operations and cash flows.
At its December 2007 meeting, the FASB ratified the consensus reached by the EITF in Issue No. 07-1, Accounting for Collaborative
Arrangements Related to the Development and Commercialization of Intellectual Property. The EITF concluded that a collaborative arrangement is one
in which the participants are actively involved and are exposed to significant risks and rewards that depend on the ultimate commercial success of the
endeavor. Revenues and costs incurred with third parties in connection with collaborative arrangements would be presented gross or net based on the
criteria in EITF Issue No. 99-19, Reporting Revenue Gross as a Principal versus Net as an Agent, and other accounting literature. Payments to or
from collaborators would be evaluated and presented based on the nature of the arrangement and its terms, the nature of the entity's business and whether
those payments are within the scope of other accounting literature. The nature and purpose of collaborative arrangements are to be disclosed along with the
accounting policies and the classification and amounts of significant financial statement amounts related to the arrangements. Activities in the arrangement
conducted in a separate legal entity should be accounted for under other accounting literature; however, required disclosure under EITF Issue No. 07-1
applies to the entire collaborative agreement. This Issue is effective for fiscal years beginning after December 15, 2008, and is to be applied using a
modified retrospective method to all periods presented for all collaborative arrangements existing as of the effective date. The Company is currently
evaluating the impact, if any, the adoption of EITF Issue No. 07-1 will have on our consolidated financial position, results of operations and cash flows.
(18) Commitments and Contingencies
The Company has agreed to indemnify, under certain circumstances, certain manufacturers and service providers from and against any and all
losses, claims, damages or liabilities arising from services provided by such manufacturers and service providers or from any use, including clinical trials, or
sale by the Company or any Company agent of any product supplied by the manufacturers.
The Company has entered into long-term agreements with various third-party contract manufacturers for the production and packaging of drug product
and vials. Under the terms of these various contracts, we are required to purchase certain minimum quantities of drug product each year.

The Company has contractual commitments of $2.8 million for drug product for the year ending December 31, 2008, primarily with Vetter
Pharma-Fertigung GmbH & Co. or Vetter for the manufacture of clinical and commercial supplies of PREOS and GATTEX. Amounts owed to Vetter are based
on firm commitments for the purchase of drug89product.  Amounts purchased under contractual inventory commitments from third-party contract
manufacturers for the years ended December 31, 2007, 2006 and 2005 were $11.4 million, $19.4 million and $23.9 million, respectively.
(19) Legal Proceedings

A consolidated shareholders' securities class action lawsuit is currently pending against the Company and certain of its present and former officers and
directors in the U.S. District Court for the District of Utah, Central Division, as Case No. 2:06cv00570 DAK. By order dated September 14, 2006, the court
consolidated four separately filed lawsuits into this action. By order dated November 17, 2006, the court appointed lead plaintiff and counsel for the
proposed class. On January 16, 2007, the lead plaintiff and its counsel filed a consolidated amended complaint asserting two federal securities claims on
behalf of lead plaintiff and all other shareholders of NPS who purchased publicly traded shares of NPS between August 7, 2001, and May 2, 2006, which
period is referred to in this paragraph as the "class period." The consolidated complaint asserts two claims: a claim founded upon Section 10(b)
of the Securities Exchange Act of 1934, or the 1934 Act, and SEC Rule 10b-5 promulgated thereunder, which is asserted against all defendants, and a claim
founded upon Section 20(a) of the 1934 Act, which is asserted against the individual defendants.  Both claims are based on the allegations that, during the
class period, NPS and the individual defendants made false and misleading statements to the investing public concerning PREOS. The consolidated
complaint alleges that false and misleading statements were made during the class period concerning the efficacy of PREOS as a treatment for
postmenopausal osteoporosis, the potential market for PREOS, the dangers of hypercalcemic toxicity as a side effect of injectable PREOS, and the
prospects of FDA approval of our NDA for injectable PREOS. The complaint also alleges claims of option backdating and insider trading of NPS stock during
the class period.  The consolidated complaint seeks compensatory damages in an unspecified amount, unspecified equitable or injunctive relief, and an
award of an unspecified amount for plaintiff's costs and attorneys fees.

On March 19, 2007, Defendants filed a motion to dismiss the consolidated complaint, which the court denied on July 3, 2007. On August 1, 2007, the
court entered a scheduling order setting a trial date for the action on April 20, 2009. On November 1, 2007, lead plaintiff filed its motion to certify the class of
shareholders that it seeks to represent in the action. On January 30, 2008, defendants filed an opposition to this motion, and it is currently pending before
the court. Although defendants believe the motion should be denied, no assurances can be given in this regard.  If lead plaintiff's motion for class
certification is granted, the parties will continue to engage in the discovery process and prepare for trial.

The Company believes the claims are without merit and intends to vigorously defend itself and the related defendants in this action.  The Company
maintains insurance for actions of this nature, which it believes is adequate.

On August 22, 2006, an NPS shareholder filed a shareholder derivative action against certain of the Company's present and former officers and
directors.  This action, which names NPS as a nominal defendant but is asserted on NPS's behalf, is pending in the Third Judicial District Court of Salt Lake
County, State of Utah, as Case No. 060913838.  The complaint asserts allegations similar to those asserted in the securities class action described above
and also alleges that the defendant directors and officers violated their fiduciary duties by making the allegedly false and misleading statements to the
investing public concerning PREOS.  The derivative complaint seeks compensatory damages in an unspecified amount, unspecified equitable or injunctive
relief and an award of an unspecified amount for plaintiff's costs and attorneys fees.

Defendants filed a motion to dismiss the lawsuit, which the Court granted by order dated July 8, 2007.   In the order, the Court also granted plaintiff
leave to propound a books and records inspection demand under Utah law and to amend his shareholder derivative complaint.   Plaintiff served a books and
records inspection demand, in response to which NPS produced the requested documents.   On December 14, 2007, defendants filed a motion to stay the
lawsuit pending resolution of the securities class action and similar shareholder derivative lawsuits filed in U.S. District Court for the District of Utah, which is
described below.   Plaintiff has opposed defendants' motion to stay, which is currently pending before the court.   If the court does not grant defendants'
motion to stay, plaintiff will be permitted to file an amended shareholder derivative complaint.

Three additional shareholder derivative suits are pending against certain of our present and former officers and directors in the U.S. District Court for the
District of Utah.  These lawsuits are titled Wagner v. Tombros, et al. (filed July 24, 2007), Alvarez v. Jackson, et al. (filed August 17, 2007), and Sutton v.
Tombros, et al. (filed November 14,
2007).  These lawsuits also allege the defendants made false and misleading statements concerning PREOS, and that
because of these statements, the defendants breached their fiduciary duties.  In addition, the Sutton complaint alleges that the defendants made false and
misleading statements concerning GATTEX, and because of these statements, the defendants breached their fiduciary duties.  All three lawsuits seek
compensatory damages in an unspecified amount, unspecified equitable or injunctive relief and an award of an unspecified amount for plaintiff's costs and
attorneys fees.

90The Wagner, Alvarez, and Sutton complaints have not yet been served on any of the defendants, and therefore the deadlines to respond to these
complaints have not been set.

We intend to vigorously defend against all the purported shareholder derivative actions, which we believe are without merit and were brought in the
name of the corporation in violation of controlling law.  We maintain insurance for actions of this nature, which we believe is adequate.

(20) Supplemental Cash Flow Information and Non-cash Investing and Financing Activities: (in thousands)

Year Ended December 31,2007


2006


2005Cash Paid for:Interest

$
31,442

$
18,530

$
20,591Income taxes


-


-


3,607Noncash Investing and Financing Activities:Unrealized gains (losses) on marketable investment securities

$
(2,069)

$
562

$
(559)Accrued acquisition of equipment, leasehold improvements andconstruction-in-progress


-


-


477Debt issued in lieu of interest


6,246


-


-Royalties transferred in lieu of interest


2,933


-


-(21) Selected Quarterly Financial Data (Unaudited)

The following is a summary of the quarterly results of operations for the years ended December 31, 2007 and 2006 (in
thousands, except for per share amounts):

Quarters EndedMarch 31


June 30


September 30


December 31Restated(in thousands, except per share amounts)














(Note 2)2007Revenues




$
9,991

$
13,115

$
29,161

$
33,981Operating income (loss)





(15,937)


(9,200)


21,412


36,690Net income (loss)





(21,144)


(14,807)


14,089


17,580Basic income (loss) per common share

$
(0.45)

$
(0.32)

$
0.30

$
0.37Diluted income (loss) per common and potential common share

$
(0.45)

$
(0.32)

$
0.28

$
0.322006Revenues




$
6,083

$
8,282

$
10,071

$
24,066Operating loss





(34,477)


(35,001)


(14,663)


(8,798)Net loss





(38,329)


(39,275)


(21,079)


(13,985)Basic and diluted loss per common and potential common share

$
(0.83)

$
(0.85)

$
(0.45)

$
(0.30)91ITEM 9.
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.Not applicable


ITEM 9A.
Controls and Procedures.a)	Evaluation of Disclosure Controls and Procedures (As Restated)

We maintain "disclosure controls and procedures" within the meaning of Rule 13a-15(e) of the Securities Exchange Act of 1934, as
amended, or the Exchange Act. Our disclosure controls and procedures, or Disclosure Controls, are designed to ensure that information required to be
disclosed by us in the reports we file under the Exchange Act, such as this Annual Report on Form 10-K, is recorded, processed, summarized and reported
within the time periods specified in the U.S. Securities and Exchange Commission's rules and forms. Our Disclosure Controls are also designed to ensure
that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as
appropriate, to allow timely decisions regarding required disclosure.

As of the end of the period covered by this Annual Report on Form 10-K, we evaluated the effectiveness of the design and operation of our disclosure
controls and procedures, which was done under the supervision and with the participation of our management, including our Chief Executive Officer and our
Chief Financial Officer. Based on the evaluation and the identification of the material weaknesses in internal control over financial reporting described below,
our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2007, our disclosure controls and procedures were not
effective.

Management determined that at December 31, 2007 we had material weaknesses because the company did not have a sufficient number of
accounting and finance personnel with an appropriate level of knowledge and experience of U.S. generally accepted accounting principles (GAAP) that are
commensurate with our financial reporting requirements. Contributing to this lack of sufficient resources was the consolidation of corporate offices to New
Jersey as part of our March 2007 restructuring and the relocation of the company's finance and accounting function from Salt Lake City, Utah, to
Bedminster, New Jersey, resulting in a complete turnover of accounting and finance personnel, and the loss of historical institutional knowledge in this
department.

On May 5, 2008, the Company determined that it needed to restate its previously issued 2007 consolidated financial statements.  Management has
considered the impact of the restatement (as described in footnote 2 to the consolidated financial statements) on its original disclosure controls and
procedures conclusion and has determined that the interest expense errors giving rise to the restatement arose from the previously disclosed material
weaknesses and that modification of the original disclosure (as provided in the preceding three paragraphs) is not necessary.
(b)	Management's Report on Internal Control over Financial Reporting. (As Restated)
Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control
system was designed to provide our management and board of directors reasonable assurance regarding the reliability of financial reporting and preparation
of financial statements for external purposes in accordance with GAAP.  Internal control over financial reporting has inherent limitations.   Internal control
over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from
human failures.  Internal control over financial reporting also can be circumvented by collusion or improper management override.  Because of such
limitations, there is a risk that material misstatements will not be prevented or detected on a timely basis by internal control over financial reporting.
However, these inherent limitations are known features of the financial reporting process.  Therefore, it is possible to design into the process safeguards to
reduce, though not eliminate, this risk.

Our management assessed the effectiveness of internal control over financial reporting as of December 31, 2007. In making our evaluation, we
used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated
Framework. Based on our evaluation we believe that, as of December 31, 2007, we had material weaknesses in internal control over financial
reporting as described below.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility
that a material misstatement of our annual or interim financial statements will92not be prevented or detected on a timely basis. Management determined that
at December 31, 2007, it maintained an insufficient number of personnel with an appropriate level of GAAP knowledge and experience commensurate
with its financial reporting requirements.  This resulted in management determining that its control environment was ineffective.  Additionally, management
has determined that it did not maintain risk assessment procedures that were adequate to effectively identify and analyze risks to the achievement of
financial reporting objectives for individual financial statement accounts and ensure that appropriate control activities are implemented on a timely basis.
Furthermore, the insufficient number of personnel resulted in supervisory and monitoring activities inadequate to ensure that deficiencies in the operation of
controls are detected on a timely basis.  These material weaknesses contributed to material weaknesses related to ineffective policies and procedures with
respect to the Company's accounting for share-based compensation, accrued liabilities, and interest expense and resulted in errors in the Company's
preliminary 2007 consolidated financial statements.

Because of the material weaknesses described above, management has concluded that we did not maintain effective internal control over financial
reporting as of December 31, 2007, based on the Internal Control—Integrated Framework issued by COSO.

On May 5, 2008, the Company determined that it needed to restate its previously issued 2007 consolidated financial
statements.  In connection with the restatement, we determined that the errors in interest expense (as described
in Note 2 to the consolidated financial statements) that resulted in the restatement were the result of the
aforementioned material weaknesses in our internal control over financial reporting.  These material weaknesses were
identified in the assessment of the effectiveness of internal control over financial reporting as of December 31,
2007, included in our original Management's Report on Internal Control over Financial Reporting included in the
previously filed Annual Report on Form 10-K for the year ended December 31, 2007.KPMG LLP, our independent registered public accounting firm, that audited the financial statement included in this annual report has issued an audit
report on our internal control over financial reporting in which they expressed an adverse opinion on the effectiveness of our internal control over financial
reporting as of December 31, 2007. This report appears on page 60 of this report.

(c) 	Change in Internal Control over Financial Reporting.

There have been no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Remediation of Material Weaknesses in Internal Control over Financial Reporting.We have commenced efforts to
address the material weaknesses in our internal control over financial reporting and the ineffectiveness of our disclosure controls and procedures. We plan
to remediate our material weaknesses by taking actions, including but not limited to the following:

•

We are actively recruiting for finance and accounting personnel with an appropriate level of GAAP accounting knowledge and
experience and will provide requisite GAAP and SEC training to personnel responsible for our financial statement preparation, and•

We will supplement existing resources with consultants where needed, including former employees where possible.
ITEM 9B.
Other Information.None.PART III

ITEM 10. Directors, Executive Officers and Corporate Governance.

Certain of the information required by this item will be contained in our definitive Proxy Statement with respect to our Annual Meeting of Stockholders, to
be held on May 22, 2008, under the captions "Election of Directors," and "Compliance with Section 16(a) of the Exchange
Act" and "Code of Ethics" and is incorporated into this section by reference. For information regarding executive officers see Part I of this
Form 10-K under the caption "Executive Officers of the Registrant."

93ITEM 11. Executive Compensation.

Certain of the information required by this item will be contained in our definitive Proxy Statement with respect to our Annual Meeting of Stockholders, to
be held on May 22, 2008, under the captions "Executive Compensation" and except for the information appearing under the captions
"Report of the Compensation Committee of the Board of Directors" is incorporated into this section by reference.
ITEM 12. Security Ownership of Certain Beneficial Owners and Management, and Related Stockholder Matters.

Certain of the information required by this item will be contained in our definitive Proxy Statement with respect to our Annual Meeting of Stockholders, to
be held on May 22, 2008, under the captions "Security Ownership of Certain Beneficial Owners and Management" and is incorporated into
this section by reference.

ITEM 13. Certain Relationships and Related Transactions, and Director Independence.

Certain of the information required by this item will be contained in our definitive Proxy Statement with respect to our Annual Meeting of Stockholders, to
be held on May 22, 2008, under the captions "Certain Relationships and Related Transactions" and is incorporated into this section by
reference.
ITEM 14. Principal Accountant Fees and Services.

Certain of the information required by this item will be contained in our definitive Proxy Statement with respect to our Annual Meeting of Stockholders, to
be held on May 22, 2008, under the captions "Principal Accountant Fees and Services" and is incorporated into this section by reference.

PART IV

ITEM 15. Exhibits and Financial Statement Schedules.

(a) The following documents are filed as part of this Annual Report on Form 10-K.

1. Financial Statements. The financial statements listed on the accompanying Index to Consolidated Financial Statements are filed
as part of this report.

2. Financial statement schedules. There are no financial statements schedules included because they are either not applicable or
the required information is shown in the consolidated financial statements or the notes thereto.

3. Exhibits. The following exhibits are filed or incorporated by reference as part of this Form 10-K.


Exhibit
Number

Description of Document3.1A

Amended and Restated Certificate of Incorporation of the Registrant (1)3.1B

Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Registrant, dated December 16, 1999
(2)3.1C

Certificate of Designation of Series A Junior Participating Preferred Stock of the Registrant, dated December 18, 1996
(3)3.1D

Amendment to Certificate of Designation of Series A Junior Participating Preferred Stock of the Registrant, dated September 5, 2000(2)3.1E

Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Registrant, dated September 30, 2003
(14)3.2A

Amended and Restated Bylaws of the Registrant (1)3.2B

Certificate of Adoption of Amendments to the Amended and Restated Bylaws of the Registrant, dated February 19, 2003
(11)944.1

Specimen Common Stock Certificate (1)4.2A

Rights Agreement, dated as of December 4, 1996, between the Registrant and American Stock Transfer & Trust, Inc., with Exhibit
A, Form of Certificate of Designation of Series A Junior Participating Preferred Stock of the Registrant; Exhibit B, Form of Right Certificate; and Exhibit C,
Summary of Rights to Purchase Shares of Preferred Stock of the Registrant (5)4.2B

First Amendment to the Rights Agreement and Certificate of Compliance with Section 27 thereof, dated December 31, 2001 (4)4.2C

Second Amendment to the Rights Agreement and Certificate of Compliance with Section 27 thereof, dated February 19, 2003
(5)4.3

Indenture, dated as of June 17, 2003, between Registrant and U.S. Bank National Association, as Trustee, including the form of 3%
Convertible Subordinated Notes due 2008 attached as Exhibit A thereto. (13)4.4A

Composite Indenture, dated as of December 22, 2004, by and between Cinacalcet Royalty Sub LLC, a wholly-owned subsidiary of
Registrant, and U.S. National Bank Association, incorporating the amendments provided for in the Supplemental Indenture dated as of February 2, 2005,
between the same parties (the "Indenture") (16)4.4B

Second Supplemental Indenture dated October 20, 2006 to the Indenture(23)4.4C

Third Supplemental Indenture dated July 9, 2007 to the Indenture(23)4.4D

Fourth Supplemental Indenture dated August 1, 2007 to the Indenture(23)4.4E

Fifth Supplemental Indenture dated August 7, 2007 to the Indenture(23)10.1A

1994 Employee Stock Purchase Plan and Form of Offering Document (1)10.1B

1994 Employee Stock Purchase Plan as amended December 1996, and Form of Offering Document (6)10.1C

1994 Employee Stock Purchase Plan, as amended December 2002 (11)10.1D

1994 Employee Stock Purchase Plan, as amended June 2003 (14)10.1E

1994 Employee Stock Purchase Plan, as amended May 2005 (18)10.2A

1998 Stock Option Plan (28)10.2B

1998 Stock Option Plan, as amended December 2002 (11)10.2C

1998 Stock Option Plan, as amended June 2003 (14)10.2D

1998 Stock Option Plan (reflects all amendments by the Board of Directors through December 2007)(29)10.3

Form of Indemnity Agreement entered into between the Registrant and each of its officers and directors (1)10.4A

Severance Pay Plan (11)10.4B

Form of Agreement Providing Specified Benefits Following Termination of Employment Incident to a Merger, Acquisition or Other
Change of Control or to Some Other Strategic Corporate Event, between the Registrant and each of its executive officers (14)10.5A

Collaborative Research and License Agreement between the Registrant and SmithKline Beecham Corporation (now GlaxoSmithKline),
dated November 1, 1993 (1)10.5B

Amendment Agreement to Collaborative Research and License Agreement between GlaxoSmithKline, effective June 29, 1995
(8)10.5C

Amendment Agreement between the Registrant and GlaxoSmithKline, dated October 28, 1996 (3)10.5D

Amendment Agreement between the Registrant and GlaxoSmithKline, dated October 27, 1997 (9)10.5E

Amendment Agreement between the Registrant and GlaxoSmithKline, dated September 26, 1997 (9)9510.5F

Amendment to Collaborative Research and License Agreement between the Registrant and GlaxoSmithKline, dated November 26, 1997
(9)10.5G

Letter, dated January 24, 2000, from SmithKline Beecham to NPS Re: Amendment Agreement to Amend the November 26, 1997
Amendment Agreement to Amend the November 26, 1997 Amendment Agreement (11)10.5H

Letter, dated May 15, 2000, from SmithKline Beecham to NPS Re: Amendment Agreement (11)10.5I

Letter, dated August 1, 2001, from GlaxoSmithKline to NPS Re: Amendment Agreement to Amend the January 24, 2000 Amendment
Agreement (11)10.5J

Amendment Agreement dated December 14, 2006 between the Registrant and SmithKline Beecham Corporation, dba
GlaxoSmithKline(24)10.6A

Patent Agreement between the Registrant and The Brigham and Women's Hospital, Inc., dated February 19, 1993 (1)10.6B

Letter dated March 15, 1993 from the Registrant to The Brigham and Women's Hospital, Inc. regarding Patent Agreement between the
Registrant and The Brigham and Women's Hospital, Inc. (11)10.6C

Amendment to Patent Agreement between the Registrant and The Brigham and Women's Hospital, Inc., effective February 7, 1996
(10)10.6D

1999 Patent Agreement Amendment between the Registrant and The Brigham and Women's Hospital, Inc., effective February 18, 1999
(11)10.7

Collaborative Research and License Agreement between the Registrant and Kirin Brewery Company, Ltd. dated June 29, 1995
(10)10.8

Development and License Agreement between the Registrant and Amgen Inc. effective as of December 27, 1995 (8)10.9

Manufacturing Agreement between NPS Allelix Corp. and SynCo Bio Partners B.V., effective as of May 17, 2001 (12)10.10

Addendum to Manufacturing Agreement between NPS Allelix Corp. and SynCo Bio Partners B.V., effective as of October 26, 2001
(12)10.11

Lease Agreement between Registrant and University of Utah, effective December 10, 2003 (14)10.12

Lease Agreement between MaRS Discovery District and Registrant, dated April 12, 2004 (15)10.13A

Distribution and License Agreement between Registrant and Nycomed Danmark ApS, dated April 26, 2004 (15)*10.13B

First Amendment to Distribution and License Agreement between the Registrant and Nycomed Danmark ApS, dated July 1, 2004
(15)*10.13C

License Agreement, dated July 2, 2007, between NPS Allelix Corp. and Nycomed Danmark ApS*(27)10.14

Compensation Agreement (17)10.15A

2005 Omnibus Incentive Plan, as amended on December 28, 2007(29)10.15B

Form of Stock Option Grant Agreement under the 2005 Omnibus Incentive Plan (20)10.16A

Non-Employee Director Deferred Compensation Program (19)10.16B

Form of Deferred Stock Unit Award Agreement (19)10.17

Employment Agreement with N. Anthony Coles, M.D. (21)10.18A

Agreement of Purchase and sale between Registrant and Biomed Realty, L.P. dated December 20, 2005 (21)10.18B

Lease Agreement between Registrant and BMR-383 Colorow Drive, LLC dated December 22, 2005 (21)10.18C

Agreement of Purchase and Sale, dated May 9, 2007, between NPS Pharmaceuticals, Inc. and BMR-383 Colorow Drive LLC
(25)9610.19

Separation Agreement dated May 11, 2006 by and between NPS Pharmaceuticals and Hunter Jackson (22)10.20

Separation Agreement dated November 10, 2006 by and between NPS Pharmaceuticals and Edward Nemeth(24)10.21

Separation Agreement dated July 31, 2007 by and between NPS Pharmaceuticals, Inc. and Gregory M. Torre(29)10.22

Agreement of Purchase and Sale, dated May 9, 2007, between NPS Allelix Corp. and Transglobe Property Management Services Ltd. in
Trust(25)10.23

Sublease Agreement, dated June 19, 2007, between NPS Pharmaceuticals, Inc. and Celanese Americas Corporation(26)10.24

Purchase and Sale Agreement, dated June 29, 2007, by and between NPS Pharmaceuticals, Inc. and the University of
Utah.(26)10.25A

Securities Purchase Agreement dated as of August 7, 2007 among NPS Pharmaceuticals, Inc. (the "Issuer") and Visium Balanced Fund,
LP, Visium Balanced Offshore Fund, Ltd., Visium Long Bias Fund, LP, Visium Long Bias Offshore Fund, Ltd. and Atlas Master Fund (collectively, the
"Investors")(23)10.25B

Form of Note issued pursuant to the Securities Purchase Agreement referred to in Exhibit 10.25A above(23)10.25C

Registration Rights Agreement dated as of August 7, 2007 among the Issuer and the Investors(23)10.26

Agreement for Sale and Assignment of Rights, dated July 16, 2007, among NPS Pharmaceuticals, Inc., NPS Allelix Corp. and
DRI*(27)10.27

Distribution and License Agreement, dated September 24, 2007, among NPS Pharmaceuticals, Inc., NPS Allelix Corp. and Nycomed
GmbH*(27)10.28

Amendment Agreement to the Distribution and License Agreement, dated September 24, 2007, among NPS Pharmaceuticals, Inc., NPS
Allelix Corp. and Nycomed GMBH*(27)10.29

License Agreement, dated September 28, 1995, between 1149336 Ontario Inc., Daniel J. Drucker, and Allelix Biopharmaceuticals
Inc.*(27)10.30

Asset Purchase Agreement, dated October 9, 2007, between Astrazeneca AB and NPS Pharmaceuticals, Inc.(29)10.31

Separation Agreement dated December 7, 2007 by and between NPS Pharmaceuticals, Inc. and Val R. Antczak(29)10.32

Separation Agreement dated November 19, 2007 by and between NPS Pharmaceuticals, Inc. and Gerard J. Michel(29)10.33A

Commercial Manufacturing Agreement, dated October 18, 2002, by and between NPS Allelix Corp. and Boehringer Ingelheim Austria GmbH*(29)10.33B

Amending Agreement, dated March 15, 2004, by and between NPS Allelix Corp. and Boehringer Ingelheim Austria GmbH*(29)10.33C

Amendment Number One to Amending Agreement, dated December 22, 2005, by and between NPS Allelix Corp. and Boehringer
Ingelheim Austria GmbH*(29)12.1

Computation Ratio of Earnings Available to Cover Fixed Charges
    PDF provided as courtesy21.1

List of Subsidiaries(29)9723.1

Consent of Independent Registered Public Accounting Firm
    PDF provided as courtesy31.1

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
    PDF provided as courtesy31.2

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
    PDF provided as courtesy32

Certification of Annual Financial Report by the Chief Executive Officer and Chief Financial Officer
furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
    PDF provided as courtesy

_______________

|(1) | Incorporated herein by reference to the Registrant's Registration Statement on Form S-1 filed on January 21, 1994 (SEC File
No. 333-74318).
|--- | -------------------------------------------------------------------------------------------------------------------------------------------

|(2) | Incorporated herein by reference to the Registrant's Registration Statement on Form S-3 filed on September 6, 2000 (SEC File
No. 333-45274, Film No. 717603).
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------

|(3) | Incorporated herein by reference to the Registrant's Current Report on Form 8-K dated December 19, 1996
(SEC File No. 000-23272, Film No. 96683282).
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------------

|(4) | Incorporated herein by reference to the Registrant's Registration Statement on Form 8-A12G/A (SEC File No. 000-23272, Film
No. 1826478, filing date December 31, 2001).
|--- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(5) | Incorporated herein by reference to the Registrant's Registration Statement on Form 8-A/A (SEC File No. 000-23272, Film
No. 03575669, filing date February 21, 2003).
|--- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(6) | Incorporated herein by reference to the Registrant's Registration Statement on Form S-8 (SEC File No. 333-17521, Film
No. 96677983, filing date December 9, 1996).
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(7) | Incorporated herein by reference to the Registrant's Definitive Proxy Statement (SEC File No. 000-23272, Film No. 98590984,
filing date April 9, 1998).
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------

|(8) | Incorporated herein by reference to Amendment No. 1 to the Registrant's Annual Report on Form 10-K for the fiscal year ended
December 31, 1995, filed on March 29, 1996.
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(9) | Incorporated herein by reference to the Registrant's Current Report on Form 8-K dated January 27, 1998
(SEC File No. 000-23272, Film No. 98513828).
|--- | ---------------------------------------------------------------------------------------------------------------------------------------------------

|(10) | Incorporated herein by reference to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 1995.
|---- | ----------------------------------------------------------------------------------------------------------------------------

|(11) | Incorporated herein by reference to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2002
(SEC File No. 000-23272, Film No. 03612691, filing date March 21, 2003).
|---- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(12) | Incorporated herein by reference to the Registrant's Annual Report on Form 10-K/A for the fiscal year ended December 31, 2002
(SEC File No. 000-23272, Film No. 03739737, filing date June 11, 2003).
|---- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(13) | Incorporated herein by reference to the Registrant's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2003
(SEC File No. 000-23272. Film No. 03838243, filing date August 12, 2003).
|---- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(14) | Incorporated herein by reference to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2003
(SEC File No. 000-23272, Film No. 04582125, filing date February 10, 2004).
|---- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(15) | Incorporated herein by reference to the Registrant's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2004
(SEC File No. 000-23272, Film No. 04962020, filing date August 9, 2004).
|---- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(16) | Incorporated herein by reference to the Registrant's Current Report on Form 8-K dated February 2, 2005 (SEC File
No. 000-23272, Film No. 05578512, filing date February 7, 2005).
|---- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(17) | Incorporated herein by reference to the Registrant's Current Report on Form 8-K dated February 9, 2005 (SEC File
No. 000-23272, Film No. 05587185, filing date February 9, 2005).
|---- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(18) | Incorporated herein by reference to the Registrant's Definitive Proxy Statement (SEC File No. 000-23272, Film
No. 05744588, filing date April 11, 2005).
|---- | --------------------------------------------------------------------------------------------------------------------------------------------------------

|(19) | Incorporated herein by reference to the Registrant's Current Report on Form 8-K dated July 1, 2005
(SEC File No. 000-23272, Film No. 05933233, filing date July 1, 2005).
|---- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(20) | Incorporated herein by reference to the Registrant's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2005
(SEC File No. 000-23272, Film No. 05974685, filing date July 26, 2005).
|---- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(21) | Incorporated herein by reference to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2005
(SEC File No. 000-23272, Film No. 06663187, filing date March 3, 2006).
|---- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(22) | Incorporated herein by reference to the Registrant's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2006
(SEC File No. 000-23272, Film No. 061002758, filing date August 3, 2006).
|---- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|(23) | Incorporated herein by reference to the Registrant's Current Report on Form 8-K dated August 31, 2007
(SEC File No. 000-23272, Film No. 071094546, filing date August 31, 2007).                         
|(24) | Incorporated herein by reference to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2006 (SEC
File No. 000-23272, Film No. 07693379, filing date March 14, 2007).     
|(25) | Incorporated herein by reference to the Registrant's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2007 (SEC
File No. 000-23272, Film No. 07833270, filing date May 9, 2007).   

98

---



|(26) | Incorporated herein by reference to the Registrant's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2007
(SEC File No. 000-23272, Film No. 071032512, filing date August 7, 2007).     
|---- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|(27) | Incorporated herein by reference to the Registrant's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2007
(SEC File No. 000-23272, Film No. 071231813, filing date August 7, 2007).
|(28) | Incorporated herein by reference to the Registrant's Definitive Proxy Statement (SEC File No. 000-23272, Film
No. 98590984, filing date April 9, 1998).                                                       
|     |                                                                                                                                                                                                               
|(29) | Incorporated herein by reference to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2007
(SEC File No. 000-23272, Film No. 08691123, filing date March 17, 2008).          
|     |                                                                                                                                                                                                               

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

|                   |  |                           |  |                                                                                                                            
|------------------ |  | ------------------------- |  | ---------------------------------------------------------------------------------------------------------------------------
|                   |  | NPS PHARMACEUTICALS, INC.
|                   |  |                          
|Date: May 19, 2008 |  | By:                       |  | /s/     FRANCOIS NADERFrancois Nader
                  President and Chief Executive Officer (Principal Executive Officer) 
|                   |  |                          
|Date: May 19, 2008 |  | By:                       |  | /s/    LUKE M. BESHARLuke M. Beshar 
                  Chief Financial Officer (Principal Financial and Accounting Officer)

99

---